
<html lang="en"     class="pb-page"  data-request-id="c578c607-ceef-486a-84e8-5c4b8f4445b5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2012.55.issue-13;wgroup:string:ACHS website Group;article:article:10.1021/jm300628c;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2" /></meta><meta name="dc.Creator" content="Mark  Zak" /></meta><meta name="dc.Creator" content="Rohan  Mendonca" /></meta><meta name="dc.Creator" content="Mercedesz  Balazs" /></meta><meta name="dc.Creator" content="Kathy  Barrett" /></meta><meta name="dc.Creator" content="Philippe  Bergeron" /></meta><meta name="dc.Creator" content="Wade S.  Blair" /></meta><meta name="dc.Creator" content="Christine  Chang" /></meta><meta name="dc.Creator" content="Gauri  Deshmukh" /></meta><meta name="dc.Creator" content="Jason  DeVoss" /></meta><meta name="dc.Creator" content="Peter S.  Dragovich" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Nico  Ghilardi" /></meta><meta name="dc.Creator" content="Paul  Gibbons" /></meta><meta name="dc.Creator" content="Stefan  Gradl" /></meta><meta name="dc.Creator" content="Chris  Hamman" /></meta><meta name="dc.Creator" content="Emily J.  Hanan" /></meta><meta name="dc.Creator" content="Eric  Harstad" /></meta><meta name="dc.Creator" content="Peter R.  Hewitt" /></meta><meta name="dc.Creator" content="Christopher A.  Hurley" /></meta><meta name="dc.Creator" content="Tian  Jin" /></meta><meta name="dc.Creator" content="Adam  Johnson" /></meta><meta name="dc.Creator" content="Tony  Johnson" /></meta><meta name="dc.Creator" content="Jane R.  Kenny" /></meta><meta name="dc.Creator" content="Michael F. T.  Koehler" /></meta><meta name="dc.Creator" content="Pawan  Bir Kohli" /></meta><meta name="dc.Creator" content="Janusz J.  Kulagowski" /></meta><meta name="dc.Creator" content="Sharada  Labadie" /></meta><meta name="dc.Creator" content="Jiangpeng  Liao" /></meta><meta name="dc.Creator" content="Marya  Liimatta" /></meta><meta name="dc.Creator" content="Zhonghua  Lin" /></meta><meta name="dc.Creator" content="Patrick J.  Lupardus" /></meta><meta name="dc.Creator" content="Robert J.  Maxey" /></meta><meta name="dc.Creator" content="Jeremy M.  Murray" /></meta><meta name="dc.Creator" content="Rebecca  Pulk" /></meta><meta name="dc.Creator" content="Madeleine  Rodriguez" /></meta><meta name="dc.Creator" content="Scott  Savage" /></meta><meta name="dc.Creator" content="Steven  Shia" /></meta><meta name="dc.Creator" content="Micah  Steffek" /></meta><meta name="dc.Creator" content="Savita  Ubhayakar" /></meta><meta name="dc.Creator" content="Mark  Ultsch" /></meta><meta name="dc.Creator" content="Anne  van Abbema" /></meta><meta name="dc.Creator" content="Stuart I.  Ward" /></meta><meta name="dc.Creator" content="Ling  Xiao" /></meta><meta name="dc.Creator" content="Yisong  Xiao" /></meta><meta name="dc.Description" content="Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2...." /></meta><meta name="Description" content="Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2...." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 28, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300628c" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300628c" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300628c" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300628c" /></link>
        
    
    

<title>Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300628c" /></meta><meta property="og:title" content="Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0007.jpeg" /></meta><meta property="og:description" content="Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and &gt;33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20). Details of the biological characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300628c"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300628c">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300628c&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300628c&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300628c&amp;href=/doi/10.1021/jm300628c" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6176-6193</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300611v" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm3006492" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery and Optimization of <i>C</i>-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Zak">Mark Zak</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rohan++Mendonca">Rohan Mendonca</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mercedesz++Balazs">Mercedesz Balazs</a></span><span class="author-xref-symbol author-aff-symbol"><sup>×</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathy++Barrett">Kathy Barrett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philippe++Bergeron">Philippe Bergeron</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wade+S.++Blair">Wade S. Blair</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christine++Chang">Christine Chang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gauri++Deshmukh">Gauri Deshmukh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++DeVoss">Jason DeVoss</a></span><span class="author-xref-symbol author-aff-symbol"><sup>×</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+S.++Dragovich">Peter S. Dragovich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nico++Ghilardi">Nico Ghilardi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Gibbons">Paul Gibbons</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan++Gradl">Stefan Gradl</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chris++Hamman">Chris Hamman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emily+J.++Hanan">Emily J. Hanan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Harstad">Eric Harstad</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+R.++Hewitt">Peter R. Hewitt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+A.++Hurley">Christopher A. Hurley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tian++Jin">Tian Jin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adam++Johnson">Adam Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tony++Johnson">Tony Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jane+R.++Kenny">Jane R. Kenny</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+F.+T.++Koehler">Michael F. T. Koehler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Pawan++Bir+Kohli">Pawan Bir Kohli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janusz+J.++Kulagowski">Janusz J. Kulagowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sharada++Labadie">Sharada Labadie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiangpeng++Liao">Jiangpeng Liao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marya++Liimatta">Marya Liimatta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhonghua++Lin">Zhonghua Lin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>×</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patrick+J.++Lupardus">Patrick J. Lupardus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+J.++Maxey">Robert J. Maxey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeremy+M.++Murray">Jeremy M. Murray</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca++Pulk">Rebecca Pulk</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Madeleine++Rodriguez">Madeleine Rodriguez</a></span><span class="author-xref-symbol author-aff-symbol"><sup>×</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Savage">Scott Savage</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Steven++Shia">Steven Shia</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Micah++Steffek">Micah Steffek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Savita++Ubhayakar">Savita Ubhayakar</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Ultsch">Mark Ultsch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∞</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anne++van+Abbema">Anne van Abbema</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stuart+I.++Ward">Stuart I. Ward</a></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ling++Xiao">Ling Xiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yisong++Xiao">Yisong Xiao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>●</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Departments of <sup>†</sup>Discovery Chemistry, <sup>‡</sup>Biochemical and Cellular Pharmacology, <sup>§</sup>Drug Metabolism and Pharmacokinetics, <sup>∥</sup>Immunology, <sup>⊥</sup>Safety Assessment, <sup>#</sup>Small Molecule Process Chemistry, <sup>∞</sup>Structural Biology, and <sup>×</sup>Translational Immunology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">○</span> <span class="aff-text">Argenta, 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United Kingdom</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">●</span> <span class="aff-text">WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, P. R. China</span></div><div class="corresp-info"><strong>*</strong>Phone: 650-467-4533. E-mail: <a href="/cdn-cgi/l/email-protection#9bf6e1faf0dbfcfef5feb5f8f4f6"><span class="__cf_email__" data-cfemail="d4b9aeb5bf94b3b1bab1fab7bbb9">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300628c&amp;href=/doi/10.1021%2Fjm300628c" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6176–6193</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 14, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 May 2012</li><li><span class="item_label"><b>Published</b> online</span>28 June 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 July 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300628c" title="DOI URL">https://doi.org/10.1021/jm300628c</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6176%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMark%2BZak%252C%2BRohan%2BMendonca%252C%2BMercedesz%2BBalazs%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D13%26contentID%3Djm300628c%26title%3DDiscovery%2Band%2BOptimization%2Bof%2BC-2%2BMethyl%2BImidazopyrrolopyridines%2Bas%2BPotent%2Band%2BOrally%2BBioavailable%2BJAK1%2BInhibitors%2Bwith%2BSelectivity%2Bover%2BJAK2%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6193%26publicationDate%3DJuly%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300628c"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3844</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">38</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300628c" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Zak&quot;},{&quot;first_name&quot;:&quot;Rohan&quot;,&quot;last_name&quot;:&quot;Mendonca&quot;},{&quot;first_name&quot;:&quot;Mercedesz&quot;,&quot;last_name&quot;:&quot;Balazs&quot;},{&quot;first_name&quot;:&quot;Kathy&quot;,&quot;last_name&quot;:&quot;Barrett&quot;},{&quot;first_name&quot;:&quot;Philippe&quot;,&quot;last_name&quot;:&quot;Bergeron&quot;},{&quot;first_name&quot;:&quot;Wade&quot;,&quot;last_name&quot;:&quot;S. Blair&quot;},{&quot;first_name&quot;:&quot;Christine&quot;,&quot;last_name&quot;:&quot;Chang&quot;},{&quot;first_name&quot;:&quot;Gauri&quot;,&quot;last_name&quot;:&quot;Deshmukh&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;DeVoss&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;S. Dragovich&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Nico&quot;,&quot;last_name&quot;:&quot;Ghilardi&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Gibbons&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;Gradl&quot;},{&quot;first_name&quot;:&quot;Chris&quot;,&quot;last_name&quot;:&quot;Hamman&quot;},{&quot;first_name&quot;:&quot;Emily&quot;,&quot;last_name&quot;:&quot;J. Hanan&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Harstad&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;R. Hewitt&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;A. Hurley&quot;},{&quot;first_name&quot;:&quot;Tian&quot;,&quot;last_name&quot;:&quot;Jin&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Tony&quot;,&quot;last_name&quot;:&quot;Johnson&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;R. Kenny&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;F. T. Koehler&quot;},{&quot;first_name&quot;:&quot;Pawan&quot;,&quot;last_name&quot;:&quot;Bir Kohli&quot;},{&quot;first_name&quot;:&quot;Janusz&quot;,&quot;last_name&quot;:&quot;J. Kulagowski&quot;},{&quot;first_name&quot;:&quot;Sharada&quot;,&quot;last_name&quot;:&quot;Labadie&quot;},{&quot;first_name&quot;:&quot;Jiangpeng&quot;,&quot;last_name&quot;:&quot;Liao&quot;},{&quot;first_name&quot;:&quot;Marya&quot;,&quot;last_name&quot;:&quot;Liimatta&quot;},{&quot;first_name&quot;:&quot;Zhonghua&quot;,&quot;last_name&quot;:&quot;Lin&quot;},{&quot;first_name&quot;:&quot;Patrick&quot;,&quot;last_name&quot;:&quot;J. Lupardus&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;J. Maxey&quot;},{&quot;first_name&quot;:&quot;Jeremy&quot;,&quot;last_name&quot;:&quot;M. Murray&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;Pulk&quot;},{&quot;first_name&quot;:&quot;Madeleine&quot;,&quot;last_name&quot;:&quot;Rodriguez&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Savage&quot;},{&quot;first_name&quot;:&quot;Steven&quot;,&quot;last_name&quot;:&quot;Shia&quot;},{&quot;first_name&quot;:&quot;Micah&quot;,&quot;last_name&quot;:&quot;Steffek&quot;},{&quot;first_name&quot;:&quot;Savita&quot;,&quot;last_name&quot;:&quot;Ubhayakar&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Ultsch&quot;},{&quot;first_name&quot;:&quot;Anne&quot;,&quot;last_name&quot;:&quot;van Abbema&quot;},{&quot;first_name&quot;:&quot;Stuart&quot;,&quot;last_name&quot;:&quot;I. Ward&quot;},{&quot;first_name&quot;:&quot;Ling&quot;,&quot;last_name&quot;:&quot;Xiao&quot;},{&quot;first_name&quot;:&quot;Yisong&quot;,&quot;last_name&quot;:&quot;Xiao&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;6176-6193&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300628c&quot;},&quot;abstract&quot;:&quot;Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 selectivity (20-fold and &gt;33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of 4 in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of 4 while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (20). Details of the biological characterization of 20 are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300628c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300628c" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300628c&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300628c" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300628c&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300628c" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300628c&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300628c&amp;href=/doi/10.1021/jm300628c" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300628c" /></input><a href="/doi/pdf/10.1021/jm300628c" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300628c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300628c%26sid%3Dliteratum%253Aachs%26pmid%3D22698084%26genre%3Darticle%26aulast%3DZak%26date%3D2012%26atitle%3DDiscovery%2Band%2BOptimization%2Bof%2BC-2%2BMethyl%2BImidazopyrrolopyridines%2Bas%2BPotent%2Band%2BOrally%2BBioavailable%2BJAK1%2BInhibitors%2Bwith%2BSelectivity%2Bover%2BJAK2%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D13%26spage%3D6176%26epage%3D6193%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292504" title="Permeability">Permeability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jmcmar.2012.55.issue-13/production/jmcmar.2012.55.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Herein we report the discovery of the <i>C</i>-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The <i>C</i>-2 methyl substituted inhibitor <b>4</b> exhibited not only improved JAK1 potency relative to unsubstituted compound <b>3</b> but also notable JAK1 vs JAK2 selectivity (20-fold and >33-fold in biochemical and cell-based assays, respectively). Features of the X-ray structures of <b>4</b> in complex with both JAK1 and JAK2 are delineated. Efforts to improve the in vitro and in vivo ADME properties of <b>4</b> while maintaining JAK1 selectivity are described, culminating in the discovery of a highly optimized and balanced inhibitor (<b>20</b>). Details of the biological characterization of <b>20</b> are disclosed including JAK1 vs JAK2 selectivity levels, preclinical in vivo PK profiles, performance in an in vivo JAK1-mediated PK/PD model, and attributes of an X-ray structure in complex with JAK1.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span></span> Accession Codes</h4><p class="last">PDB codes are as follows: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F08">4F08</a> for <b>3</b> complexed with JAK2; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EHZ">4EHZ</a> for <b>4</b> complexed with JAK1; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F09">4F09</a> for <b>4</b> complexed with JAK2; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EI4">4EI4</a> for <b>20</b> complexed with JAK1.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07136" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07136" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The Janus protein tyrosine kinases (JAK1,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> JAK2,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> JAK3,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and TYK2<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>) are key intracellular mediators of helical cytokine<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> signaling pathways. The cytokine ligands signal to cells by interacting with the extracellular portions of homo- or heterodimeric cell surface transmembrane receptors,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> which are further engaged with JAKs in their cytoplasmic domains. Upon ligand binding, these receptors induce activation of the associated JAKs, a mandatory initial step for all downstream signaling events, since the receptors themselves have no intrinsic kinase activity. JAK activation results in a cascade of phosphorylation and recognition events that culminate in the phosphorylation, dimerization, and nuclear translocation of one or several signal transducer and activator of transcription (STAT)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> proteins. Once inside the nucleus, the STATs modulate gene transcription and expression.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">The JAKs are activated in specific patterns by different cytokines that play essential roles in immune function,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> inflammation,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and hematopoiesis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> For example, members of the γ common (γ<sub>c</sub>) subfamily, namely, interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, activate JAK1 and JAK3 but never JAK2 or TYK2.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The importance of the γ<sub>c</sub> cytokines to the immune system is highlighted by the observation of SCID (severe combined immunodeficiency) when loss of function mutations occur in the γ<sub>c</sub> chain or JAK3.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Another large subfamily of cytokines shares the glycoprotein 130 (gp130) signal transducing subunit and includes IL-6, IL-11, IL-27, and several other cytokines. Signaling by these cytokines always involves JAK1 activation, and JAK2 and TYK2 are also consistently engaged.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> IL-6 is heavily implicated in immune response, and excessive stimulation of this pathway is linked to various autoimmune and chronic inflammatory conditions.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Finally, the receptor for erythropoietin (EPO) represents a subfamily of homodimeric receptors that also includes the receptors for prolactin, thrombopoietin, and growth hormone. The EPO pathway activates JAK2 exclusively<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and is essential to red blood cell formation or erythropoiesis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">Each JAK isoform is employed by multiple cytokine pathways, and by extension, the biological activities of many cytokines may be abrogated by inhibition of a single JAK isoform. Since several of these cytokine activities regulate immune function, targeted inhibition of JAKs offers an attractive opportunity for therapeutic intervention against rheumatoid arthritis (RA) and other immunologic disorders. A number of small molecule JAK inhibitors have been evaluated in clinical trials for the treatment of RA, including tofacitinib/CP-690,550 (<b>1</b>)<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18-21)</a> and ruxolitinib/INCB018424 (<b>2</b>).<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> The preclinical characteristics of both molecules, including the JAK isoform potency and selectivity, have been extensively profiled by other groups.<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25, 26)</a> Consistent with these previously reported results, our biochemical assays show that <b>1</b> inhibits JAK1, JAK2, and JAK3 to an approximately equal extent and is less potent against TYK2, while <b>2</b> is a JAK1, JAK2, and TYK2 inhibitor with reduced potency against JAK3 (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). The JAK1 and JAK2 biochemical results are supported by our cell-based measures of both JAK1 and JAK2 potency. Phosphorylation of STAT3 in TF-1 cells following IL-6 stimulation is driven predominantly by JAK1 kinase activity and forms the basis of our cellular assessment of JAK1 inhibition (IL6-pSTAT3 assay).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The corresponding assessment of cellular JAK2 inhibition is also carried out in TF-1 cells but relies on measurement of phospho-STAT5 levels following EPO stimulation (EPO-pSTAT5 assay).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Compounds <b>1</b> and <b>2</b> show significant activity in both cell-based assays. Each molecule’s IL6-pSTAT3 EC<sub>50</sub> is less than 55 nM and is within ±2-fold of its corresponding EPO-pSTAT5 value, indicating potent inhibition of both JAK1 and JAK2 function in TF-1 cells.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibition of biochemical and cell-based JAK activity by <b>1</b> and <b>2</b>. Superscript letters indicate the following: (a) biochemical assays; (b) arithmetic mean of at least three separate runs (<i>n</i> ≥ 3), where on average, the coefficients of variation were less than 0.3 times the mean for biochemical assays and less than 0.5 times the mean for cell-based assays; (c) cell-based measure of JAK1 inhibition; (d) cell-based measure of JAK2 inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Both <b>1</b> and <b>2</b> have demonstrated clinical efficacy in patients suffering from RA.<a onclick="showRef(event, 'ref20 ref21 cit23a ref24'); return false;" href="javascript:void(0);" class="ref ref20 ref21 cit23a ref24">(20, 21, 23a, 24)</a> Although suppression of JAK3 and TYK2 activity may contribute to these favorable clinical outcomes, several lines of evidence point to JAK1 inhibition playing a critical and potentially dominant role. The first evidence comes from the divergent in vitro potency profiles of these compounds against the individual Janus kinase family members. Compounds <b>1</b> and <b>2</b> have considerably reduced potency against either TYK2 or JAK3, respectively, demonstrating that significant suppression of those kinase activities is likely not a prerequisite to observing clinical modulation of immune function. The second piece of evidence comes from the biology surrounding the proinflammatory cytokine IL-6. Although IL-6 activates three Janus family members (JAK1, JAK2, and TYK2), knockout studies in mice show that JAK1 is especially important to signal transduction. Indeed, after IL-6 stimulation, cells from JAK1 deficient mice show profound reductions in downstream signaling compared to wild type, whereas cells deficient in TYK2 or JAK2 maintain robust IL-6 responsiveness.<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28-30)</a> The clinical success of the biological agent tocilizumab<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> against RA is therefore consistent with the hypothesis that selective JAK1 inhibition will lead to therapeutic immune modulation. Tocilizumab is a neutralizing antibody directed against the IL-6 receptor α chain and is believed to exert its therapeutic effects by inhibiting the activity of the JAK1 dependent cytokine IL-6. The final evidence supporting JAK1 as an appropriate target for immune modulation comes from recent work suggesting that JAK1 rather than JAK3 kinase function is dominant in driving the activity of the immunorelevant γ<sub>c</sub> cytokines.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p last">On the basis of the above lines of evidence, we believed that a selective JAK1 inhibitor would provide efficacy against RA. We further believed that an ideal RA therapy would minimize inhibition of JAK2. JAK2 plays an integral role in the EPO signaling pathway necessary for red blood cell formation, and its inactivation leads to anemia in animal models.<a onclick="showRef(event, 'ref30 ref33'); return false;" href="javascript:void(0);" class="ref ref30 ref33">(30, 33)</a> Additionally, hemoglobin reduction and anemia have been noted in human patients enrolled in clinical trials of compounds <b>1</b> and <b>2</b>, both potent inhibitors of JAK2 activity.<a onclick="showRef(event, 'ref20 ref34'); return false;" href="javascript:void(0);" class="ref ref20 ref34">(20, 34)</a> The authors describing the results of one such trial note that hemoglobin reductions at higher doses of tofacitinib (>5 mg b.i.d.) may be the result of effects on hematopoiesis due to JAK2 inhibition.<a onclick="showRef(event, 'cit20a'); return false;" href="javascript:void(0);" class="ref cit20a">(20a)</a> On the basis of the published clinical results, we believed that even subtle selectivity for JAK1 over JAK2, on the order of 5- to 10-fold, could widen the therapeutic index for JAK1 mediated anti-RA effects relative to JAK2 dependent anemia. We therefore embarked on a program to identify potent and orally bioavailable small molecule inhibitors of JAK1, with selectivity over JAK2,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> as potential therapies for RA and other immunologic disorders.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of the imidazopyrrolopyridine <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>) represented an important initial step in our JAK1 program.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> As previously reported,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a><b>3</b> was found to be a moderately potent biochemical inhibitor of JAK1 (<i>K</i><sub>i</sub> = 46 nM) with reduced potency for JAK2 (<i>K</i><sub>i</sub> = 250 nM), resulting in a biochemical JAK1 selectivity index (<i>K</i><sub>i</sub>(JAK2)/<i>K</i><sub>i</sub>(JAK1)) of 5.4-fold. Compound <b>3</b> also showed modest potency in the cell-based measurement of JAK1 inhibition (IL6-pSTAT3 EC<sub>50</sub> = 1400 nM). Similar to the biochemical assay results, <b>3</b> was less potent in the cell-based measure of JAK2 inhibition (EPO-pSTAT5 EC<sub>50</sub> > 8800 nM). Since its low potency precluded definitive assessment of EC<sub>50</sub> in the JAK2-driven EPO-pSTAT5 assay,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> it was not possible to report the unequivocal cell-based JAK1 selectivity index of <b>3</b> (EC<sub>50</sub>(EPO-pSTAT5)/EC<sub>50</sub>(IL6-pSTAT3)), beyond stating that it was greater than 6.3-fold. Intrigued by the emerging JAK1 selectivity displayed by compound <b>3</b>, we wished to synthesize related analogues with similar selectivity but improved potency.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of compound <b>3</b> and inhibition of biochemical and cell-based JAK1/JAK2 activity. Superscript letters indicate the following: (a) biochemical assays; (b) arithmetic mean of eight separate runs (<i>n</i> = 8), where on average, the coefficients of variation were less than 0.3 times the mean for biochemical assays; (c) <i>K</i><sub>i</sub>(JAK2)/<i>K</i><sub>i</sub>(JAK1); (d) cell-based measure of JAK1 inhibition; (e) arithmetic mean of three separate runs (<i>n</i> = 3), where on average, the coefficients of variation were less than 0.5 times the mean for cell-based assays; (f) cell-based measure of JAK2 inhibition; (g) see ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a>; (h) EC<sub>50</sub>(EPO-pSTAT5)/EC<sub>50</sub>(IL6-pSTAT3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">During the optimization campaign of inhibitor <b>3</b>, a very promising <i>C</i>-2 methyl substituted analogue <b>4</b> was identified. As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, compound <b>4</b> exhibited notably increased biochemical inhibition of JAK1 (<i>K</i><sub>i</sub> = 10 nM), with only a minimal gain against JAK2 (<i>K</i><sub>i</sub> = 200 nM) relative to the des-methyl analogue <b>3</b>. The larger increase in JAK1 relative to JAK2 inhibition of compound <b>4</b> resulted in another positive outcome, namely, increased JAK1 selectivity (biochemical JAK1 selectivity indexes: <b>3</b>, 5.4-fold; <b>4</b>, 20-fold). Also of note, the <i>C</i>-2 methyl group’s amplification of biochemical JAK1 inhibition was mirrored in the cell-based measure of JAK1 potency (IL6-pSTAT3 EC<sub>50</sub>: compound <b>3</b>, 1400 nM; compound <b>4</b>, 250 nM). The weak potency of both compounds <b>3</b> and <b>4</b> in the cellular measure of JAK2 inhibition (EPO-pSTAT5 EC<sub>50</sub>: compound <b>3</b>, >8800 nM; compound <b>4</b>, >8200 nM)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> precluded a definitive conclusion on the impact of the <i>C</i>-2 methyl group on the cell-based JAK1 selectivity index. However, it is likely that the cell-based JAK1 selectivity index of compound <b>4</b> (>33-fold) was greater than that of <b>3</b> (>6.3-fold).</div><div class="NLM_p">Despite the promising selectivity profile and increased JAK1 inhibition relative to its <i>C</i>-2 unsubstituted counterpart, compound <b>4</b> was still not an ideal development candidate. A further increase in cell-based potency was desired, and furthermore, <b>4</b> displayed poor apparent permeability as measured by flux through MDCK cells in transwell culture (A/B <i>P</i><sub>app</sub> = 0.4 × 10<sup>–6</sup> cm/s). The low permeability elicited concern that <b>4</b> would be poorly absorbed through the intestine after oral dosing, thus potentially limiting its oral bioavailability (vide infra). The topological polar surface area (TPSA)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> of compound <b>4</b> was relatively low (58 Å<sup>2</sup>), pointing toward a very low measured log <i>D</i><sub>7.2</sub> (0.1) as the probable explanation for the recalcitrant permeability. As such, a series of analogues (<b>5</b>–<b>9</b>) with increased log <i>D</i><sub>7.2</sub> <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> was synthesized. Additionally, as a means to further enhance permeability, these initial derivatives were all designed to contain only a single hydrogen-bond donor (HBD), one less than in compound <b>4</b>.</div><div class="NLM_p">As hoped, increasing the log <i>D</i><sub>7.2</sub> of the single HBD-containing analogues resulted in MDCK permeability improvements to the moderate (<b>6</b> and <b>9</b>) or high (<b>5</b>, <b>7</b>, and <b>8</b>) range (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). A trend in the opposite direction was identified for human hepatocyte stability, with the most lipophilic compounds <b>5</b> and <b>7</b> exhibiting the worst metabolic stability. Fortunately, compound <b>6</b> balanced moderate permeability with excellent stability in human hepatocytes, demonstrating that an optimal range of physicochemical properties existed in this series. The initial series of analogues (<b>5</b>–<b>9</b>) also highlighted the fact that JAK1 biochemical and cell-based potency could be maintained or improved relative to <b>4</b> with a wide array of 4-piperidine replacements. The JAK1 selectivity indexes, however, were all significantly eroded by replacing the 4-piperidine group resident in <b>4</b> with any of the HBD-lacking R-groups listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. In fact, the three compounds with improved cellular potency (<b>5</b>, <b>6</b>, and <b>7</b>) all exhibited cell-based JAK1 selectivity indexes of less than 5-fold. These findings indicated that combining the <i>C</i>-2 methyl group with a HBD-containing R-group could be important to JAK1 selectivity. As such, focus was shifted to preparing additional analogues of <b>4</b> with R-groups containing HBD moieties.</div><div class="NLM_p">In an attempt to balance optimal properties, lipophilicity restraints were put in place in the subsequent design of compounds <b>10</b>–<b>24</b>, with log <i>D</i><sub>7.2</sub> <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> values higher than that of compound <b>4</b> (permeability considerations) but lower than those of compounds <b>5</b> and <b>7</b> (metabolic stability concerns) targeted for the majority of analogues. The 3-substituted piperidine <b>10</b> was found to be more lipophilic than the corresponding 4-substituted analogue (<b>4</b>), presumably because of closer proximity of the basic center to the electron-withdrawing tricyclic system. However, <b>10</b> displayed a large loss in biochemical JAK1 potency with only minimal gain in MDCK permeability relative to <b>4</b>. Increasing log <i>D</i><sub>7.2</sub> and modulating the basicity of the 4-piperidine group with fluorine atoms proved to be a more fruitful line of investigation. The <i>trans</i>-monofluoro analogue <b>11</b> displayed superior biochemical and cell-based JAK1 potency relative to its cis counterpart <b>12</b> and the starting point compound <b>4</b>. Additionally, compound <b>11</b> had much improved MDCK permeability relative to <b>4</b>, and although JAK1 vs JAK2 selectivity was somewhat diminished, reasonable JAK1 biochemical and cell-based indexes were maintained (5.3-fold and 15-fold, respectively). The difluorinated piperidine <b>13</b> also had improved MDCK permeability relative to <b>4</b>. Among the <i>trans</i>-1,4-diaminocyclohexanes examined (<b>14</b>–<b>17</b>), only the most lipophilic analogue (compound <b>17</b>) was found to exhibit high levels of MDCK permeability. Unfortunately the promising MDCK permeability of compound <b>17</b> came at the expense of reduced stability in human hepatocytes relative to compound <b>4</b>. Although a related example (compound <b>14</b>) displayed suboptimal permeability, it was modestly enhanced relative to <b>4</b>. Biochemical and cell-based JAK1 potency were also improved, while excellent human hepatocyte stability was maintained. These findings, coupled with respectable JAK1 selectivity indexes (biochemical, 6.2-fold; cell based, 15-fold), allowed <b>14</b> to remain of interest for further progression. Compounds <b>15</b> and <b>16</b>, bearing <i>N</i>-sulfonylmethyl and <i>N</i>-acetyl moieties, respectively, both lost significant potency in the cell-based assays. A series of hydroxylated cyclohexanes (<b>18</b>–<b>22</b>) and cyclopentanes (<b>23</b> and <b>24</b>) as replacements for the 4-piperidine group of <b>4</b> was subsequently examined. Similar to previous examples, the regio- and stereochemistries of the hydroxyl substituents were important in modulating potency and selectivity. The <i>trans</i>-3-hydroxy analogue <b>20</b> struck the best balance among the hydroxylated derivatives and exhibited excellent biochemical and cell-based potency, acceptable JAK1 selectivity indexes (biochemical, 6.7-fold; cell-based, 18-fold), and greatly improved membrane permeability (MDCK A/B, 7.0 × 10<sup>–6</sup> cm/s) relative to the starting point <b>4</b>. <b>20</b> also exhibited a high degree of stability in human hepatocytes. By comparison, the remaining cyclohexanol isomers (<b>18</b>, <b>19</b>, <b>21</b>, and <b>22</b>) and cyclopentanol analogues (<b>23</b> and <b>24</b>) lost varying degrees of JAK1 potency and selectivity.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Biological and Physical Properties of Imidazopyrrolopyridine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0011.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Unless otherwise indicated, all compounds are single isomers. Where the possibility of chirality exists, data from only the most potent enantiomer are shown.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Biochemical assays. For brevity, only JAK1 and JAK2 data are reported. JAK3 and TYK2 inhibition data may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Unless otherwise noted, all biochemical and cell-based assay results are reported as the arithmetic mean of at least three separate runs (<i>n</i> = 3). On average, the coefficients of variation were less than 0.3 times the mean for biochemical assays and less than 0.5 times the mean for cell-based assays.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last"><i>K</i><sub>i</sub>(JAK2)/<i>K</i><sub>i</sub>(JAK1).</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Cell-based JAK1 assay.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Cell-based JAK2 assay.</p></div><div class="footnote" id="t1fn7"><sup>Table g</sup><p class="last">EC<sub>50</sub>(EPO-pSTAT5)/EC<sub>50</sub>(IL6-pSTAT3).</p></div><div class="footnote" id="t1fn8"><sup>Table h</sup><p class="last">Measured log of distribution coefficient between octanol and aqueous pH 7.2 buffer.</p></div><div class="footnote" id="t1fn9"><sup>Table i</sup><p class="last">Topological polar surface area.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div><div class="footnote" id="t1fn10"><sup>Table j</sup><p class="last">Apparent permeability in MDCK transwell culture. A/B, apical-to-basolateral.</p></div><div class="footnote" id="t1fn11"><sup>Table k</sup><p class="last">In vitro stability in cryopreserved human hepatocytes.</p></div><div class="footnote" id="t1fn12"><sup>Table l</sup><p class="last">Arithmetic mean of 11 runs (<i>n</i> = 11)</p></div><div class="footnote" id="t1fn13"><sup>Table m</sup><p class="last">See ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a>.</p></div><div class="footnote" id="t1fn14"><sup>Table n</sup><p class="last">Absolute stereochemistry assigned arbitrarily.</p></div><div class="footnote" id="t1fn15"><sup>Table o</sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn16"><sup>Table p</sup><p class="last">Relative stereochemistry known but absolute stereochemistry assigned arbitrarily.</p></div><div class="footnote" id="t1fn17"><sup>Table q</sup><p class="last"><i>n</i> = 2.</p></div><div class="footnote" id="t1fn18"><sup>Table r</sup><p class="last"><i>n</i> = 1.</p></div><div class="footnote" id="t1fn19"><sup>Table s</sup><p class="last">Racemic mixture.</p></div></div><div></div></div><div class="NLM_p">The biochemical and cell-based measures of JAK1 and JAK2 inhibition led to similar conclusions about JAK1 vs JAK2 selectivity of the compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. Although there was a trend toward subtly increased selectivity in the cellular context, less than a 2-fold difference between biochemical and cell-based measures of selectivity for any given compound was common. Even in the most extreme case (compound <b>19</b>) only a 3.4-fold difference was observed between the biochemical and cell-based JAK1 selectivity indexes. Furthermore, the compounds with the greatest levels of cell-based selectivity (<b>4</b>, <b>11</b>, <b>14</b>, and <b>20</b>) all exhibited biochemical JAK1 selectivity indexes of greater than 5-fold, which reflected statistically significant differences in those compounds’ JAK1 relative to JAK2 <i>K</i><sub>i</sub> values.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> While compound <b>4</b> was undeniably the most selective JAK1 inhibitor listed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>, a number of better balanced molecules with greatly increased chances of progression as orally delivered drug candidates were identified. Notably, compounds <b>11</b>, <b>14</b>, and <b>20</b> all offered improvements in both JAK1 potency and permeability relative to <b>4</b> while retaining cell-based JAK1 selectivity indexes of 15-fold or more. Both compound <b>4</b> and a number of optimized analogues were progressed to in vivo rat PK studies to evaluate the impact of MDCK apparent permeability on oral exposure.</div><div class="NLM_p">The in vivo rat PK parameters of reference compound <b>1</b> have been previously reported.<a onclick="showRef(event, 'ref19 ref42'); return false;" href="javascript:void(0);" class="ref ref19 ref42">(19, 42)</a> As summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, compound <b>1</b> exhibited relatively high clearance after intravenous (iv) delivery, with oral bioavailability (<i>F</i>) greater than 2-fold higher than the predicted theoretical maximum (<i>F</i><sub>max</sub>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The compounds in the current work all exhibited similarly high in vivo clearance in the rat, while exposure and bioavailability varied widely after oral dosing. Two compounds (<b>11</b> and <b>20</b>) exhibited a similar profile to compound <b>1</b> in that oral bioavailability was substantially better than would be expected based on iv clearance.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It is unclear how the unexpectedly high oral exposure was achieved or whether the same mechanism was responsible for each compound.</div><div class="NLM_p">Despite possessing an incomplete understanding of why bioavailability for certain compounds was so good in the face of high clearance, several observations allowed us to optimize oral exposure. In vitro MDCK apparent permeability did indeed appear to play an important role in influencing the in vivo oral PK parameters, with the low permeability compounds (<b>4</b> and <b>14</b>) exhibiting the poorest oral bioavailability and exposure. A combination of at least moderate permeability coupled with high solubility at pH 7.4 appeared to be the best in vitro predictor of good in vivo oral exposure. Compound <b>17</b> exhibited the best MDCK permeability but worst pH 7.4 solubility relative to the other compounds tested and exhibited intermediate levels of oral exposure and bioavailability. By comparison, <b>11</b> and <b>20</b> balanced moderate permeability with excellent pH 7.4 solubility and achieved high levels of oral bioavailability and exposure. To help benchmark the potential biological relevance of these oral exposures, unbound plasma concentrations following oral dosing were compared to the corresponding in vitro EC<sub>50</sub> values in the IL6-pSTAT3 cell-based assay. The oral exposure profiles of compounds <b>4</b> and <b>14</b> were not sufficient to reach even transient maximum concentrations of free drug in excess of the corresponding IL6-pSTAT3 EC<sub>50</sub> values. The greatly improved permeability of <b>17</b> relative to <b>4</b> and <b>14</b> translated to significantly better oral exposure, and consequently, unbound plasma concentrations of this compound exceeded the IL6-pSTAT3 EC<sub>50</sub> for a portion of the dosing interval (0.5 h). The optimized R-groups of compounds <b>11</b> and <b>20</b> resulted in yet greater improvements to oral PK parameters, with notable increases to AUC, <i>C</i><sub>max</sub>, and bioavailability relative to <b>4</b>. The oral PK profiles of <b>11</b> and <b>20</b>, coupled with their potent cell-based inhibition of JAK1 activity, were sufficient to maintain unbound plasma concentrations in excess of IL6-pSTAT3 EC<sub>50</sub> for 4.0 and 5.6 h, respectively. Despite the relatively high iv clearance of compound <b>20</b> in the rat, we were encouraged by the observed level of target coverage after a single and relatively modest oral dose (2 mg/kg) and thus subjected it to further in vivo characterization.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vivo Rat PK Parameters and Supporting in Vitro Properties of <i>C</i>-2 Methylimidazopyrrolopyridine Analogues</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">aq solubility (mM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center">in vivo PK parameters (rat): 0.4 mg/kg (iv) and 2 mg/kg (po)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">pH 7.4</th><th class="colsep0 rowsep0" align="center">pH 2.0</th><th class="colsep0 rowsep0" align="center">MDCK <i>P</i><sub>app</sub>, A/B<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a>(×10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">MDCK <i>P</i><sub>app</sub>, (B/A<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a>)/(A/B)</th><th class="colsep0 rowsep0" align="center">% PPB (rat)<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">rat hepatocyte,<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">CL iv<a class="ref internalNav" href="#t2fn6" aria-label="f">f</a>(mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center">AUC po<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a>(μM·h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> po<a class="ref internalNav" href="#t2fn7" aria-label="g">g</a>(μM)</th><th class="colsep0 rowsep0" align="center"><i>F</i> <a class="ref internalNav" href="#t2fn8" aria-label="h">h</a> (%)</th><th class="colsep0 rowsep0" align="center"><i>F</i><sub>max</sub> <a class="ref internalNav" href="#t2fn9" aria-label="i">i</a> (%)</th><th class="colsep0 rowsep0" align="center">(% <i>F</i> <a class="ref internalNav" href="#t2fn8" aria-label="h">h</a>)/(% <i>F</i><sub>max</sub> <a class="ref internalNav" href="#t2fn9" aria-label="i">i</a>)</th><th class="colsep0 rowsep0" align="center">time above EC<sub>50</sub> <a class="ref internalNav" href="#t2fn10" aria-label="j">j</a>(h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">62,<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a> 43<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">2.1<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">0.28,<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a> 1.7<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">27,<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a> 87<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">11,<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a> 39<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left">2.5,<a class="ref internalNav" href="#t2fn11" aria-label="k">k</a> 2.2<a class="ref internalNav" href="#t2fn12" aria-label="l">l</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">>1.5</td><td class="colsep0 rowsep0" align="left">>5.0</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">>8.0</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">0.1</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">>1.5</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn13" aria-label="m">m</a></td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">1.2</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">1.6</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">5.3</td><td class="colsep0 rowsep0" align="left">4.5</td><td class="colsep0 rowsep0" align="left">172</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">>1.5</td><td class="colsep0 rowsep0" align="left">>5.0</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">>8.0</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">0.04</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">1.4</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">54</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">>1.5</td><td class="colsep0 rowsep0" align="left">>5.0</td><td class="colsep0 rowsep0" align="left">7.0</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">>8.0</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">3.4</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">118</td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">5.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Thermodynamic solubility of solid powder in aqueous buffer.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Apparent permeability in MDCK transwell culture. A/B, apical-to-basolateral.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">B/A, basolateral-to-apical.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Rat plasma protein binding.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last">In vitro stability in cryopreserved rat hepatocytes.</p></div><div class="footnote" id="t2fn6"><sup>f</sup><p class="last">Intravenous dosing. Samples <b>4</b>, <b>11</b>, <b>14</b>, <b>17</b>, and <b>20</b> were formulated as solutions in PEG400/citrate buffer (pH<sub>5.0</sub>). Data are the average from three separate animals.</p></div><div class="footnote" id="t2fn7"><sup>g</sup><p class="last">Oral dosing. Samples <b>4</b>, <b>11</b>, <b>14</b>, <b>17</b>, and <b>20</b> were formulated as suspensions in MCT. Data are the average from three separate animals.</p></div><div class="footnote" id="t2fn8"><sup>h</sup><p class="last">Experimental oral bioavailability.</p></div><div class="footnote" id="t2fn9"><sup>i</sup><p class="last">Theoretical maximum achievable oral bioavailability.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></p></div><div class="footnote" id="t2fn10"><sup>j</sup><p class="last">Amount of time unbound drug plasma concentrations following 2 mg/kg po dose remained in excess of in vitro IL6-pSTAT3 EC<sub>50</sub>. The unbound concentration of test compound was calculated by the equation [compound]<sub>unbound</sub> = [compound]<sub>total</sub>(1 – (PPB/100)).</p></div><div class="footnote" id="t2fn11"><sup>k</sup><p class="last">Data obtained or calculated from ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">19</a>. Oral doses normalized to 2 mg/kg.</p></div><div class="footnote" id="t2fn12"><sup>l</sup><p class="last">Data obtained or calculated from ref <a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">42</a>. Oral doses normalized to 2 mg/kg.</p></div><div class="footnote" id="t2fn13"><sup>m</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">The plasma concentration vs time curves after both oral and iv administration of compound <b>20</b> in the dog as well as relevant in vitro and in vivo PK parameters are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. As observed in other species, <b>20</b> exhibited low dog plasma protein binding (50%) as well as excellent in vitro hepatocyte stability (<i>t</i><sub>1/2</sub> > 8.0 h). Gratifyingly, compound <b>20</b> also exhibited favorable in vivo PK characteristics in the dog, with low iv clearance (5.8 mL min<sup>–1</sup> kg<sup>–1</sup>) observed. The low iv clearance, coupled with good MDCK permeability, and high aqueous solubility were all consistent with the excellent oral bioavailability observed for compound <b>20</b>. Indeed, the experimental bioavailability (95%) was only marginally higher than the theoretical <i>F</i><sub>max</sub> of 81%.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The oral exposure achieved by compound <b>20</b> translated to free plasma concentrations in excess of the corresponding in vitro IL6-pSTAT3 EC<sub>50</sub> value for 15 h after a single oral dose of 2 mg/kg. The excellent in vivo PK profile of compound <b>20</b> in the dog provided further impetus for additional preclinical characterization.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Exposure vs time profiles after iv and oral doses of compound <b>20</b> in the dog and relevant in vitro and in vivo parameters. Superscript letters indicate the following: (a) total plasma concentration of <b>20</b> after intravenous dosing (0.4 mg/kg), where the sample formulated is as a solution in PEG400/citrate buffer (pH<sub>5.0</sub>) and data are the average from three separate animals; (b) total plasma concentration of <b>20</b> after oral dosing (2 mg/kg), where the sample is formulated as a suspension in MCT and data are the average from three separate animals; (c) unbound plasma concentration of <b>20</b> after oral dosing (2 mg/kg), [<b>20</b>]<sub>unbound</sub> = [<b>20</b>]<sub>total</sub>(1 – (PPB/100)); (d) in vitro IL6-pSTAT3 EC<sub>50</sub> measured in TF-1 cells (87 nM); (e) dog plasma protein binding; (f) in vitro stability in cryopreserved dog hepatocytes; (g) theoretical maximum of achievable oral bioavailability (see ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">43</a> for calculation, and a hepatic blood flow of 30.9 mL min<sup>–1</sup> kg<sup>–1</sup> in the dog is assumed); (h) amount of time unbound drug plasma concentration following 2 mg/kg po dose remains in excess of in vitro IL6-pSTAT3 EC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, compound <b>20</b> was evaluated in a number of additional in vitro assays measuring either inhibition of JAK1 or off-target activities. Compound <b>20</b> exhibited low human plasma protein binding (40% bound) and did not distribute preferentially into red blood cells and thus maintained potent activity in an in vitro TF-1 cell-based measure of JAK1 inhibition conducted in the presence of human whole blood (IL6-pSTAT3 whole blood EC<sub>50</sub> = 160 nM). Compound <b>20</b> also exhibited negligible reversible or time-dependent inhibition of cytochrome P450s (CYP) and was thus considered to be at low risk for causing CYP-mediated drug–drug interactions. Risk of in vivo QT interval prolongation was also predicted to be low because of the lack of a significant effect in an in vitro hERG patch clamp assay (8.4% inhibition at 10 μM <b>20</b>). The ability of <b>20</b> to inhibit the activities of the remaining two members of the JAK family was determined in biochemical assays: JAK3 <i>K</i><sub>i</sub> = 22 nM and TYK2 <i>K</i><sub>i</sub> = 6.2 nM. Finally, inhibitor <b>20</b> was found to have high selectivity for the JAK family within the broader kinome, as revealed by the results of a screen against a panel of non-JAK kinases at 0.1 μM (>50-fold over its JAK1 <i>K</i><sub>i</sub>). Of the 178 kinases tested, most (170 kinases) were inhibited to only a minimal (<50%) extent while just eight were inhibited at a more potent level (six at 50–75% inhibition, two at >75% inhibition).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Measures of Either JAK1 Inhibition or Off-Target Activities of Compound <b>20</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">IL6-pSTAT3 whole blood,<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> EC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">reversible CYP inhibition, IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">evidence of time-dependent CYP inhibition?</th><th class="colsep0 rowsep0" align="center">hERG: % inhibition at 10 μM<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></th><th class="colsep0 rowsep0" align="center">JAK3 <i>K</i><sub>i</sub> <a class="ref internalNav" href="#t3fn6" aria-label="f">f</a> (nM)</th><th class="colsep0 rowsep0" align="center">TYK2 <i>K</i><sub>i</sub> <a class="ref internalNav" href="#t3fn6" aria-label="f">f</a> (nM)</th><th class="colsep0 rowsep0" align="center">no. of non-JAK kinases<a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">% inhibition at 0.1 μM <a class="ref internalNav" href="#t3fn8" aria-label="h">h</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">160<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>10<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">no<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a><sup>,</sup><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">8.4</td><td class="colsep0 rowsep0" align="left">22<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">6.2<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">170</td><td class="colsep0 rowsep0" align="center">→</td><td class="colsep0 rowsep0" align="left"><50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6<a class="ref internalNav" href="#t3fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="center">→</td><td class="colsep0 rowsep0" align="left">50–75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2<a class="ref internalNav" href="#t3fn10" aria-label="j">j</a></td><td class="colsep0 rowsep0" align="center">→</td><td class="colsep0 rowsep0" align="left">>75</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">In vitro IL6-pSTAT3 cell-based assay conducted in TF-1 cells in the presence of human whole blood.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Arithmetic mean of eight separate runs with eight separate blood donors.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">CYP isoforms tested (LCMS/MS probes used): 3A4 (testosterone and midazolam), 2C9 (warfarin), 2D6 (dextromethorphan), 2C19 (mephenytoin), 1A2 (phenacetin).</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Absence of shift in AUC of the CYP inhibition curve of <b>20</b> with and without NADPH preincubation.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Patch clamp assay conducted by ChanTest.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">Biochemical assays.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">Arithmetic mean of six separate runs.</p></div><div class="footnote" id="t3fn8"><sup>h</sup><p class="last">Off-target kinase inhibition assessed by SelectScreen Kinase Profiling Services (Invitrogen-Life Technologies, Madison, WI, U.S.). JAK1 was included as a positive control and exhibited >95% inhibition at the concentration of <b>20</b> tested (0.1 μM).</p></div><div class="footnote" id="t3fn9"><sup>i</sup><p class="last">Non-JAK kinases exhibiting 50–75% inhibition at 0.1 μM <b>20</b>: CSF1R, MAP2K1, MINK1, cRAF, RSK3, RSK4.</p></div><div class="footnote" id="t3fn10"><sup>j</sup><p class="last">Non-JAK kinases exhibiting >75% inhibition at 0.1 μM <b>20</b>: SGK3, LRRK2.</p></div></div></div><div class="NLM_p">To further assess the biological activity of <b>20</b>, its ability to inhibit JAK1-mediated cytokine signaling was examined in vivo in a PK/PD experiment in the mouse. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, mice were pretreated with ascending oral doses of compound <b>20</b> ranging from 3 to 100 mg/kg, followed by a 1 μg intraperitoneal (ip) injection of IL-6 cytokine 30 min later. An additional 30 min after IL-6 administration, concentrations of compound <b>20</b> and pSTAT3 were measured in plasma and snap-frozen spleens, respectively. As further demonstrated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, the increasing plasma concentrations achieved with ascending oral doses of <b>20</b> in the mouse were associated with decreasing pSTAT3 levels in the spleens of IL-6 treated animals. Indeed, at a dose of 100 mg/kg <b>20</b>, pSTAT3 expression was reduced to levels comparable to those of control animals untreated with IL-6, indicating that robust in vivo suppression of JAK1-mediated signaling was achieved.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0013.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design and results of an IL-6 induced pSTAT3 PK/PD study of compound <b>20</b> in the mouse<sup> </sup>(c). (a) Measured 1 h after dosing of <b>20</b>. (b) Measured 30 min after dosing of IL-6. (c) Five animals were used in each of the control and dosing arms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an attempt to understand the intriguing effect of the <i>C</i>-2 methyl substituent on JAK1 potency and selectivity, X-ray crystal structures of several imidazopyrrolopyridines in the presence of JAK1 and/or JAK2 were generated. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, the first structure generated was that of compound <b>3</b> in complex with JAK2. The inhibitor occupied the ATP-binding site of JAK2, with the tricyclic core interacting with the kinase hinge region and forming hydrogen bond contacts with E930 (3.1 Å) and L932 (3.1 Å). The piperidine extended beneath the P-loop but did not form any direct polar interactions with the protein. The piperidine moiety further adopted a chair conformation, placing the tricyclic core in an equatorial position, and was rotated by approximately 90° relative to the plane of tricyclic system.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of <b>3</b> in complex with JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F08">4F08</a>). The ligand <b>3</b> is shown in orange. Hydrogen-bond interactions with the hinge residues L932 and E930 are shown as dashed black lines. The side chains differing between JAK1 and JAK2 are highlighted in green. The corresponding JAK1 side chains are noted in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a. The structure is of insufficient resolution (2.8 Å) to observe bound waters around the ligand.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The X-ray structures of compound <b>4</b> in complex with both JAK1 and JAK2 are shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a and Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b, respectively. The general features of both structures were similar, although subtle differences did exist. The ligand’s interactions with the hinge backbone were virtually identical in both isoforms, with the pyridine N engaging either the L959 (JAK1) or L932 (JAK2) amide NH and with the pyrrole NH pairing with the E957 (JAK1) or E930 (JAK2) carbonyl oxygen. As previously observed with compound <b>3</b>, the piperidine group extending beneath the JAK P-loops adopted a chair conformation and oriented the tricyclic core in an equatorial disposition. Also similar to compound <b>3</b>, the free piperidine NH of <b>4</b> did not directly contact the JAK proteins; however, the crystal structures of <b>4</b> were of sufficient resolution to reveal its association with two crystallographic water molecules residing beneath the P-loops of JAK1 and JAK2. In the case of JAK1, these waters were tightly associated with the piperidine moiety of the ligand at distances of 2.9 and 2.8 Å, respectively, while the association was looser in JAK2, 3.2 and 3.3 Å. The weaker interactions between the ligand and the waters residing beneath the JAK2 P-loop compared to their JAK1 counterparts likely reflect a slightly less optimal fit for compound <b>4</b> in the JAK2 ATP binding pocket and may be a contributing factor to the JAK1 vs JAK2 selectivity observed for compound <b>4</b>.</div><div class="NLM_p">A third crystallographic water molecule was observed to be associated with inhibitor <b>4</b> in the X-ray crystal structure in complex with JAK2. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b, this water molecule interacted with the available imidazole N lone pair of compound <b>4</b> at a distance of 2.8 Å. A similar interaction was observed in the X-ray structure of <b>4</b> in complex with JAK1 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a), where the hydrogen bond-accepting capacity of the imidazole unit was satisfied by a molecule of ethylene glycol, a component of the crystallization solution that presumably replaced a water molecule in the crystal lattice.</div><div class="NLM_p">The residue differences in the ATP-binding sites of JAK1 and JAK2 are highlighted in green in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a and Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>b. Compound <b>4</b> did not generally approach any of these closely enough to provide a clear justification for the observed isoform selectivity. One exception, however, was the E966 (JAK1) → D939 (JAK2) residue difference. In the case of JAK2, the <i>C</i>-2 methyl group was too far from the D939 side chain (5.1 Å) for an interaction to take place. By contrast, in JAK1, the <i>C</i>-2 methyl group of <b>4</b> approached a carboxylate O-atom of the E966 side chain within 3.4 Å, a distance similar to the combined van der Waals radii of the two moieties.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> The close approach of the <i>C</i>-2 methyl group to the JAK1 E966 side chain was suggestive of a potential interaction between the two groups and could be a further contributing factor to the JAK1 vs JAK2 selectivity profile of compound <b>4</b>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0002.jpeg" id="GRAPHIC-d4516e2552-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) X-ray structure of <b>4</b> in complex with JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EHZ">4EHZ</a>). (b) X-ray structure of <b>4</b> in complex with JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F09">4F09</a>). Compound <b>4</b> is depicted in orange. Hydrogen bonds to the ligand are depicted as dashed black lines. Backbone hinge atoms contacting <b>4</b> are highlighted (E957 and L959 for JAK1; E930 and L932 for JAK2). Notable crystallographic waters are denoted as red spheres (waters modeled into electron density peaks of >1.5σ). A molecule of ethylene glycol (teal) is observed in part a. The double-headed black arrows highlight the proximity of the <i>C</i>-2 methyl group of the ligand to a key residue difference between JAK1 (E966) and JAK2 (D939). The resolutions of the X-ray structures are 2.2 Å for JAK1 (a) and 2.4 Å for JAK2 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to further understand the effect of the <i>C</i>-2 methyl group on JAK potency, the bound conformations of ligands <b>3</b> and <b>4</b> were examined in more detail. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, the crystallographically determined conformations of <b>3</b> in complex with JAK2 and of <b>4</b> in complex with both JAK1 and JAK2 were all found to be virtually identical. We therefore concluded that the <i>C</i>-2 methyl substituent was unlikely to have a large impact upon the bound conformations of ligands in either JAK1 or JAK2.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0003.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Bound conformations of <b>3</b> in complex with JAK2 (green) and of <b>4</b> in complex with JAK1 (pink) and JAK2 (yellow) determined by X-ray crystallography. For clarity, the structures of the proteins have been omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To ascertain whether the methyl group impacted <i>unbound</i> conformations, quantum mechanical (QM) calculations<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> were performed using two aqueous solvent models. As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>, these calculations identified two distinct local minimum energy conformations of unbound <b>3</b> and <b>4</b>. One local minimum (<b>out</b>) oriented the piperidine ring junction H atom away from the tricyclic core and was equivalent to the bound conformations observed experimentally in the X-ray structures (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). The other local minimum (<b>in</b>) rotated the piperidine moiety by 180° such that the ring junction H atom pointed toward the tricyclic core. Both QM models indicated that the experimentally observed bound conformation for compound <b>3</b> (<b>3</b><sub><b>out</b></sub>) was higher in energy than its rotational isomer <b>3</b><sub><b>in</b></sub> by 0.8 kcal/mol. Additional QM calculations using the same solvent models indicated that addition of the methyl group to the <i>C</i>-2 position of the tricyclic core (compound <b>4</b>) reversed the bias of the unbound ligand such that <b>4</b><sub><b>out</b></sub> was predicted to be 0.9–1.0 kcal/mol lower in energy than the rotational isomer <b>4</b><sub><b>in</b></sub>. The preference of ligand <b>4</b> for the bound conformation could contribute to its greater potency against JAK1 and JAK2 relative to compound <b>3</b>. The conformational bias of compound <b>4</b> toward the bound conformation does not, however, offer additional insight into why it is more JAK1 selective than compound <b>3</b>. We consider it likely that the observed potency and selectivity profiles are influenced by multiple factors including the ligands’ interactions with crystallographic waters, the close approach of <i>C</i>-2 methyl substituted analogues to E966 in JAK1, and the different conformational preferences of the unbound ligands.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0004.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Relative energies of <b>out</b> vs <b>in</b> conformations of compounds <b>3</b> and <b>4</b> calculated with aqueous solvent models.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>, the X-ray structure of compound <b>20</b> in complex with JAK1 displayed several similar attributes to the corresponding structure of <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a). The pyrrolopyridine moiety present in <b>20</b> anchored it to the L959 and E957 hinge residues of the ATP-binding site. The <i>C</i>-2 methyl group resident in <b>20</b> approached the E966 side chain within 3.5 Å, again potentially contributing to the biochemical JAK1 vs JAK2 selectivity profile. The free imidazole lone pair of <b>20</b> was satisfied by an interaction with a crystallographic water observed at a distance of 2.9 Å from the ligand. Reminiscent of the piperidine moiety of compound <b>4</b>, the substituted cyclohexane ring present in <b>20</b> extended beneath the P-loop of JAK1 in a chair conformation, adopting the <b>out</b> rotational isomer and placing the tricyclic core in an equatorial disposition. As further demonstrated by Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>, a water molecule was observed beneath the P-loop in a location similar to one of the crystallographic waters associating with the piperidine moiety of <b>4</b>. However, unlike <b>4</b>, there was no hydrogen bond interaction between this water molecule and ligand <b>20</b>. The water was instead pushed into the back pocket by ∼1 Å, presumably because of the hydrophobic environment created by the cyclohexane. Additionally, the axial hydroxyl group pendent to the cyclohexane ring of <b>20</b> formed a hydrogen bond with the backbone carbonyl oxygen of a residue conserved between JAK1 and JAK2 (R1007 in JAK1) at a distance of 2.7 Å. Although the corresponding X-ray structure in complex with JAK2 was not generated, it is likely that a similar interaction takes place between <b>20</b> and JAK2 as well.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0005.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray structure of <b>20</b> in complex with JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EI4">4EI4</a>). Compound <b>20</b> is depicted in orange. Hydrogen bonds to the ligand are depicted as dashed black lines. The backbone hinge atoms contacting <b>20</b> are highlighted (E957 and L959). An additional residue (R1007) forming a hydrogen bond with <b>20</b> is shown in white. Notable crystallographic waters are denoted as red spheres (waters modeled into electron density peaks of >1.5σ). The double-headed black arrow highlights the proximity of the <i>C</i>-2 methyl group of the ligand to a key residue difference between JAK1 (E966) and JAK2 (D939). The resolution of the X-ray structure is 2.2 Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32422" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32422" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, preparation of the <i>C</i>-2 methylimidazopyrrolopyridine analogues <b>4</b>–<b>24</b> commenced with S<sub>N</sub>Ar substitution of activated aryl chloride <b>25</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> with amines <b>5a</b>, <b>7a</b>–<b>14a</b>, and <b>18a</b>–<b>24a</b> to deliver nitro anilines <b>5b</b>, <b>7b</b>–<b>14b</b>, and <b>18b</b>–<b>24b</b>. Reduction of the nitro groups under catalytic hydrogenation or reducing metal conditions led to dianilines <b>5c</b>, <b>7c</b>–<b>14c</b>, and <b>18c</b>–<b>24c</b>. Two subsequent general methods were then used to effect conversion to the corresponding <i>C</i>-2 methylimidazoles (intermediates <b>d</b>). The dianilines <b>c</b> could be treated with triethyl orthoacetate in the presence of acid to promote cyclization and dehydration and afford the corresponding <i>C</i>-2 methyl imidazoles <b>d</b>. Alternatively, it was possible to access these imidazoles by engaging the dianiline precursors <b>c</b> with an in situ generated imidate reagent produced by the action of triethyloxonium tetrafluoroborate on acetamide. After imidazole formation, the <b>d</b> series of intermediates was subjected to basic hydrolysis conditions to remove the phenylsulfonamide protecting groups liberating the corresponding free indoles <b>10e</b>–<b>14e</b> and <b>5</b>, <b>7</b>–<b>9</b>, and <b>18</b>–<b>24</b>. The <i>N</i>-benzyl group protecting intermediate <b>10e</b> was removed under transfer hydrogenolysis conditions at ambient atmospheric pressure to afford N-unsubstituted 3-piperidine <b>10</b>. The benzyl group resident in difluoropiperidine <b>13e</b> was found to be more resilient toward deprotection, and recourse to a high pressure, continuous flow H-Cube reactor was necessary to effect its removal to afford <b>13</b>. The Boc groups protecting monofluoropiperidines <b>11e</b> and <b>12e</b> and 4-aminocyclohexane <b>14e</b> were removed with acid to provide final compounds <b>11</b> and <b>12</b> and intermediate <b>14f</b>, respectively. <b>14f</b> was converted to final products <b>14</b>, <b>15</b>, <b>16</b>, and <b>17</b> by reaction of the primary amine with acrylonitrile, methanesulfonyl chloride, acetic anhydride, and methyl chloroformate, respectively. A portion of <i>N-</i>benzyl protected piperidine <b>5</b>, prepared above, was converted to free piperidine <b>4</b> via transfer hydrogenolysis conditions under ambient atmospheric pressure. Finally, a portion of <b>4</b> was converted to <b>6</b> by alkylation of the free amine of the piperidine group with acrylonitrile.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0006.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of <i>C</i>-2 Methylimidazopyrrolopyridine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DIPEA, <i>i</i>-PrOH, 65–120 °C; (ii) Fe, NH<sub>4</sub>Cl, MeOH, H<sub>2</sub>O, reflux; (ii′) H<sub>2</sub>, Pd/C, EtOH, THF, 50 °C; (iii) triethyl orthoacetate, <i>p</i>-TsOH, toluene, reflux; (iii′) acetamide, Et<sub>3</sub>(O<sup>+</sup>)BF<sub>4</sub><sup>–</sup>, THF, EtOH, 25 → 70 °C; (iv) NaOH, H<sub>2</sub>O, MeOH or EtOH, 50 °C; (v) Pd(OH)<sub>2</sub>, ammonium formate, MeOH, 75 °C; (v′) H-Cube, Pd(OH)<sub>2</sub> cartridge, 50 psi, 80 °C; (vi) TFA, H<sub>2</sub>O, 25 °C; (vii) acrylonitrile, EtOH, 75 °C; (viii) MsCl, DIPEA, THF, 25 °C; (ix) Ac<sub>2</sub>O, DIPEA, THF, 25 °C (x) methyl chloroformate, DIPEA, THF, 25 °C.</p><p><span class="fn-label">Scheme b</span>Relative stereochemistry between substituents on piperidine, cyclohexane, or cyclopentane rings.</p><p><span class="fn-label">Scheme c</span>Not applicable.</p><p><span class="fn-label">Scheme d</span>Racemic mixture.</p><p><span class="fn-label">Scheme e</span>Single enantiomer, (<i>S</i>)-stereochemistry.</p><p><span class="fn-label">Scheme f</span>Single enantiomer, (<i>R</i>,<i>R</i>)-stereochemistry</p><p class="last"><span class="fn-label">Scheme g</span>Enantiomers separated by preparative chiral SFC.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The <i>C</i>-2 methyl substituted imidazopyrrolopyridine analogue <b>4</b> was found to exhibit not only increased JAK1 inhibition but also increased JAK1 vs JAK2 selectivity relative to the unsubstituted analogue <b>3</b>. Differences observed between the X-ray structures of compound <b>4</b> in complex with JAK1 and JAK2 suggested hypotheses for the observed selectivity profile: (1) the close approach of the <i>C</i>-2 methyl group of <b>4</b> to E966 in JAK1 but not D939 in JAK2; (2) the tighter association between ligand <b>4</b> and crystallographic waters under the P-loop of JAK1 compared with the corresponding waters in JAK2. Additionally, an analysis comparing the QM-calculated solution conformations of imidazopyrrolopyridines <b>3</b> and <b>4</b> to their bound X-ray structures in complex with JAK1 and/or JAK2 indicated that the <i>C</i>-2 methyl group’s enforcement of the bound conformation likely contributed to the increased potency of <b>4</b>. Despite the increased JAK1 potency and selectivity of compound <b>4</b>, suboptimal membrane permeability limited its plasma exposure after oral administration in the rat and precluded its progression as an orally administered therapeutic. As such, an optimization campaign was undertaken in the <i>C</i>-2 methylimidazopyrrolopyridine series aimed at improving the permeability and oral exposure of <b>4</b> while maintaining measurable selectivity for JAK1 over JAK2. Compound <b>20</b>, the end result of this optimization effort, possessed a favorable balance of in vitro properties, leading to promising levels of oral exposure in the rat despite relatively high iv clearance. In the dog, excellent oral exposure of <b>20</b> was observed, consistent with low iv clearance, good MDCK permeability, and high aqueous solubility. Furthermore, compound <b>20</b> exhibited potent inhibition in an in vitro cell-based measure of JAK1 activity in the presence of human whole blood (whole blood IL6-pSTAT3 EC<sub>50</sub> = 160 nM) while maintaining significant cell-based selectivity for JAK1 over JAK2 (JAK1 cell-based selectivity index of 18-fold). The combination of favorable oral PK characteristics and potent whole blood activity allowed <b>20</b> to exert a substantial effect in an in vivo IL6-stimulated pSTAT3 PK/PD study in the mouse. On the basis of its balanced suite of favorable physicochemical properties, its potency and selectivity for JAK1, and promising in vivo PK profile, compound <b>20</b> was selected for further progression in preclinical in vitro and in vivo safety studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26020" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26020" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> General</h3><div class="NLM_p last">Unless otherwise indicated, all reagents and solvents were purchased from commercial sources and used without further purification. Moisture or oxygen sensitive reactions were conducted under an atmosphere of argon or nitrogen gas. Unless otherwise stated, <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded at 298–300 K using Varian Unity Inova or Bruker Avance DRX400 instruments operating at the indicated frequencies. Chemical shifts are expressed in ppm relative to an internal standard, tetramethylsilane (0.00 ppm). The following abbreviations are used: br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. Unless otherwise indicated, all <sup>13</sup>C peaks are singlets. Purification by silica gel chromatography was carried out using either hand-packed glass columns or Teledyne Isco CombiFlash systems with prepacked cartridges. Some basic compounds were purified by capture on SCX (strong cation exchange) sulfonic acid cartridges, followed by elution with methanolic ammonia. Racemic mixtures of final compounds were separated into individual enantiomers by chiral SFC under the indicated conditions. Chemical and chiral (where applicable) purities were >95% for all final compounds as assessed by LCMS and chiral SFC (supercritical fluid) analysis, respectively. Further details on the analytical conditions used for individual compounds may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. High resolution mass spectrometry (HRMS) data were collected on a Waters time of flight (LCT Premier XE) instrument using electrospray ionization.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> <i>N</i>-(1-Benzylpiperidin-4-yl)-5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>5b</b>)</h3><div class="NLM_p last">A mixture of 4-chloro-5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine (<b>25</b>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (500 mg, 1.48 mmol), 1-benzylpiperidin-4-amine (<b>5a</b>) (337 mg, 1.78 mmol), DIPEA (380 μL, 2.22 mmol), and <i>i</i>-PrOH (7.4 mL) was heated at 120 °C for 12 min using microwave irradiation. The cooled mixture was diluted with DCM (30 mL), loaded onto diatomaceous earth, and purified by chromatography on silica gel (gradient 0–50% EtOAc in DCM) to afford 499 mg (69%) of the title product as a yellow foam. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 9.10 (m, 2H), 8.19 (d, <i>J</i> = 7.9 Hz, 2H), 7.60 (m, 2H), 7.51 (t, <i>J</i> = 7.8 Hz, 2H), 7.30 (m, 5H), 6.69 (d, <i>J</i> = 4.2 Hz, 1H), 4.00 (m, 1H), 3.57 (s, 2H), 2.85 (m, 2H), 2.31 (m, 2H), 2.11 (m, 2H), 1.79 (m, 2H). LCMS (method LCMS1, ESI) <i>t</i><sub>R</sub> = 3.35 min, <i>m</i>/<i>z</i> = 492.6 [M + H]<sup>+</sup>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> <i>N</i><sup>4</sup>-(1-Benzylpiperidin-4-yl)-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-4,5-diamine (<b>5c</b>)</h3><div class="NLM_p last">A mixture of <b>5b</b> (442 mg, 899 μmol), iron powder (∼325 mesh, 201 mg, 3.60 mmol), and ammonium chloride (289 mg, 5.39 mmol) was suspended in a mixture of MeOH and water (3:1, 12 mL) and was heated at reflux for 4 h. The cooled mixture was filtered through Celite, washing with MeOH (50 mL). The filtrate was concentrated under vacuum, and the resulting residue was partitioned between a saturated aqueous sodium bicarbonate solution (25 mL) and DCM (25 mL). The layers were separated. Then the aqueous phase was re-extracted with DCM (2 × 25 mL). The combined organic extracts were washed with brine (25 mL), dried over sodium sulfate, filtered, and concentrated under vacuum to afford a dark pink residue. Purification by column chromatography on silica gel (gradient 0–10% MeOH in DCM) afforded 321 mg (77%) of the title compound as an off-white solid. LCMS (LCMS1, ESI): <i>t</i><sub>R</sub> = 2.55 min, <i>m</i>/<i>z</i> = 462.5 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> 1-(1-Benzylpiperidin-4-yl)-2-methyl-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>5d</b>)</h3><div class="NLM_p last">A mixture of <b>5c</b> (325 mg, 0.704 mmol), triethyl orthoacetate (394 μL, 2.16 mmol), and <i>p</i>-toluenesulfonic acid monohydrate (20.0 mg, 0.115 mmol) in toluene (10 mL) was heated to reflux for 20 h. After the mixture was cooled to room temperature, EtOAc (25 mL) was added. The organic phase was washed with a saturated aqueous solution of sodium hydrogen carbonate, water, and brine (1 × 20 mL each), then dried over sodium sulfate, filtered, and concentrated to dryness under vacuum. Purification of the residue by column chromatography on silica gel (gradient 0–50% EtOAc in DCM) gave 301 mg (88%) of the title compound as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.79 (s, 1H), 8.23 (d, <i>J</i> = 7.8 Hz, 2H), 7.85 (d, <i>J</i> = 4.0 Hz, 1H), 7.54 (t, <i>J</i> = 7.4 Hz, 1H), 7.46 (t, J = 7.7 Hz, 2H), 7.39 (m, 5H), 7.31 (m, 1H), 4.36 (m, 1H), 3.62 (s, 2H), 3.13 (m, 2H), 2.66 (s, 3H), 2.58 (m, 2H), 2.21 (t, <i>J</i> = 11.7 Hz, 2H), 1.85 (m, 2H). LCMS (method LCMS1, ESI): <i>t</i><sub>R</sub> = 3.16 min, <i>m</i>/<i>z</i> = 486.4 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 1-(1-Benzylpiperidin-4-yl)-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>5</b>)</h3><div class="NLM_p last">A mixture of <b>5d</b> (275 mg, 566 μmol) in MeOH (20 mL) was treated with a 1 M aqueous NaOH solution (5 mL) and stirred at room temperature for 18 h. The majority of the MeOH was removed under vacuum, and the resulting suspension was extracted with EtOAc (3 × 20 mL). The combined organic extracts were washed with water and brine (1 × 20 mL each), dried over sodium sulfate, filtered, and concentrated to dryness under vacuum. Purification of the residue by column chromatography on silica gel (gradient 0–10% MeOH in DCM) afforded a residue which was triturated with diethyl ether (10 mL) to give 137 mg (70%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.78 (s, 1H), 8.46 (s, 1H), 7.51 (t, <i>J</i> = 3.0 Hz, 1H), 7.41 (m, 4H), 7.28 (t, <i>J</i> = 7.1 Hz, 1H), 6.96 (s, 1H), 4.48 (m, 1H), 3.62 (s, 2H), 3.04 (d, <i>J</i> = 11.2 Hz, 2H), 2.62 (s, 3H), 2.57 (m, 2H), 2.23 (t, <i>J</i> = 11.7 Hz, 2H), 1.88 (d, <i>J</i> = 12.4 Hz, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.2, 144.2, 138.4, 134.6, 134.1, 132.0, 128.6, 128.3, 126.9, 123.6, 104.3, 99.5, 62.0, 54.9, 52.3 29.5, 14.4. LCMS (method LCMS2, ESI): <i>t</i><sub>R</sub> = 1.83 min, <i>m</i>/<i>z</i> = 346.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 346.2032; found, 346.2061.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 2-Methyl-1-(piperidin-4-yl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>4</b>)</h3><div class="NLM_p last">A mixture of <b>5</b> (1.70 g, 4.92 mmol), palladium hydroxide (20 wt % on carbon, 492 mg, 707 μmol), and ammonium formate (4.44 g, 70.6 mmol) in MeOH (120 mL) was heated at 75 °C for 3 h. The cooled mixture was filtered through Celite and concentrated to dryness under vacuum. The residue obtained was triturated with EtOAc (10 mL) to afford the crude title compound as a beige solid (1.1 g, 87%). Then 200 mg of the crude product was purified by preparative HPLC (column, Phenomenex Gemini C18, 21.2 cm × 250 cm, 5 μm; detection, UV 254 nm; mobile phase A, water containing 0.1% NH<sub>4</sub>OH; mobile phase B, CH<sub>3</sub>CN containing 0.1% NH<sub>4</sub>OH; flow rate of 18 mL/min; gradient 5–30% B over 15 min) and then by an Isolute SCX-2 column chromatography (gradient, MeOH to 2 M NH<sub>3</sub> in MeOH) to afford 78 mg of the pure title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (s, 1H), 8.45 (s, 1H), 7.43 (t, <i>J</i> = 3.0 Hz, 1H), 6.96 (s, 1H), 4.48 (s, 1H), 3.16 (d, <i>J</i> = 12.2 Hz, 2H), 2.71 (t, <i>J</i> = 12.2 Hz, 2H), 2.62 (s, 3H), 2.38 (m, 3H), 1.79 (d, <i>J</i> = 12.1 Hz, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.2, 144.3, 134.6, 134.1, 132.2, 123.3, 104.2, 100.1, 53.4, 45.6, 30.6, 14.5. LCMS (method LCMS2, ESI): <i>t</i><sub>R</sub> = 0.68 min, <i>m</i>/<i>z</i> = 256.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 256.1562; found, 256.1574.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 3-(4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)piperidin-1-yl)propanenitrile (<b>6</b>)</h3><div class="NLM_p last">Compound <b>4</b> was treated with conditions similar to those used to convert <b>14f</b> to <b>14</b> (vide infra), to produce the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.73 (s, 1H), 8.45 (s, 1H), 7.42–7.35 (m, 1H), 6.94 (s, 1H), 4.48 (m, 1H), 3.12 (d, <i>J</i> = 11.3 Hz, 2H), 2.81–2.66 (m, 4H), 2.62 (s, 3H), 2.59–2.52 (m, 2H), 2.29 (t, <i>J</i> = 11.0 Hz, 2H), 1.90 (d, <i>J</i> = 8.3 Hz, 2H). LCMS (method LCMS2, ESI) <i>t</i><sub>R</sub> = 1.06 min, <i>m</i>/<i>z</i> = 309.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>N</i>-Cyclohexyl-5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-amine (<b>7b</b>)</h3><div class="NLM_p last">A mixture of <b>25</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a>(10.0 g, 29.6 mmol), cyclohexylamine (<b>7a</b>) (3.40 mL, 30.0 mmol), and DIPEA (11.0 mL, 65.0 mmol) in <i>i</i>-PrOH (150 mL) was heated at 80 °C for 14 h. The mixture was then cooled to 25 °C and stirred for an additional 6 h. A yellow solid precipitated from solution and was collected by vacuum filtration, then washed with <i>i</i>-PrOH (1 × 30 mL) and air-dried to afford the title compound as a yellow solid (10.45 g, 90%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.93 (s, 1H), 8.91 (s, 1H), 8.13 (d, <i>J</i> = 7.6 Hz, 2H), 7.82 (d, <i>J</i> = 4.1 Hz, 1H), 7.77 (t, <i>J</i> = 7.4 Hz, 1H), 7.66 (t, <i>J</i> = 7.8 Hz, 2H), 6.99 (d, <i>J</i> = 4.2 Hz, 1H), 4.12–4.01 (m, 1H), 2.02–1.93 (m, 2H), 1.76–1.54 (m, 3H), 1.55–1.38 (m, 4H), 1.33–1.20 (m, 1H). LCMS (method LCMS3, ESI): <i>t</i><sub>R</sub> = 1.33 min, <i>m</i>/<i>z</i> = 401.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>N</i><sup>4</sup>-Cyclohexyl-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridine-4,5-diamine (<b>7c</b>)</h3><div class="NLM_p last">A suspension of <b>7b</b> (10.0 g, 25.0 mmol) and palladium on carbon (2.7 g, 10%, wet, Degussa, E101 NE/W) in a 3:1 mixture of THF and EtOH (200 mL) was stirred under a hydrogen atmosphere (balloon) at 50 °C for 13 h. The reaction mixture was cooled to 25 °C and then was filtered through Celite. The filtrate was concentrated under reduced pressure to afford the crude title product (9.61 g, 100%) as a rose foam. LCMS (method LCMS3, ESI): <i>t</i><sub>R</sub> = 0.83 min, <i>m</i>/<i>z</i> = 371.2 [M + H]<sup>+</sup>. This material was used in subsequent reactions without additional purification or characterization.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 1-Cyclohexyl-2-methyl-6-(phenylsulfonyl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>7d</b>)</h3><div class="NLM_p last"><i>p</i>-Toluenesulfonic acid monohydrate (0.429 g, 2.26 mmol) was added to a solution of <b>7c</b> (1.04 g, 2.82 mmol) and triethyl orthoacetate (1.29 mL, 7.05 mmol) in toluene (10 mL) at 25 °C. The reaction mixture was heated at 105 °C for 13 h, then was cooled to 25 °C and partitioned between half-saturated aqueous NaHCO<sub>3</sub> solution (100 mL) and a 1:1 mixture of EtOAc and heptane (2 × 125 mL). The organic layers were dried over MgSO<sub>4</sub>, filtered, and the filtrate was concentrated under reduced pressure. Purification of the resulting solid by column chromatography on silica gel (gradient 0–8% MeOH in DCM) afforded the title product (0.572 g, 52%) as a beige solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.80 (s, 1H), 8.23 (d, <i>J</i> = 7.8 Hz, 2H), 7.80 (d, <i>J</i> = 4.0 Hz, 1H), 7.55 (t, <i>J</i> = 7.4 Hz, 1H), 7.47 (t, <i>J</i> = 7.7 Hz, 2H), 7.26 (s, 1H), 6.90 (br s, 1H), 4.43–4.25 (m, 1H), 2.67 (s, 3H), 2.30–2.11 (m, 2H), 2.11–1.99 (m, 3H), 1.99–1.81 (m, 2H), 1.57–1.41 (m, 2H). LCMS (method LCMS3, ESI): <i>t</i><sub>R</sub> = 0.99 min, <i>m</i>/<i>z</i> = 395.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 1-Cyclohexyl-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>7</b>)</h3><div class="NLM_p last">Sodium hydroxide (10 mL of a 1.0 M aqueous solution) was added to a solution of <b>7d</b> (0.574 g, 1.46 mmol) in MeOH (20 mL) at 25 °C. The reaction mixture was stirred at 50 °C for 14 h, then was cooled to 25 °C, and the majority of MeOH was removed under vacuum. The mixture was then partitioned between water (100 mL) and EtOAc (2 × 200 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and the filtrate was concentrated under reduced pressure. Purification of the residue by preparative HPLC (column, Gemini-NX, 5 cm × 10 cm, 10 μm; detection, UV 254 nm; mobile phase A, water containing 0.1% NH<sub>4</sub>OH; mobile phase B, CH<sub>3</sub>CN; flow rate of 18 mL/min; gradient 5–95% B over 15 min) afforded the title compound (0.181 g, 49%) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.77 (s, 1H), 8.45 (s, 1H), 7.45 (t, <i>J</i> = 2.9 Hz, 1H), 6.71 (s, 1H), 4.53–4.35 (m, 1H), 2.62 (s, 3H), 2.34–2.18 (m, 2H), 1.92 (t, <i>J</i> = 13.8 Hz, 4H), 1.78 (d, <i>J</i> = 11.3 Hz, 1H), 1.64–1.36 (m, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.2, 144.2, 134.6, 134.2, 132.0, 123.3, 104.0, 99.6, 54.6, 30.1, 25.1, 24.4, 14.4. LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 3.26 min, <i>m</i>/<i>z</i> = 255.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 255.1610; found, 255.1676.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 2-Methyl-1-(tetrahydro-2<i>H</i>-pyran-4-yl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>8</b>)</h3><div class="NLM_p last"><b>8</b> was synthesized by methods similar to those used for <b>7</b>, substituting 4-aminotetrahydropyran (<b>8a</b>) for cyclohexylamine (<b>7a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.82 (s, 1H), 8.47 (s, 1H), 7.48 (d, <i>J</i> = 3.1 Hz, 1H), 6.72 (d, <i>J</i> = 3.1 Hz, 1H), 4.75 (m, 1H), 4.11 (dd, <i>J</i> = 11.5, 4.7 Hz, 2H), 3.60 (t, <i>J</i> = 11.3 Hz, 2H), 2.65 (s, 3H), 2.60–2.49 (m, 2H), 1.87 (dd, <i>J</i> = 12.6, 4.3 Hz, 2H). LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 2.55 min, <i>m</i>/<i>z</i> = 257.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Methyl-1-(tetrahydro-2<i>H</i>-pyran-3-yl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>9</b>)</h3><div class="NLM_p last">(±)-<b>9</b> was synthesized by methods similar to those used for <b>7</b> and substituting (±)-3-aminotetrahydropyran (<b>9a</b>) for cyclohexylamine (<b>7a</b>). <b>9</b> was separated from <i>ent</i>-<b>9</b> by preparative chiral SFC (column, Chiralpak AD, 2.12 cm × 25 cm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, MeOH; flow rate of 50 mL/min; gradient, isocratic, A/B = 75:25). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>9</b>, analytical chiral SFC (method SFC1) <i>t</i><sub>R</sub> = 1.12 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.81 (s, 1H), 8.46 (s, 1H), 7.47 (s, 1H), 6.81 (d, <i>J</i> = 3.2 Hz, 1H), 4.61 (m, 1H), 4.01 (m, 3H), 3.75–3.56 (m, 1H), 2.65 (s, 3H), 2.56–2.46 (m, 1H, overlaps with DMSO-<i>d</i><sub>6</sub>), 2.09 (d, <i>J</i> = 14.7 Hz, 1H), 1.92 (m, 2H). LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 2.64 min, <i>m</i>/<i>z</i> = 257.1 [M + H]<sup>+</sup>. For <i>ent</i>-<b>9</b>, analytical chiral SFC (method SFC1) <i>t</i><sub>R</sub> = 1.28 min. <sup>1</sup>H NMR and LCMS data match those of <b>9</b>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (<i>S</i>)-2-Methyl-1-(piperidin-3-yl)-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>10</b>)</h3><div class="NLM_p last"><b>10</b> was synthesized by methods similar to those used for <b>4</b> and <b>5</b> and substituting (<i>S</i>)-1-benzylpiperidin-3-amine (<b>10a</b>) for 1-benzylpiperidin-4-amine (<b>5a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.76 (s, 1H), 8.45 (s, 1H), 7.45 (t, <i>J</i> = 3.0 Hz, 1H), 6.86–6.76 (m, 1H), 4.49 (s, 1H), 3.10–2.92 (m, 2H), 2.74–2.65 (m, 1H), 2.63 (s, 3H), 2.45–2.30 (m, 2H), 2.01 (d, <i>J</i> = 12.1 Hz, 1H), 1.85 (d, <i>J</i> = 12.3 Hz, 1H), 1.77–1.60 (m, 1H). LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 2.05 min, <i>m</i>/<i>z</i> = 256.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (±)-<i>trans</i>-<i>tert</i>-Butyl 3-Fluoro-4-(5-nitro-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-ylamino)piperidine-1-carboxylate (<b>11b</b>)</h3><div class="NLM_p last">A mixture of <b>25</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (1.77 g, 5.23 mmol), (±)-<i>trans</i>-<i>tert</i>-butyl 4-amino-3-fluoropiperidine-1-carboxylate (<b>11a</b><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>) (878 mg, 4.02 mmol), and DIPEA (1.65 mL, 9.50 mmol) in <i>i</i>-PrOH (10 mL) was stirred overnight at 82 °C, then cooled to room temperature. An off-white solid precipitated from solution and was collected by filtration and washed with water to yield 1.62 g (78%) of the title compound. This material was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.96–8.89 (m, 2H), 8.13 (d, <i>J</i> = 7.4, 2H), 7.86–7.83 (m, 1H), 7.76 (t, <i>J</i> = 8.0 Hz, 1H), 7.65 (t, <i>J</i> = 8.0 Hz, 2H), 7.20–7.15 (m, 1H), 4.88–4.69 (m, 1H), 4.57–4.41 (m, 1H), 4.18–4.04 (m, 1H), 3.88–3.74 (m, 1H), 3.26–3.02 (m, 2H), 2.08–1.96 (m, 1H), 1.81–1.69 (m, 1H), 1.42 (s, 9H). LCMS (method LCMS5, ESI): <i>t</i><sub>R</sub> = 1.22 min, <i>m</i>/<i>z</i> = 520.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> (±)-<i>trans</i>-<i>tert</i>-Butyl 4-(5-Amino-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-ylamino)-3-fluoropiperidine-1-carboxylate (<b>11c</b>)</h3><div class="NLM_p last">10% palladium on activated carbon (0.025 g, 0.023 mmol) was added to <b>11b</b> (0.618 g, 1.19 mmol) in EtOAc (10 mL), and the mixture was stirred at 50 °C under an atmosphere of hydrogen (balloon) for 16 h. The mixture was then filtered through diatomaceous earth and the filtrate concentrated under vacuum to give 540 mg (92%) of the title compound as an off-white solid. This material was used immediately in the next step without further purification. LCMS (method LCMS5, ESI): <i>t</i><sub>R</sub> = 0.88 min, <i>m</i>/<i>z</i> = 490.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> (±)-<i>trans</i>-<i>tert</i>-Butyl 3-Fluoro-4-(2-methyl-6-(phenylsulfonyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)piperidine-1-carboxylate (<b>11d</b>)</h3><div class="NLM_p last">A mixture of <b>11c</b> (0.540 g, 1.10 mmol) and triethyl orthoacetate (1.01 mL, 5.52 mmol) in acetic acid (5 mL) was heated at 120 °C for 10 min. The mixture was then cooled to room temperature and concentrated under vacuum. Purification of the residue by column chromatography on silica gel (gradient 0–100% (20% MeOH/EtOAc) in heptane) gave 476 mg (84%) of the title compound as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 8.66 (s, 1H), 8.16 (d, <i>J</i> = 7.3 Hz, 2H), 7.94 (d, <i>J</i> = 3.7 Hz, 1H), 7.71 (t, <i>J</i> = 7.4 Hz, 1H), 7.62 (t, <i>J</i> = 7.8 Hz, 2H), 6.48 (br, 1H), 5.17–5.08 (m, 1H), 5.02–4.93 (m, 2H), 4.48–4.35 (m, 1H), 4.19–4.07 (m, 1H), 3.22–3.05 (m, 1H), 2.63 (s, 3H), 2.31–2.19 (m, 1H), 2.19–2.08 (m, 1H), 1.49 (s, 9H). LCMS (method LCMS5, ESI): <i>t</i><sub>R</sub> = 1.07 min, <i>m</i>/<i>z</i> = 514.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (±)-<i>trans</i>-<i>tert</i>-Butyl 3-Fluoro-4-(2-methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)piperidine-1-carboxylate (<b>11e</b>)</h3><div class="NLM_p last">Sodium hydroxide (1 M aqueous solution, 5 mL) was added to a mixture of <b>11d</b> (0.476 g, 0.927 mmol) in EtOH (5 mL) and tetrahydrofuran (8 mL). The reaction mixture was heated at 50 °C for 2 h. The mixture was then cooled to room temperature and concentrated under vacuum. Purification of the residue by column chromatography on silica gel (gradient 0–100% (20% MeOH/EtOAc) in heptane) gave 238 mg (69%) of the title compound as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.93 (s, 1H), 8.51 (s, 1H), 7.42 (s, 1H), 6.19 (s, 1H), 5.28–5.21 (m, 1H), 5.12–5.08 (m, 1H), 4.98–4.87 (m, 1H), 4.48–4.35 (m, 1H), 4.19–4.07 (m, 1H), 3.22–3.05 (m, 2H), 2.62 (s, 3H), 2.19–2.08 (m, 1H), 1.52 (s, 9H). LCMS (method LCMS5, ESI): <i>t</i><sub>R</sub> = 0.14 min, <i>m</i>/<i>z</i> = 374.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>trans</i>-1-(4-Fluoropiperidin-3-yl)-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>11</b>)</h3><div class="NLM_p last">To a mixture of <b>11e</b> (238 mg, 0.637 mmol) in dioxane (5 mL) was added HCl (4 M solution in dioxane, 1 mL). The reaction mixture was stirred at room temperature for 2 h, then concentrated to dryness under vacuum to give the crude racemic title product. <b>11</b> was separated from <i>ent</i>-<b>11</b> by preparative chiral SFC (column, Chiralpak IC, 21.2 mm × 250 mm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, MeOH containing 0.1% DEA; flow rate of 50 mL/min; gradient, isocratic, A/B = 70:30). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>11</b>, white solid (36.5 mg, 21%). Analytical chiral SFC (method SFC2): <i>t</i><sub>R</sub> = 0.89 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.83 (s, 1H), 8.49 (s, 1H), 7.47 (s, 1H), 6.86 (s, 1H), 5.34–5.10 (m, 1H), 4.71–4.52 (m, 1H), 3.59–3.41 (m, 1H), 3.15–3.02 (m, 1H), 2.83–2.64 (m, 3H), 2.60 (s, 3H), 2.07–1.93 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 150.1, 144.3, 134.8, 134.2, 131.3, 123.8, 103.9, 99.6, 88.5 (d, <i>J</i> = 176.7 Hz), 57.8 (d, <i>J</i> = 17.7 Hz), 49.6 (d, <i>J</i> = 22.3 Hz), 44.3, 30.6 (d, <i>J</i> = 5.2 Hz), 14.2. LCMS (method LCMS6, ESI): <i>t</i><sub>R</sub> = 3.70 min, <i>m</i>/<i>z</i> = 274.0 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 274.1468; found, 274.1463. For <i>ent</i>-<b>11</b>, white solid (31.3 mg, 18%). Analytical chiral SFC (method SFC2): <i>t</i><sub>R</sub> = 1.24 min. <sup>1</sup>H NMR and LCMS data match those for <b>11</b>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>cis</i>-1-(3-Fluoropiperidin-4-yl)-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>12</b>)</h3><div class="NLM_p last">(±)-<b>12</b> was synthesized by methods similar to those used for (±)-<b>11</b> and substituting (±)-<i>cis</i>-<i>tert</i>-butyl 4-amino-3-fluoropiperidine-1-carboxylate (<b>12a</b><a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a>) for (±)-<i>trans</i>-<i>tert</i>-butyl 4-amino-3-fluoropiperidine-1-carboxylate (<b>11a</b>). <b>12</b> was separated from <i>ent</i>-<b>12</b> by preparative chiral SFC (column, Chiralpak AD, 2.12 cm × 25 cm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, EtOH containing 0.1% DEA; flow rate of 40 mL/min; gradient, isocratic, A/B = 65:35). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>12</b>, white solid. Analytical chiral SFC (method SFC3): <i>t</i><sub>R</sub> = 1.34 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.68 (s, 1H), 8.44 (s, 1H), 7.38 (s, 1H), 6.86 (s, 1H), 4.90 (s, 1H), 4.78 (s, 1H), 3.25–2.94 (m, 4H), 2.86–2.73 (m, 2H), 2.65 (s, 3H), 1.81 (br, 1H). LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 0.75 min, <i>m</i>/<i>z</i> = 274.1 [M + H]<sup>+</sup>. For <i>ent</i>-<b>12</b>, white solid. Analytical chiral SFC (method SFC3): <i>t</i><sub>R</sub> = 1.91 min. <sup>1</sup>H NMR and LCMS data match those of <b>12</b>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (±)-1-(3,3-Difluoropiperidin-4-yl)-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>13</b>)</h3><div class="NLM_p last">(±)-1-(1-Benzyl-3,3-difluoropiperidin-4-yl)-2-methyl-1,6-dihydroimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridine (<b>13e</b>) was synthesized by methods similar to those used for <b>5</b> and substituting (±)-1-benzyl-3,3-difluoropiperidin-4-amine (<b>13a</b><a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a>) for 1-benzylpiperidin-4-amine (<b>5a</b>). A solution of <b>13e</b> (69.0 mg, 0.181 mmol) in THF (6 mL) was hydrogenated on a ThalesNano H-Cube continuous-flow hydrogenation reactor (1 mL/min, 50 psi, 80 °C, one pass) using a 20% Pd(OH)<sub>2</sub>/C CatCart. The effluent was collected and concentrated to dryness under vacuum. The residue was purified by preparative HPLC (column, Gemini-NX, 3 cm × 10 cm, 10 μm; detection, UV 254 nm; mobile phase A, water containing 0.1% NH<sub>4</sub>OH; mobile phase B, CH<sub>3</sub>CN containing 0.1% NH<sub>4</sub>OH; flow rate of 20 mL/min; gradient 5–95% B over 15 min) to afford 25.0 mg (47%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 360 K) δ: 11.16 (br, 1H), 8.43 (s, 1H), 7.30 (d, <i>J</i> = 3.5 Hz, 1H), 6.80 (t, <i>J</i> = 3.3 Hz, 1H), 5.01 (br, 1H), 3.30 (t, <i>J</i> = 13.3 Hz, 1H), 3.23–3.04 (m, 2H), 2.94–2.82 (m, 2H), 2.63 (s, 3H), 2.62–2.54 (m, 1H), 2.04 (br, 1H). LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 1.98 min, <i>m</i>/<i>z</i> = 292.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>trans</i>-<i>tert</i>-Butyl 4-(2-Methyl-6-(phenylsulfonyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexylcarbamate (<b>14d</b>)</h3><div class="NLM_p last"><i>trans</i>-<i>tert</i>-Butyl 4-(5-amino-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-ylamino)cyclohexylcarbamate (<b>14c</b>) was synthesized by methods similar to those used for <b>7c</b>, substituting <i>trans</i>-<i>tert</i>-butyl 4-aminocyclohexylcarbamate (<b>14a</b>) for cyclohexylamine (<b>7a</b>). A mixture of <b>14c</b> (10.0 g, 20.6 mmol), triethyl orthoacetate (15.0 mL, 82.4 mmol), and acetic acid (120 mL) was heated to reflux for 20 min. After cooling to room temperature, the mixture was concentrated to dryness under vacuum. The residue was dissolved in EtOAc (150 mL), and the organic layer was washed with aqueous saturated sodium hydrogen carbonate solution (3 × 50 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated to dryness under vacuum. Purification of the residue by column chromatography on silica gel (gradient, DCM to neat EtOAc to 5% MeOH in EtOAc) and trituration (diethyl ether, 20 mL) provided 8.30 g (79%) of the title compound as a gray solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.80 (s, 1H), 8.23 (m, 2H), 7.81 (d, <i>J</i> = 4.1 Hz, 1H), 7.51 (m, 3H), 6.86 (br s, 1H), 4.50 (m, 1H), 4.35 (m, 1H), 3.74 (m, 1H), 2.68 (s, 3H), 2.34 (m, 4H), 1.98 (m, 2H), 1.48 (s, 9H), 1.43 (m, 2H). LCMS (method LCMS7, ESI): <i>t</i><sub>R</sub> = 3.29 min, <i>m</i>/<i>z</i> = 510.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>trans</i>-<i>tert</i>-Butyl 4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexylcarbamate (<b>14e</b>)</h3><div class="NLM_p last">Aqueous sodium hydroxide solution (29.4 mL, 2.0 M) was added to a solution of <b>14d</b> (6.00 g, 11.8 mmol) in MeOH (150 mL) and THF (150 mL). The reaction mixture was stirred at room temperature for 5 h, then extracted with DCM (3 × 75 mL). The combined organic extracts were washed with brine (1 × 50 mL), then dried over sodium sulfate, filtered, and concentrated to dryness under vacuum. The resulting residue was triturated (DCM, 10 mL) and air-dried to afford 3.08 g (71%) of the title compound as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.80 (s, 1H), 8.45 (s, 1H), 7.49 (m, 1H), 6.95 (d, <i>J</i> = 7.3 Hz, 1H), 6.64 (d, <i>J</i> = 3.3 Hz, 1 H), 4.42 (m, 1H), 3.56 (m, 1H), 2.63 (s, 3H), 2.35 (m, 2H), 1.96 (m, 4H), 1.51 (m, 2H), 1.42 (s, 9H). LCMS (method LCMS7, ESI): <i>t</i><sub>R</sub> = 2.18 min, <i>m</i>/<i>z</i> = 370.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>trans</i>-4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanamine (<b>14f</b>)</h3><div class="NLM_p last">To a slurry of <b>14e</b> (3.08 g, 8.34 mmol) and water (150 mL) was added trifluoroacetic acid (25 mL) at room temperature. The mixture was stirred for 2 h and then concentrated to dryness under vacuum. Purification of the residue by flash chromatography (SCX-2, gradient, MeOH to 2 M NH<sub>3</sub> in MeOH) afforded the title compound as a colorless oil (2.24 g, 100%) which was used directly in the next step without further purification. LCMS (method LCMS7, ESI): <i>t</i><sub>R</sub> = 0.55 and 0.67 min, <i>m</i>/<i>z</i> = 270.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>trans</i>-3-(4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexylamino)propanenitrile (<b>14</b>)</h3><div class="NLM_p last">A mixture of <b>14f</b> (2.24 g, 8.34 mmol) and acrylonitrile (2.75 mL, 41.7 mmol) in EtOH (100 mL) was heated to 80 °C for 2 h. After cooling to room temperature, the reaction mixture was concentrated to dryness under vacuum. The residue was triturated with diethyl ether and EtOAc (10 mL each) and air-dried. Purification of the resulting solid by column chromatography on silica gel (gradient 0–20% [2 M NH<sub>3</sub> in MeOH] in DCM) followed by trituration with acetonitrile (3 mL) afforded 750 mg (28%) of the title compound as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.77 (s, 1H), 8.45 (s, 1H), 7.44 (t, <i>J</i> = 3.0 Hz, 1H), 6.70 (s, 1Hs), 4.45 (m, 1H), 2.87 (m, 2H), 2.77 (m, 1H), 2.62 (m, 5H), 2.33 (m, 2H), 2.09 (d, <i>J</i> = 12.5 Hz, 2 H), 1.92 (m, 3H), 1.37 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.3, 144.2, 134.6, 134.2, 123.5, 120.2, 104.0, 99.6, 54.3, 42.0, 31.8, 28.8, 18.4, 14.4. LCMS (method LCMS2, ESI): <i>t</i><sub>R</sub> = 1.24 min, <i>m</i>/<i>z</i> = 323.2 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 323.1984; found, 323.1999.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>trans</i>-<i>N</i>-(4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)methanesulfonamide (<b>15</b>)</h3><div class="NLM_p last">Methanesulfonyl chloride (24 μL, 0.31 mmol) was added to a solution of <b>14f</b> (67.5 mg, 0.251 mmol) and triethylamine (105 μL, 0.75 mmol) in DCM (2 mL) at room temperature, and the reaction mixture was stirred for 16 h. The reaction mixture was loaded directly onto a silica gel column, eluting with a gradient of 0–10% MeOH in EtOAc. The appropriate fractions were collected and concentrated to dryness under vacuum. The residue was triturated with water (1 mL), then heated at 40 °C under vacuum for 16 h to afford the title compound as a white solid (44.1 mg, 51%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.78 (s, 1H), 8.45 (s, 1H), 7.47 (t, <i>J</i> = 3.0 Hz, 1H), 7.16 (d, <i>J</i> = 7.0 Hz, 1H), 6.72 (dd, <i>J</i> = 3.5, 1.9 Hz, 1 H), 4.43 (m, 1H), 3.46 (m, 1H), 3.02 (s, 3H), 2.63 (s, 3H), 2.37 (m, 2H), 2.13 (d, <i>J</i> = 12.6 Hz, 2H), 1.92 (d, <i>J</i> = 12.3 Hz, 2 H), 1.61 (t, <i>J</i> = 12.8 Hz, 2H). LCMS (method LCMS2, ESI) <i>t</i><sub>R</sub> = 2.00 min, <i>m</i>/<i>z</i> = 348.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>trans</i>-<i>N</i>-(4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexyl)acetamide (<b>16</b>)</h3><div class="NLM_p last">Acetic anhydride (21 μL, 0.22 mmol) was added to a mixture of <b>14f</b> (54.3 mg, 0.202 mmol) and DIPEA (44 μL, 0.25 mmol) in DCM (2 mL). The reaction mixture was stirred for 1 h at room temperature, then concentrated to dryness under vacuum. The residue was purified by column chromatography on silica gel (gradient 0–10% [2 M NH<sub>3</sub> in MeOH] in DCM) to give the title compound (50.2 mg, 87%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.80 (s, 1H), 8.46 (s, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 1H), 7.49 (t, <i>J</i> = 3.0 Hz, 1H), 6.65 (dd, <i>J</i> = 3.4, 1.9 Hz, 1H), 4.48 (m, 1H), 3.83 (m, 1H), 2.64 (s, 3H), 2.36 (m, 2H), 2.98 (m, 4H), 1.84 (s, 3H), 1.52 (m, 2H). LCMS (method LCMS2, ESI) <i>t</i><sub>R</sub> = 1.89 min, <i>m</i>/<i>z</i> = 312.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>trans</i>-Methyl 4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexylcarbamate (<b>17</b>)</h3><div class="NLM_p last"><b>17</b> was synthesized by methods similar to those used for <b>16</b> and substituting methyl chloroformate for acetic anhydride. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.80 (s, 1H), 8.45 (s, 1H), 7.49 (t, <i>J</i> = 3.0 Hz, 1H), 7.25 (s, 1H), 6.64 (s, 1H), 4.45 (s, 1H), 3.56 (m, 4H), 2.63 (s, 3H), 2.35 (m, 2H), 2.04 (m, 2H), 1.94 (m, 2H), 1.52 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 155.9, 149.3, 144.2, 134.7, 134.1, 131.9, 123.6, 103.9, 99.3, 59.7, 53.6, 51.1, 48.5, 31.2, 14.0. LCMS (method LCMS2, ESI) <i>t</i><sub>R</sub> = 2.18 min, <i>m</i>/<i>z</i> = 328.3 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 328.1773; found, 328.1761.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>trans</i>-4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>18</b>)</h3><div class="NLM_p last"><b>18</b> was synthesized by methods similar to those used for <b>20</b> (vide infra) and substituting <i>trans</i>-4-aminocyclohexanol (<b>18a</b>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.75 (s, 1H), 8.44 (s, 1H), 7.44 (t, <i>J</i> = 2.9 Hz, 1H), 6.65 (s, 1H), 4.76 (d, <i>J</i> = 3.9 Hz, 1H), 4.46 (br s, 1H), 3.77 (br s, 1H), 2.62 (s, 3H), 2.38–2.26 (m, 2H), 2.03 (d, <i>J</i> = 11.1 Hz, 2H), 1.88 (d, <i>J</i> = 11.2 Hz, 2H), 1.67–1.46 (m, 2H). LCMS (method LCMS4, ESI) <i>t</i><sub>R</sub> = 2.42 min, <i>m</i>/<i>z</i> = 271.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> <i>cis</i>-4-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>19</b>)</h3><div class="NLM_p last"><b>19</b> was synthesized by methods similar to those used for <b>20</b> (vide infra) and substituting <i>cis</i>-4-aminocyclohexanol (<b>19a</b>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.66 (s, 1H), 8.43 (s, 1H), 7.39 (d, <i>J</i> = 2.3 Hz, 1H), 7.36 (s, 1H), 4.87 (s, 1H), 4.41 (br, 1H), 4.03 (s, 1H), 2.76–2.61 (m, 2H), 2.61 (s, 3H), 1.88 (d, <i>J</i> = 13.2 Hz, 2H), 1.70 (t, <i>J</i> = 13.5 Hz, 2H), 1.61 (d, <i>J</i> = 11.7 Hz, 2H). LCMS (method LCMS4, ESI) <i>t</i><sub>R</sub> = 2.54 min, <i>m</i>/<i>z</i> = 271.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (1<i>R</i>,3<i>R</i>)-3-(5-Amino-1-(phenylsulfonyl)-1<i>H</i>-pyrrolo[2,3-<i>b</i>]pyridin-4-ylamino)cyclohexanol (<b>20c</b>)</h3><div class="NLM_p last">(1<i>R</i>,3<i>R</i>)-3-Aminocyclohexanol (<b>20a</b>,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> 8.91 g, 76.3 mmol) was added to a stirred suspension of <b>25</b><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> (24.5 g, 72.6 mmol) and DIPEA (13.3 mL, 76.3 mmol) in MeOH (120 mL) at room temperature. The reaction mixture was heated to 65 °C and stirred at that temperature for 3 h. The mixture was then cooled to room temperature, and 10% palladium on carbon (7.6 g, 3.6 mmol) was added. The reaction mixture was pressurized to 100 psi with hydrogen and stirred at room temperature for 18 h. The reaction mixture was filtered, and the filtrate was concentrated to dryness under vacuum to afford the title compound as a thick yellow oil. LCMS (method LCMS8, ESI): <i>t</i><sub>R</sub> = 2.17 min, <i>m</i>/<i>z</i> = 387.1 [M + H]<sup>+</sup>. This material was used immediately without further purification or characterization in the next step.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (1<i>R</i>,3<i>R</i>)-3-(2-Methyl-6-(phenylsulfonyl)imidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>20d</b>)</h3><div class="NLM_p last">Triethyloxonium tetrafluoroborate (22.8 g, 116 mmol) was added to a slurry of acetamide (7.11 g, 120 mmol) in tetrahydrofuran (THF) (125 mL). The reaction mixture was stirred for 1 h at room temperature. Then a solution of <b>20c</b> (31.0 g, 80.2 mmol) in EtOH (220 mL) was added. The reaction mixture was heated to 70 °C and stirred at that temperature for 2 h. The reaction mixture was then cooled to room temperature, and water (150 mL) was added. The mixture was extracted with 2-methyltetrahydrofuran (2 × 250 mL). Then the combined organic layers were dried over sodium sulfate, filtered, and concentrated to dryness. Ethanol (200 mL) was added, and the mixture was warmed to 50 °C. After a solution formed, the mixture was then cooled to room temperature, at which point a white solid precipitated. The solid was isolated by filtration, then dried under vacuum to afford the title compound (24.0 g, 73%) as a faintly yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.79 (s, 1H), 8.22 (d, <i>J</i> = 8.2 Hz, 2H), 7.78 (d, <i>J</i> = 4.0 Hz, 1H), 7.58–7.41 (m, 3H), 6.90 (s, 1H), 4.48–4.42 (m, 1H), 3.99–3.85 (m, 1H), 2.68 (s, 3H), 2.41–1.48 (m, 8H). LCMS (method LCMS8, ESI): <i>t</i><sub>R</sub> = 2.52 min, <i>m</i>/<i>z</i> = 411.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (1<i>R</i>,3<i>R</i>)-3-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>20</b>)</h3><div class="NLM_p last">An aqueous 1 M solution of sodium hydroxide (168 mL, 168 mmol) was added to a slurry of <b>20d</b> (24.0 g, 58.5 mmol) in EtOH (240 mL) at room temperature. The reaction mixture was stirred at 50 °C for 18 h, then cooled to room temperature. The majority of the EtOH was removed under vacuum. Then the residual mixture was extracted with methyl ethyl ketone (2 × 250 mL). The combined organic layers were washed with brine (1 × 100 mL), then dried over magnesium sulfate and filtered. The filtrate was concentrated to dryness and then <i>i</i>-PrOH (50 mL) was added to the residue. After the resulting slurry was stirred at room temperature for 24 h, the solid was isolated by filtration and dried under vacuum for 18 h to afford the title compound as a white solid (14.7 g, 93%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.77 (s, 1H), 8.44 (s, 1H), 7.43 (s, 1H), 6.67 (s, 1H), 4.79 (overlapping s and br s, 2H), 4.21 (s, 1H), 2.61 (s, 3H), 2.48–2.17 (m, 2H), 2.06–1.84 (m, 3H), 1.78 (d, <i>J</i> = 12.2 Hz, 1H), 1.74–1.58 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.1, 144.2, 134.6, 131.9, 123.5, 104.0, 99.5, 64.6, 50.0, 36.9, 30.9, 29.8, 19.1, 14.4. LCMS (method LCMS4, ESI): <i>t</i><sub>R</sub> = 2.71 min, <i>m</i>/<i>z</i> = 271.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 271.1559; found, 271.1596.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>cis</i>-3-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>21</b>)</h3><div class="NLM_p last">(±)-<b>21</b> was synthesized by methods similar to those used for <b>20</b> and substituting (±)-<i>cis</i>-3-aminocyclohexanol (<b>21a</b><a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <b>21</b> was separated from <i>ent</i>-<b>21</b> by preparative chiral SFC (column, Phenomenex Lux Cellulose-2, 21.2 mm × 250 mm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, EtOH containing 0.1% triethylamine; flow rate of 50 mL/min; gradient, isocratic, A/B = 70:30). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>21</b>, white solid. Analytical chiral SFC (method SFC4): <i>t</i><sub>R</sub> = 0.85 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.78 (s, 1H), 8.45 (s, 1H), 7.46 (t, <i>J</i> = 2.9 Hz, 1H), 6.69 (s, 1H), 4.87 (d, <i>J</i> = 4.9 Hz, 1H), 4.49 (br s, 1H), 3.74–3.63 (m, 1H), 2.61 (s, 3H), 2.28–2.02 (m, 3H), 1.97 (br d, <i>J</i> = 9.9 Hz, 1H), 1.89 (br d, <i>J</i> = 13.3 Hz, 1H), 1.83 (br d, <i>J</i> = 9.9 Hz, 1H), 1.59–1.27 (m, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.2, 144.2, 134.7, 134.2, 131.8, 123.5, 103.9, 99.7, 67.8, 52.9, 48.5, 34.2, 29.0, 21.7, 14.4. LCMS (method LCMS4, ESI) <i>t</i><sub>R</sub> = 2.63 min, <i>m</i>/<i>z</i> = 271.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 271.1559; found, 271.1571. For <i>ent</i>-<b>21</b>, white solid. Analytical chiral SFC (method SFC4): <i>t</i><sub>R</sub> = 0.71 min. <sup>1</sup>H NMR and LCMS data match those for <b>21</b>.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>trans</i>-2-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclohexanol (<b>22</b>)</h3><div class="NLM_p last">(±)-<b>22</b> was synthesized by methods similar to those used for <b>20</b> and substituting (±)-<i>cis</i>-2-aminocyclohexanol (<b>22a</b>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <b>22</b> was separated from <i>ent</i>-<b>22</b> by preparative chiral SFC (column, Chiralpak AD, 2.12 mm × 25 mm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, MeOH; flow rate of 50 mL/min; gradient, isocratic, A/B = 60:40). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>22</b>, white solid. Analytical chiral SFC (method SFC5): <i>t</i><sub>R</sub> = 0.74 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.72 (s, 1H), 8.45 (s, 1H), 7.42 (s, 1H), 6.58 (s, 1H), 4.83 (d, <i>J</i> = 5.5 Hz, 1H), 4.28–4.16 (m, 1H), 4.14–4.06 (m, 1H), 2.58 (s, 3H), 2.41–2.30 (m, 1H), 2.10 (br d, <i>J</i> = 12.1 Hz, 1H), 1.95–1.73 (m, 3H), 1.65–1.38 (m, 3H). LCMS (method LCMS4, ESI) <i>t</i><sub>R</sub> = 2.87 min, <i>m</i>/<i>z</i> = 271.0 [M + H]<sup>+</sup>. For <i>ent</i>-<b>22</b>, white solid. Analytical chiral SFC (method SFC5): <i>t</i><sub>R</sub> = 0.52 min. <sup>1</sup>H NMR and LCMS data match those of <b>22</b>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>trans</i>-3-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclopentanol (<b>23</b>)</h3><div class="NLM_p last">An amount of 1.6 g (3.1 mmol) of the <i>N</i>-<i>tert</i>-butyl carbamate protected precursor to (±)-<i>trans</i>-3-aminocyclopentanol (<b>23a</b>) was synthesized as previously described,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> then treated with a 4 M solution of HCl in EtOAc (15 mL). The reaction mixture was stirred for 3 h at room temperature and then concentrated to dryness under vacuum. The crude residue was used immediately without further purification or characterization in the next step. (±)-<b>23</b> was synthesized by methods similar to those used for <b>20</b> and substituting (±)-<i>trans</i>-3-aminocyclopentanol (<b>23a</b>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <b>23</b> was separated from <i>ent</i>-<b>23</b> by preparative chiral SFC (column, Chiralpak AD, 30 mm × 250 mm, 5 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, MeOH containing 0.2% DEA; flow rate of 50 mL/min; gradient, isocratic, A/B = 70:30). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>23</b>, white solid. Analytical chiral SFC (method SFC6): <i>t</i><sub>R</sub> = 6.26 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.81 (s, 1H), 8.46 (s, 1H), 7.43 (s, 1H), 6.43 (s, 1H), 5.28–5.21 (m, 1H), 4.92 (s, 1H), 4.51 (s, 1H), 2.61 (s, 3H), 2.49–2.32 (m, 2H), 2.28–2.12 (m, 2H), 2.05–1.97 (m, 1H), 1.81–1.71 (m, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 149.7, 144.1, 134.7, 134.1, 132.0, 123.7, 104.3, 97.9, 70.1, 54.8, 33.6, 27.8, 14.6. LCMS (method LCMS9, ESI) <i>t</i><sub>R</sub> = 0.77 min, <i>m</i>/<i>z</i> = 257.1 [M + H]<sup>+</sup>. HRMS [M + H]<sup>+</sup> expected, 257.1402; found, 257.1413. For <i>ent</i>-<b>23</b>, white solid. Analytical chiral SFC (method SFC6): <i>t</i><sub>R</sub> = 6.48 min. <sup>1</sup>H NMR and LCMS data match those of <b>23</b>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>cis</i>-3-(2-Methylimidazo[4,5-<i>d</i>]pyrrolo[2,3-<i>b</i>]pyridin-1(6<i>H</i>)-yl)cyclopentanol (<b>24</b>)</h3><div class="NLM_p last">The <i>N</i>-<i>tert</i>-butyl carbamate protected precursor to (±)-<i>cis</i>-3-aminocyclopentanol (<b>24a</b>) was synthesized as previously described.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The <i>tert</i>-butyl carbamate protecting group was removed as described above for example <b>23</b>. (±)-<b>24</b> was synthesized by methods similar to those used for <b>20</b> and substituting (±)-<i>cis</i>-3-aminocyclopentanol (<b>24a</b>) for (1<i>R</i>,3<i>R</i>)-3-aminocyclohexanol (<b>20a</b>). <b>24</b> was separated from <i>ent</i>-<b>24</b> by preparative chiral SFC (column, Chiralpak AD, 30 mm × 250 mm, 20 μm; detection, UV 220 nm; mobile phase A, CO<sub>2</sub>; mobile phase B, MeOH containing 0.2% DEA; flow rate of 50 mL/min; gradient, isocratic, A/B = 75:25). Isolation and concentration of the appropriate fractions afforded two products with the following characteristics. For <b>24</b>, white solid. Analytical chiral SFC (method SFC6): <i>t</i><sub>R</sub> = 6.65 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 11.72 (s, 1H), 8.43 (s, 1H), 7.42–7.40 (m, 1H), 7.10–7.09 (m, 1H), 5.10 (d, <i>J</i> = 5.4 Hz, 1H), 4.89–4.85 (m, 1H), 4.38–4.35 (m, 1H), 2.60 (s, 3H), 2.49–2.41 (m, 2H), 2.22–2.14 (m, 1H), 1.98–1.91 (m, 2H), 1.88–1.83 (m, 1H). LCMS (method LCMS9, ESI) <i>t</i><sub>R</sub> = 0.86 min, <i>m</i>/<i>z</i> = 256.9 [M + H]<sup>+</sup>. For <i>ent</i>-<b>24</b>: white solid. Analytical chiral SFC (method SFC6): <i>t</i><sub>R</sub> = 6.80 min. <sup>1</sup>H NMR and LCMS data match those for <b>24</b>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48"><a href="/doi/suppl/10.1021/jm300628c">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87834" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87834" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Details of analytical LCMS and SFC methods; experimental log <i>D</i> measurement procedures; thermodynamic solubility measurement procedures; in vitro and in vivo ADME experimental procedures; experimental details for IL6-induced pSTAT3 PK/PD study of compound <b>20</b> in the mouse; protein expression/purification and crystallographic methods and procedures for <b>3</b> (in complex with JAK2), <b>4</b> (in complex with JAK1 and JAK2), <b>20</b> (in complex with JAK1); details of JAK biochemical and cell-based assays; details of in vitro hERG assay; details of QM calculations and methods; biochemical inhibition of JAK3 and TYK2 by compounds <b>3</b>–<b>24</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300628c/suppl_file/jm300628c_si_001.pdf">jm300628c_si_001.pdf (287.3 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300628c" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Zak</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d9b4a3b8b299bebcb7bcf7bab6b4"><span class="__cf_email__" data-cfemail="402d3a212b0027252e256e232f2d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rohan Mendonca</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mercedesz Balazs</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathy Barrett</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philippe Bergeron</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wade S. Blair</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christine Chang</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gauri Deshmukh</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason DeVoss</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter S. Dragovich</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nico Ghilardi</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Gibbons</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan Gradl</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chris Hamman</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emily J. Hanan</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Harstad</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter R. Hewitt</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher A. Hurley</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tian Jin</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam Johnson</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tony Johnson</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane R. Kenny</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael F. T. Koehler</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pawan Bir Kohli</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janusz J. Kulagowski</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sharada Labadie</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiangpeng Liao</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marya Liimatta</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhonghua Lin</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patrick J. Lupardus</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert J. Maxey</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeremy M. Murray</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca Pulk</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Madeleine Rodriguez</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Savage</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Steven Shia</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Micah Steffek</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Savita Ubhayakar</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Ultsch</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne van Abbema</span> - <span class="hlFld-Affiliation affiliation">Departments of †Discovery Chemistry, ‡Biochemical and
Cellular Pharmacology, §Drug Metabolism and
Pharmacokinetics, ∥Immunology, ⊥Safety Assessment, #Small Molecule Process Chemistry, ∞Structural Biology, and ×Translational Immunology, Genentech, Inc., 1 DNA Way, South San
Francisco, California 94080, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stuart I. Ward</span> - <span class="hlFld-Affiliation affiliation">Argenta, 8/9 Spire Green
Centre, Flex Meadow, Harlow, Essex, CM19 5TR, United
Kingdom</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ling Xiao</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yisong Xiao</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec Co.,
Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone,
Shanghai 200131, P. R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d4516e5725-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i49">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58563" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58563" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Michael Hayes, Mengling Wong, Baiwei Lin, Deven Wang, Yutao Jiang, and Yanzhou Liu for purification and analytical support; Daniel Hascall, Grady Howes, Gigi Yuen, and Garima Porwal for compound management support; Hoa Le and Qin Yue for ADME support; Emile Plise and Jonathan Cheng for MDCK data; Erlie Delarosa for hepatocyte stability; Ning Liu for microsomal stability; Suzanne Tay for TDI studies; Jasleen Sodhi for reversible CYP inhibition measurement; Quynh Ho for plasma protein binding measurement; Paroma Chakravarty and Wei Jia for formulations support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i50" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i50"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i51" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i51"> Abbreviations Used</h2><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">aq</td><td class="NLM_def"><p class="first last">aqueous</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">b.i.d.</td><td class="NLM_def"><p class="first last">twice daily</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Boc</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl carbamate</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum concentration</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">D</td><td class="NLM_def"><p class="first last">aspartic acid</p></td></tr><tr><td class="NLM_term">DEA</td><td class="NLM_def"><p class="first last">diethylamine</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">E</td><td class="NLM_def"><p class="first last">glutamic acid</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal effective concentration</p></td></tr><tr><td class="NLM_term"><i>ent</i></td><td class="NLM_def"><p class="first last">enantiomer</p></td></tr><tr><td class="NLM_term">EPO</td><td class="NLM_def"><p class="first last">erythropoietin</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">Ex</td><td class="NLM_def"><p class="first last">example</p></td></tr><tr><td class="NLM_term"><i>F</i></td><td class="NLM_def"><p class="first last">oral bioavailability</p></td></tr><tr><td class="NLM_term"><i>F</i><sub>max</sub></td><td class="NLM_def"><p class="first last">theoretical maximum achievable oral bioavailability</p></td></tr><tr><td class="NLM_term">h</td><td class="NLM_def"><p class="first last">hour</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen-bond donor</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HRMS</td><td class="NLM_def"><p class="first last">high resolution mass spectrometry</p></td></tr><tr><td class="NLM_term">IL-6</td><td class="NLM_def"><p class="first last">interleukin-6</p></td></tr><tr><td class="NLM_term"><i>i</i>-PrOH</td><td class="NLM_def"><p class="first last">isopropyl alcohol</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">ip</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">JAK</td><td class="NLM_def"><p class="first last">Janus kinase</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub>(JAK2)/<i>K</i><sub>i</sub>(JAK1)</td><td class="NLM_def"><p class="first last">JAK1 biochemcal selectivity index</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub>(EPO-pSTAT5)/EC<sub>50</sub>(IL6-pSTAT3)</td><td class="NLM_def"><p class="first last">JAK1 cellular selectivity index</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term">L</td><td class="NLM_def"><p class="first last">leucine</p></td></tr><tr><td class="NLM_term">LCMS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">log <i>D</i><sub>7.2</sub></td><td class="NLM_def"><p class="first last">log of partition coefficient between octanol and pH 7.2 aqueous buffer</p></td></tr><tr><td class="NLM_term">MCT</td><td class="NLM_def"><p class="first last">methylcellulose/Tween</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney</p></td></tr><tr><td class="NLM_term">MeOH</td><td class="NLM_def"><p class="first last">methanol</p></td></tr><tr><td class="NLM_term">MF</td><td class="NLM_def"><p class="first last">myelofibrosis</p></td></tr><tr><td class="NLM_term">min</td><td class="NLM_def"><p class="first last">minute</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">N</td><td class="NLM_def"><p class="first last">asparagine</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr><tr><td class="NLM_term">PEG400</td><td class="NLM_def"><p class="first last">polyethylene glycol 400</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PK/PD</td><td class="NLM_def"><p class="first last">pharmacokinetic/pharmakodynamic</p></td></tr><tr><td class="NLM_term">po</td><td class="NLM_def"><p class="first last">by mouth</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">psi</td><td class="NLM_def"><p class="first last">pounds per square inch</p></td></tr><tr><td class="NLM_term"><i>p</i>-TsOH</td><td class="NLM_def"><p class="first last"><i>p</i>-toluenesulfonic acid</p></td></tr><tr><td class="NLM_term">R</td><td class="NLM_def"><p class="first last">arginine</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">S</td><td class="NLM_def"><p class="first last">serine</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">QM</td><td class="NLM_def"><p class="first last">quantum mechanical</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TPSA</td><td class="NLM_def"><p class="first last">topological polar surface area</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr><tr><td class="NLM_term">Y</td><td class="NLM_def"><p class="first last">tyrosine</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 49 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurban, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralph, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zurcher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span> </span><span class="NLM_article-title">Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2057</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1128%2FMCB.11.4.2057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=1848670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK3MXlslyju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=2057-2065&author=A.+F.+Wilksauthor=A.+G.+Harpurauthor=R.+R.+Kurbanauthor=S.+J.+Ralphauthor=G.+Zurcherauthor=A.+Ziemiecki&title=Two+novel+protein-tyrosine+kinases%2C+each+with+a+second+phosphotransferase-related+catalytic+domain%2C+define+a+new+class+of+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase</span></div><div class="casAuthors">Wilks, Andrew F.; Harpur, Ailsa G.; Kurban, R. R.; Ralph, Stephen J.; Zuercher, Gisela; Ziemiecki, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2057-65</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The protein tyrosine kinases (PTKs) are a burgeoning family of proteins, each of which bears a conserved domain of 250-300 amino acids capable of phosphorylating substrate proteins on tyrosine residues.  Recently, the existence of 2 highly conserved sequence elements within the catalytic domain was exploited to generate PTK-specific degenerate oligonucleotide primers.  By application of the polymerase chain reaction, portions of the catalytic domains of several novel PTKs were amplified.  Here, the primary sequence is reported of one of these new PTKs, JAK1 (from Janus kinase), a member of a new class of PTK characterized by the presence of a 2nd phosphotransferase-related domain immediately N-terminal to the PTK domain.  The sequence was derived from the cDNA sequence of a human fibroblast clone.  The 2nd phosphotransferase domain bears all the hallmarks of a protein kinase, although its structure differed significantly from that of the PTK and threonine/serine kinase family members.  A 2nd member of this family (JAK2) was partially characterized and exhibited a similar array of kinase-related domains.  JAK1 is a large, widely expressed membrane-assocd. phosphoprotein of ∼130 kDa.  The PTK activity of JAK1 was located in the C-terminal PTK-like domain.  The role of the 2nd kinase-like domain is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8XPv7ZSQ7kbVg90H21EOLACvtfcHk0liX-fiGYErCLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlslyju7s%253D&md5=7094cf98426dbe3ed5470ced76dc839b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.4.2057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.4.2057%26sid%3Dliteratum%253Aachs%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DKurban%26aufirst%3DR.%2BR.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DZurcher%26aufirst%3DG.%26aulast%3DZiemiecki%26aufirst%3DA.%26atitle%3DTwo%2520novel%2520protein-tyrosine%2520kinases%252C%2520each%2520with%2520a%2520second%2520phosphotransferase-related%2520catalytic%2520domain%252C%2520define%2520a%2520new%2520class%2520of%2520protein%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D2057%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">JAK2, a third member of the JAK family of protein tyrosine kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=1620548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK38XmtVOrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1992&pages=1347-1353&author=A.+G.+Harpurauthor=A.+C.+Andresauthor=A.+Ziemieckiauthor=R.+R.+Astonauthor=A.+F.+Wilks&title=JAK2%2C+a+third+member+of+the+JAK+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2, a third member of the JAK family of protein tyrosine kinases</span></div><div class="casAuthors">Harpur, Ailsa G.; Andres, Anne Catherine; Ziemiecki, Andrew; Aston, Raja R.; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1347-53</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">CDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs) were isolated.  The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs.  The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity.  The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homol. domains do not appear to be a feature of other known proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGgx2uwGEN7Vg90H21EOLACvtfcHk0liX-fiGYErCLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmtVOrtLc%253D&md5=db385133406115942157615e9c56b47f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26aulast%3DZiemiecki%26aufirst%3DA.%26aulast%3DAston%26aufirst%3DR.%2BR.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DJAK2%252C%2520a%2520third%2520member%2520of%2520the%2520JAK%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DOncogene%26date%3D1992%26volume%3D7%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirken, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortaldo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVicar, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=151-153&author=J.+A.+Johnstonauthor=M.+Kawamuraauthor=R.+A.+Kirkenauthor=Y.+Q.+Chenauthor=T.+B.+Blakeauthor=K.+Shibuyaauthor=J.+R.+Ortaldoauthor=D.+W.+McVicarauthor=J.+J.+O%E2%80%99Shea&title=Phosphorylation+and+activation+of+the+Jak-3+Janus+kinase+in+response+to+interleukin-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DKawamura%26aufirst%3DM.%26aulast%3DKirken%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DBlake%26aufirst%3DT.%2BB.%26aulast%3DShibuya%26aufirst%3DK.%26aulast%3DOrtaldo%26aufirst%3DJ.%2BR.%26aulast%3DMcVicar%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DPhosphorylation%2520and%2520activation%2520of%2520the%2520Jak-3%2520Janus%2520kinase%2520in%2520response%2520to%2520interleukin-2%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D151%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cwik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=153-157&author=B.+A.+Witthuhnauthor=O.+Silvennoinenauthor=O.+Miuraauthor=K.+S.+Laiauthor=C.+Cwikauthor=E.+T.+Liuauthor=J.+N.+Ihle&title=Involvement+of+the+Jak-3+Janus+kinase+in+signalling+by+interleukins+2+and+4+in+lymphoid+and+myeloid+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BS.%26aulast%3DCwik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DInvolvement%2520of%2520the%2520Jak-3%2520Janus%2520kinase%2520in%2520signalling%2520by%2520interleukins%25202%2520and%25204%2520in%2520lymphoid%2520and%2520myeloid%2520cells%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D153%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Firmbach-Kraft, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shows, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla-Favera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolewski, J. J.</span><span> </span><span class="NLM_article-title">tyk2, prototype of a novel class of non-receptor tyrosine kinase genes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=tyk2%2C+prototype+of+a+novel+class+of+non-receptor+tyrosine+kinase+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0lj5ulUAq_5sBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3Dtyk2%252C%2520prototype%2520of%2520a%2520novel%2520class%2520of%2520non-receptor%2520tyrosine%2520kinase%2520genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Huising, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruiswijk, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flik, G.</span><span> </span><span class="NLM_article-title">Phylogeny and evolution of class-I helical cytokines</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1677%2Fjoe.1.06591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=16614377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkslaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2006&pages=1-25&author=M.+O.+Huisingauthor=C.+P.+Kruiswijkauthor=G.+Flik&title=Phylogeny+and+evolution+of+class-I+helical+cytokines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phylogeny and evolution of class-I helical cytokines</span></div><div class="casAuthors">Huising, Mark O.; Kruiswijk, Corine P.; Flik, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-25</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The class-I helical cytokines constitute a large group of signaling mols. that play key roles in a plethora of physiol. processes including host defense, immune regulation, somatic growth, reprodn., food intake and energy metab., regulation of neural growth and many more.  Despite little primary amino acid sequence similarity, the view that all contemporary class-I helical cytokines have expanded from a single ancestor is widely accepted, as all class-I helical cytokines share a similar three-dimensional fold, signal via related class-I helical cytokine receptors and activate similar intracellular signaling cascades.  Virtually all of our knowledge on class-I helical cytokine signaling derives from research on primate and rodent species.  Information on the presence, structure and function of class-I helical cytokines in non-mammalian vertebrates and non-vertebrates is fragmentary.  Consequently, our ideas about the evolution of this versatile multigene family are often based on a limited comparison of human and murine orthologs.  In the last 5 years, whole genome sequencing projects have yielded draft genomes of the early vertebrates, pufferfish (Takifugu rubripes), spotted green pufferfish (Tetraodon nigroviridis) and zebrafish (Danio rerio).  Fuelled by this development, fish orthologs of a no. of mammalian class-I helical cytokines have recently been discovered.  In this review, we have characterised the mammalian class-I helical cytokine family and compared it with the emerging class-I helical cytokine repertoire of teleost fish.  This approach offers important insights into cytokine evolution as it identifies the helical cytokines shared by fish and mammals that, consequently, existed before the divergence of teleosts and tetrapods.  A 'fish-mammalian' comparison will identify the class-I helical cytokines that still await discovery in fish or, alternatively, may have been evolutionarily recent addns. to the mammalian cytokine repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOL7tSlCn0fbVg90H21EOLACvtfcHk0lj5ulUAq_5sBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkslaqsb0%253D&md5=624f0cc6441665e8cd0ecb4559ba6fe8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1677%2Fjoe.1.06591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.1.06591%26sid%3Dliteratum%253Aachs%26aulast%3DHuising%26aufirst%3DM.%2BO.%26aulast%3DKruiswijk%26aufirst%3DC.%2BP.%26aulast%3DFlik%26aufirst%3DG.%26atitle%3DPhylogeny%2520and%2520evolution%2520of%2520class-I%2520helical%2520cytokines%26jtitle%3DJ.%2520Endocrinol.%26date%3D2006%26volume%3D189%26spage%3D1%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Bazan, J. F.</span><span> </span><span class="NLM_article-title">Structural design and molecular evolution of a cytokine receptor superfamily</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6934</span><span class="NLM_x">–</span> <span class="NLM_lpage">6938</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=6934-6938&author=J.+F.+Bazan&title=Structural+design+and+molecular+evolution+of+a+cytokine+receptor+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBazan%26aufirst%3DJ.%2BF.%26atitle%3DStructural%2520design%2520and%2520molecular%2520evolution%2520of%2520a%2520cytokine%2520receptor%2520superfamily%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D6934%26epage%3D6938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">STATs and gene regulation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">1630</span><span class="NLM_x">–</span> <span class="NLM_lpage">1635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1630-1635&author=J.+E.+Darnell&title=STATs+and+gene+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%2520and%2520gene%2520regulation%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D1630%26epage%3D1635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lg1cs-m87TjRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">O’shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Cytokine signaling in 2002: new surprises in the Jak/Stat pathway</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S121</span><span class="NLM_x">–</span> <span class="NLM_lpage">S131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S121-S131&issue=Suppl.&author=J.+J.+O%E2%80%99sheaauthor=M.+Gadinaauthor=R.+D.+Schreiber&title=Cytokine+signaling+in+2002%3A+new+surprises+in+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCytokine%2520signaling%2520in%25202002%253A%2520new%2520surprises%2520in%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3DSuppl%26spage%3DS121%26epage%3DS131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Schindler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, T.</span><span> </span><span class="NLM_article-title">JAK-STAT signaling: from interferons to cytokines</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">20059</span><span class="NLM_x">–</span> <span class="NLM_lpage">20063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+signaling%3A+from+interferons+to+cytokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520signaling%253A%2520from%2520interferons%2520to%2520cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">STATs: signal transducers and activators of transcription</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1996&pages=331-334&author=J.+N.+Ihle&title=STATs%3A+signal+transducers+and+activators+of+transcription"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DSTATs%253A%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%26jtitle%3DCell%26date%3D1996%26volume%3D84%26spage%3D331%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">–</span> <span class="NLM_lpage">6737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0lg1cs-m87TjRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=1-11&author=J.+J.+O%E2%80%99Shea&title=Jaks%2C+STATs%2C+cytokine+signal+transduction%2C+and+immunoregulation%3A+Are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJaks%252C%2520STATs%252C%2520cytokine%2520signal%2520transduction%252C%2520and%2520immunoregulation%253A%2520Are%2520we%2520there%2520yet%253F%26jtitle%3DImmunity%26date%3D1997%26volume%3D7%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lgirdSXkH826w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">A new modality for immunosuppression: targeting the JAK/STAT pathway</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=555-564&author=J.+J.+O%E2%80%99Sheaauthor=M.+Pesuauthor=D.+C.+Borieauthor=P.+S.+Changelian&title=A+new+modality+for+immunosuppression%3A+targeting+the+JAK%2FSTAT+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DA%2520new%2520modality%2520for%2520immunosuppression%253A%2520targeting%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D555%26epage%3D564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Clark, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, R.</span><span> </span><span class="NLM_article-title">The human hematopoietic colony-stimulating factors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1987&pages=1229-1237&author=S.+C.+Clarkauthor=R.+Kamen&title=The+human+hematopoietic+colony-stimulating+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DS.%2BC.%26aulast%3DKamen%26aufirst%3DR.%26atitle%3DThe%2520human%2520hematopoietic%2520colony-stimulating%2520factors%26jtitle%3DScience%26date%3D1987%26volume%3D236%26spage%3D1229%26epage%3D1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Metcalf, D.</span><span> </span><span class="NLM_article-title">The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1989&pages=27-30&author=D.+Metcalf&title=The+molecular+control+of+cell+division%2C+differentiation+commitment+and+maturation+in+haemopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalf%26aufirst%3DD.%26atitle%3DThe%2520molecular%2520control%2520of%2520cell%2520division%252C%2520differentiation%2520commitment%2520and%2520maturation%2520in%2520haemopoietic%2520cells%26jtitle%3DNature%26date%3D1989%26volume%3D339%26spage%3D27%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quelle, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1993&pages=227-236&author=B.+A.+Witthuhnauthor=F.+W.+Quelleauthor=O.+Silvennoinenauthor=T.+Yiauthor=B.+Tangauthor=O.+Miuraauthor=J.+N.+Ihle&title=JAK2+associates+with+the+erythropoietin+receptor+and+is+tyrosine+phosphorylated+and+activated+following+stimulation+with+erythropoietin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DQuelle%26aufirst%3DF.%2BW.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJAK2%2520associates%2520with%2520the%2520erythropoietin%2520receptor%2520and%2520is%2520tyrosine%2520phosphorylated%2520and%2520activated%2520following%2520stimulation%2520with%2520erythropoietin%26jtitle%3DCell%26date%3D1993%26volume%3D74%26spage%3D227%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Rochman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">New insights into the regulation of T cells by gamma(c) family cytokines</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fnri2580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=19543225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=480-490&author=Y.+Rochmanauthor=R.+Spolskiauthor=W.+J.+Leonard&title=New+insights+into+the+regulation+of+T+cells+by+gamma%28c%29+family+cytokines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the regulation of T cells by γc family cytokines</span></div><div class="casAuthors">Rochman, Yrina; Spolski, Rosanne; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">480-490</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Common cytokine receptor γ-chain (γc) family cytokines have crucial roles in the development, proliferation, survival and differentiation of multiple cell lineages of both the innate and adaptive immune systems.  In this Review, the authors focus on the current understanding of the distinct and overlapping effects of interleukin-2 (IL-2), IL-7, IL-9, IL-15 and IL-21, as well as the IL-7-related cytokine thymic stromal lymphopoietin (TSLP), on the survival and proliferation of conventional αβ T cells, γδ T cells and regulatory T cells.  This knowledge potentially allows for the therapeutic manipulation of immune responses for the treatment of cancer, autoimmunity, allergic diseases and immunodeficiency, as well as for vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GBlSyD8_NLVg90H21EOLACvtfcHk0lgirdSXkH826w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D&md5=a6c7285b05193002b89be7233d11f271</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnri2580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2580%26sid%3Dliteratum%253Aachs%26aulast%3DRochman%26aufirst%3DY.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520insights%2520into%2520the%2520regulation%2520of%2520T%2520cells%2520by%2520gamma%2528c%2529%2520family%2520cytokines%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D480%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Stahl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farruggella, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quelle, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopulos, G. D.</span><span> </span><span class="NLM_article-title">Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=92-95&author=N.+Stahlauthor=T.+G.+Boultonauthor=T.+Farruggellaauthor=N.+Y.+Ipauthor=S.+Davisauthor=B.+A.+Witthuhnauthor=F.+W.+Quelleauthor=O.+Silvennoinenauthor=G.+Barbieriauthor=S.+Pellegriniauthor=J.+N.+Ihleauthor=G.+D.+Yancopulos&title=Association+and+activation+of+Jak-Tyk+kinases+by+CNTF-LIF-OSM-IL-6+%CE%B2+receptor+components"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DN.%26aulast%3DBoulton%26aufirst%3DT.%2BG.%26aulast%3DFarruggella%26aufirst%3DT.%26aulast%3DIp%26aufirst%3DN.%2BY.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DQuelle%26aufirst%3DF.%2BW.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DBarbieri%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26aulast%3DYancopulos%26aufirst%3DG.%2BD.%26atitle%3DAssociation%2520and%2520activation%2520of%2520Jak-Tyk%2520kinases%2520by%2520CNTF-LIF-OSM-IL-6%2520%25CE%25B2%2520receptor%2520components%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D92%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishimoto, T.</span><span> </span><span class="NLM_article-title">Immunotherapeutic implication of IL-6 blockade</span> <span class="citation_source-journal">Immunotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=T.+Tanakaauthor=T.+Kishimoto&title=Immunotherapeutic+implication+of+IL-6+blockade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKishimoto%26aufirst%3DT.%26atitle%3DImmunotherapeutic%2520implication%2520of%2520IL-6%2520blockade%26jtitle%3DImmunotherapy%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gouilleux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haldosen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norstedt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groner, B.</span><span> </span><span class="NLM_article-title">Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=2005-2013&author=F.+Gouilleuxauthor=C.+Pallardauthor=I.+Dusanter-Fourtauthor=H.+Wakaoauthor=L.+A.+Haldosenauthor=G.+Norstedtauthor=D.+Levyauthor=B.+Groner&title=Prolactin%2C+growth+hormone%2C+erythropoietin+and+granulocyte-macrophage+colony+stimulating+factor+induce+MGF-Stat5+DNA+binding+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGouilleux%26aufirst%3DF.%26aulast%3DPallard%26aufirst%3DC.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DWakao%26aufirst%3DH.%26aulast%3DHaldosen%26aufirst%3DL.%2BA.%26aulast%3DNorstedt%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DGroner%26aufirst%3DB.%26atitle%3DProlactin%252C%2520growth%2520hormone%252C%2520erythropoietin%2520and%2520granulocyte-macrophage%2520colony%2520stimulating%2520factor%2520induce%2520MGF-Stat5%2520DNA%2520binding%2520activity%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D2005%26epage%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pallard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouilleux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisselbrecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span> </span><span class="NLM_article-title">Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">15942</span><span class="NLM_x">–</span> <span class="NLM_lpage">15945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=15942-15945&author=C.+Pallardauthor=F.+Gouilleuxauthor=M.+Charonauthor=B.+Gronerauthor=S.+Gisselbrechtauthor=I.+Dusanter-Fourt&title=Interleukin-3%2C+erythropoietin%2C+and+prolactin+activate+a+STAT5-like+factor+in+lymphoid+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPallard%26aufirst%3DC.%26aulast%3DGouilleux%26aufirst%3DF.%26aulast%3DCharon%26aufirst%3DM.%26aulast%3DGroner%26aufirst%3DB.%26aulast%3DGisselbrecht%26aufirst%3DS.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26atitle%3DInterleukin-3%252C%2520erythropoietin%252C%2520and%2520prolactin%2520activate%2520a%2520STAT5-like%2520factor%2520in%2520lymphoid%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D15942%26epage%3D15945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects</span> <span class="citation_source-journal">J. Recept. Signal. Transduction Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.3109%2F10799899909036684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=10071797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=741-772&author=R.+C.+Skoda&title=Specificity+of+signaling+by+hematopoietic+cytokine+receptors%3A+instructive+versus+permissive+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects</span></div><div class="casAuthors">Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor and Signal Transduction Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">741-772</span>CODEN:
                <span class="NLM_cas:coden">JRETET</span>;
        ISSN:<span class="NLM_cas:issn">1079-9893</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review with 163 refs.  The helical cytokines constitute a family of proteins with a common three-dimensional structure.  They exert a wide variety of biol. effects with a preference for the hematopoietic system.  The effects of helical cytokines are mediated by cell surface receptors, which belong to the cytokine receptor superfamily and signal by activating cytoplasmic tyrosine kinases of the Janus kinase (Jak) family and other downstream signaling pathways.  The relevance of each of these pathways for eliciting a specific cellular response remains to be detd.  This review will focus on cytokine receptors which play a role in the regulation of hematopoiesis and summarize data that address the question how specificity of signaling is achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquBbee9L17arVg90H21EOLACvtfcHk0lhkh72OgQaZgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWgsL0%253D&md5=65b9b15109627fbac2586c29f8086102</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.3109%2F10799899909036684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899909036684%26sid%3Dliteratum%253Aachs%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DSpecificity%2520of%2520signaling%2520by%2520hematopoietic%2520cytokine%2520receptors%253A%2520instructive%2520versus%2520permissive%2520effects%26jtitle%3DJ.%2520Recept.%2520Signal.%2520Transduction%2520Res.%26date%3D1999%26volume%3D19%26spage%3D741%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenisch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, H. F.</span><span> </span><span class="NLM_article-title">Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1995&pages=59-67&author=H.+Wuauthor=X.+Liuauthor=R.+Jaenischauthor=H.+F.+Lodish&title=Generation+of+committed+erythroid+BFU-E+and+CFU-E+progenitors+does+not+require+erythropoietin+or+the+erythropoietin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DGeneration%2520of%2520committed%2520erythroid%2520BFU-E%2520and%2520CFU-E%2520progenitors%2520does%2520not%2520require%2520erythropoietin%2520or%2520the%2520erythropoietin%2520receptor%26jtitle%3DCell%26date%3D1995%26volume%3D83%26spage%3D59%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0lhkh72OgQaZgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lg5zDIO1R7fCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+DMARDs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0lg5zDIO1R7fCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=22006202" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D64%26spage%3D970%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">Tofacitinib has completed several late stage clinical trials and recently received a recommendation for approval in RA from the FDA Advisory Committee.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1999</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol900350k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1999-2002&author=Q.+Linauthor=D.+Meloniauthor=Y.+Panauthor=M.+Xiaauthor=J.+Rodgersauthor=S.+Shepardauthor=M.+Liauthor=L.+Galyaauthor=B.+Metcalfauthor=T.+Y.+Yueauthor=P.+Liuauthor=J.+Zhou&title=Enantioselective+synthesis+of+Janus+kinase+inhibitor+INCB018424+via+an+organocatalytic+aza-Michael+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol900350k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol900350k%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DEnantioselective%2520synthesis%2520of%2520Janus%2520kinase%2520inhibitor%2520INCB018424%2520via%2520an%2520organocatalytic%2520aza-Michael%2520reaction%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1999%26epage%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Williams, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, L.</span><span> </span><span class="NLM_article-title">Initial efficacy of INCB018424, a selective janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">Supp.l 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=62&issue=Supp.l+2&author=W.+V.+Williamsauthor=P.+Scherleauthor=J.+Shiauthor=R.+Newtonauthor=E.+McKeeverauthor=J.+Fridmanauthor=K.+Vaddiauthor=R.+Levyauthor=L.+Moreland&title=Initial+efficacy+of+INCB018424%2C+a+selective+janus+kinase+1+%26+2+%28JAK1%262%29+inhibitor+in+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DMcKeever%26aufirst%3DE.%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DMoreland%26aufirst%3DL.%26atitle%3DInitial%2520efficacy%2520of%2520INCB018424%252C%2520a%2520selective%2520janus%2520kinase%25201%2520%2526%25202%2520%2528JAK1%25262%2529%2520inhibitor%2520in%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26issue%3DSupp.l%25202%26spage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last"> The abstract is online at <a href="http://www.abstracts2view.com/eular/view.php?nu=EULAR08L_OP-0044" class="extLink">http://www.abstracts2view.com/eular/view.php?nu=EULAR08L_OP-0044</a> (accessed May 30, 2012).</p></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span> A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects with Active Rheumatoid Arthritis. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00550043?term=incb018424&amp;rank=19" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00550043?term=incb018424&rank=19</a> (accessed June 5,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+Study+Exploring+the+Safety%2C+Tolerability+and+Efficacy+of+a+4+Week+Course+of+INCB018424+in+Subjects+with+Active+Rheumatoid+Arthritis.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00550043%3Fterm%3Dincb018424%26rank%3D19+%28accessed+June+5%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24a"><span><span class="NLM_label">(a) </span> In addition to being studied in early stage trials for RA, ruxolitinib has also been extensively evaluated as a treatment for myelofibrosis (MF). Recently, the Food and Drug Administration (FDA) granted marketing approval to ruxolitinib as a treatment for patients with MF. Incyte Press Release. <a href="http://investor.incyte.com/phoenix.zhtml?c=69764&amp;p=irol-newsArticle&amp;ID=1631201&amp;highlight" class="extLink">http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1631201&highlight</a> (accessed May 30,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+In+addition+to+being+studied+in+early+stage+trials+for+RA%2C+ruxolitinib+has+also+been+extensively+evaluated+as+a+treatment+for+myelofibrosis+%28MF%29.+Recently%2C+the+Food+and+Drug+Administration+%28FDA%29+granted+marketing+approval+to+ruxolitinib+as+a+treatment+for+patients+with+MF.+Incyte+Press+Release.+http%3A%2F%2Finvestor.incyte.com%2Fphoenix.zhtml%3Fc%3D69764%26p%3Dirol-newsArticle%26ID%3D1631201%26highlight+%28accessed+May+30%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Incyte and Eli Lilly have progressed another small molecule JAK1/2 inhibitor (INCB028050/LY3009104) into clinical trials for rheumatoid arthritis. </p></div><span class="NLM_contrib-group">Greenwald, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span> </span><span class="NLM_article-title">A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2172&issue=Suppl.+10&author=M.+W.+Greenwaldauthor=R.+Fidelus-Gortauthor=R.+Levyauthor=J.+Liangauthor=K.+Vaddiauthor=W.+V.+Williamsauthor=R.+Newton&title=A+randomized+dose-ranging%2C+placebo-controlled+study+of+INCB028050%2C+a+selective+JAK1+and+JAK2+inhibitor+in+subjects+with+active+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DM.%2BW.%26aulast%3DFidelus-Gort%26aufirst%3DR.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DA%2520randomized%2520dose-ranging%252C%2520placebo-controlled%2520study%2520of%2520INCB028050%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520in%2520subjects%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D2172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit24c"><span><span class="NLM_label">(c) </span> Further information on a phase 2a clinical trial of INCB028050/LY3009104 may be found in an Incyte press release: <a href="http://investor.incyte.com/phoenix.zhtml?c=69764&amp;p=irol-newsArticle&amp;ID=1494997&amp;highlight=" class="extLink">http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1494997&highlight=</a> (accessed June 6,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Further+information+on+a+phase+2a+clinical+trial+of+INCB028050%2FLY3009104+may+be+found+in+an+Incyte+press+release%3A+http%3A%2F%2Finvestor.incyte.com%2Fphoenix.zhtml%3Fc%3D69764%26p%3Dirol-newsArticle%26ID%3D1494997%26highlight%3D+%28accessed+June+6%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2ebHm1L_hvuOoLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.+G.+Zerwes&title=Identification+of+a+potent+Janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DIdentification%2520of%2520a%2520potent%2520Janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeltz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">3109</span><span class="NLM_x">–</span> <span class="NLM_lpage">3117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lg3Ztxc2vDj6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Van Abbema, A.; Kanada, H.; Chang, C.; Bir Kohli, P.; Smith, J.; Barrett, K.; Lewin-Koh, N.; Johnson, A. R.; Ghilardi, N.; Blair, W.</span><span> </span><span class="NLM_article-title">Determination of the JAK-dependence of cytokine pathways using small molecule inhibitors</span>. Unpublished results. Experimental details of the biochemical and cell-based assays reported herein may be found in the <span class="NLM_xref">Supporting Information</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Van+Abbema%2C+A.%3B+Kanada%2C+H.%3B+Chang%2C+C.%3B+Bir+Kohli%2C+P.%3B+Smith%2C+J.%3B+Barrett%2C+K.%3B+Lewin-Koh%2C+N.%3B+Johnson%2C+A.+R.%3B+Ghilardi%2C+N.%3B+Blair%2C+W.+Determination+of+the+JAK-dependence+of+cytokine+pathways+using+small+molecule+inhibitors.+Unpublished+results.+Experimental+details+of+the+biochemical+and+cell-based+assays+reported+herein+may+be+found+in+the+Supporting+Information."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26atitle%3DDetermination%2520of%2520the%2520JAK-dependence%2520of%2520cytokine%2520pathways%2520using%2520small%2520molecule%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+Jaks+in+cytokine-induced+biologic+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520Jaks%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Shimoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibamori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekiguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, K.</span><span> </span><span class="NLM_article-title">Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=561-571&author=K.+Shimodaauthor=K.+Koujiauthor=K.+Aokiauthor=T.+Matsudaauthor=A.+Miyamotoauthor=M.+Shibamoriauthor=M.+Yamashitaauthor=A.+Numataauthor=K.+Takaseauthor=S.+Kobayashiauthor=S.+Shibataauthor=Y.+Asanoauthor=H.+Gondoauthor=K.+Sekiguchiauthor=K.+Nakayamaauthor=T.+Nakayamaauthor=T.+Okamuraauthor=S.+Okamuraauthor=Y.+Nihoauthor=K.+Nakayama&title=Tyk2+plays+a+restricted+role+in+IFN%CE%B1+signaling%2C+although+it+is+required+for+IL-12-mediated+T+cell+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DKouji%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DA.%26aulast%3DShibamori%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DNumata%26aufirst%3DA.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DShibata%26aufirst%3DS.%26aulast%3DAsano%26aufirst%3DY.%26aulast%3DGondo%26aufirst%3DH.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DS.%26aulast%3DNiho%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%26atitle%3DTyk2%2520plays%2520a%2520restricted%2520role%2520in%2520IFN%25CE%25B1%2520signaling%252C%2520although%2520it%2520is%2520required%2520for%2520IL-12-mediated%2520T%2520cell%2520function%26jtitle%3DImmunity%26date%3D2000%26volume%3D13%26spage%3D561%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+van+Deursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubbert-Roth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos-Remus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovensky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alecock, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alten, R.</span><span> </span><span class="NLM_article-title">Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=987-997&author=J.+S.+Smolenauthor=A.+Beaulieuauthor=A.+Rubbert-Rothauthor=C.+Ramos-Remusauthor=J.+Rovenskyauthor=E.+Alecockauthor=T.+Woodworthauthor=R.+Alten&title=Effect+of+interleukin-6+receptor+inhibition+with+tocilizumab+in+patients+with+rheumatoid+arthritis+%28OPTION+study%29%3A+a+double-blind%2C+placebo-controlled%2C+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DBeaulieu%26aufirst%3DA.%26aulast%3DRubbert-Roth%26aufirst%3DA.%26aulast%3DRamos-Remus%26aufirst%3DC.%26aulast%3DRovensky%26aufirst%3DJ.%26aulast%3DAlecock%26aufirst%3DE.%26aulast%3DWoodworth%26aufirst%3DT.%26aulast%3DAlten%26aufirst%3DR.%26atitle%3DEffect%2520of%2520interleukin-6%2520receptor%2520inhibition%2520with%2520tocilizumab%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520%2528OPTION%2520study%2529%253A%2520a%2520double-blind%252C%2520placebo-controlled%252C%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D987%26epage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Haan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolvering, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.chembiol.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=21439476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=314-323&author=C.+Haanauthor=C.+Rolveringauthor=F.+Raulfauthor=M.+Kappauthor=P.+Druckesauthor=G.+Thomaauthor=I.+Behrmannauthor=H.+G.+Zerwes&title=Jak1+has+a+dominant+role+over+Jak3+in+signal+transduction+through+%CE%B3c-containing+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors</span></div><div class="casAuthors">Haan, Claude; Rolvering, Catherine; Raulf, Friedrich; Kapp, Manuela; Drueckes, Peter; Thoma, Gebhard; Behrmann, Iris; Zerwes, Hans-Guenter</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-323</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Genetic deficiency of Jak3 leads to abrogation of signal transduction through the common gamma chain (γc) and thus to immunodeficiency suggesting that specific inhibition of Jak3 kinase may result in immunosuppression.  Jak1 cooperates with Jak3 in signaling through γc-contg. receptors.  Unexpectedly, a Jak3-selective inhibitor was less efficient in abolishing STAT5 phosphorylation than pan-Jak inhibitors.  We therefore explored the roles of Jak1 and Jak3 kinase functionality in signaling using a reconstituted system.  The presence of kinase-inactive Jak1 but not kinase-inactive Jak3 resulted in complete abolishment of STAT5 phosphorylation.  Specific inhibition of the "analog-sensitive" mutant AS-Jak1 but not AS-Jak3 by the ATP-competitive analog 1NM-PP1 abrogated IL-2 signaling, corroborating the data with the selective Jak3 inhibitor.  Jak1 thus plays a dominant role over Jak3 and these data challenge the notion that selective ATP-competitive Jak3 kinase inhibitors will be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUv04vX29Zk7Vg90H21EOLACvtfcHk0ljja5VwxL0ECg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrtrw%253D&md5=0109f316cfe0bee40f80a79f244e6ba5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHaan%26aufirst%3DC.%26aulast%3DRolvering%26aufirst%3DC.%26aulast%3DRaulf%26aufirst%3DF.%26aulast%3DKapp%26aufirst%3DM.%26aulast%3DDruckes%26aufirst%3DP.%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DJak1%2520has%2520a%2520dominant%2520role%2520over%2520Jak3%2520in%2520signal%2520transduction%2520through%2520%25CE%25B3c-containing%2520cytokine%2520receptors%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D314%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Frenzel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDoom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capecchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">A functional Jak2 tyrosine kinase domain is essential for mouse development</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.yexcr.2006.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=16887119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=2735-2744&author=K.+Frenzelauthor=T.+A.+Wallaceauthor=I.+McDoomauthor=H.+D.+Xiaoauthor=M.+R.+Capecchiauthor=K.+E.+Bernsteinauthor=P.+P.+Sayeski&title=A+functional+Jak2+tyrosine+kinase+domain+is+essential+for+mouse+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">A functional Jak2 tyrosine kinase domain is essential for mouse development</span></div><div class="casAuthors">Frenzel, Kristen; Wallace, Tiffany A.; McDoom, Issam; Xiao, Hong D.; Capecchi, Mario R.; Bernstein, Kenneth E.; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2735-2744</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling.  As a part of a study to det. biol. functions of Jak2, we used mol. modeling to identify W1038 as a residue that is crit. for tyrosine kinase function.  Mutation of W1038, in tandem with E1046, generates a dominant-neg. form of the Jak2 protein.  Mice that were engineered to express two copies of this dominant-neg. Jak2 protein died in utero.  Addnl., heterozygous mice expressing Jak2 with kinase activity that is moderately reduced when compared to wild-type activity appear phenotypically normal.  Collectively, these data suggest that Jak2 kinase activity is essential for normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_eBTfkGGF3rVg90H21EOLACvtfcHk0ljTxtjYpqmz3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D&md5=347e54bb72e8fdb6cce0563020c5656e</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2006.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2006.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DT.%2BA.%26aulast%3DMcDoom%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DH.%2BD.%26aulast%3DCapecchi%26aufirst%3DM.%2BR.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DA%2520functional%2520Jak2%2520tyrosine%2520kinase%2520domain%2520is%2520essential%2520for%2520mouse%2520development%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2006%26volume%3D312%26spage%3D2735%26epage%3D2744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0ljTxtjYpqmz3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="note"><p class="first last">A summary of previous disclosures of compounds exhibiting JAK1 vs JAK2 selectivity is presented in ref <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">36</a>. Additionally, a number of publications describing JAK2 inhibitors with varying JAK family and other kinase selectivity profiles have appeared recently. These include the following: </p></div><div class="NLM_citation" id="cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schenkel, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span> </span><span class="NLM_article-title">Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8440</span><span class="NLM_x">–</span> <span class="NLM_lpage">8450</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200911r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8440-8450&author=L.+B.+Schenkelauthor=X.+Huangauthor=A.+Chengauthor=H.+L.+Deakauthor=E.+Dohertyauthor=R.+Emkeyauthor=Y.+Guauthor=H.+Gunaydinauthor=J.+L.+Kimauthor=J.+Leeauthor=R.+Lobergauthor=P.+Olivieriauthor=J.+Pistilloauthor=J.+Tangauthor=Q.+Wanauthor=H.+L.+Wangauthor=S.+W.+Wangauthor=M.+C.+Wellsauthor=B.+Wuauthor=V.+Yuauthor=L.+Liuauthor=S.+Geuns-Meyer&title=Discovery+of+potent+and+highly+selective+thienopyridine+Janus+kinase+2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1021%2Fjm200911r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200911r%26sid%3Dliteratum%253Aachs%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLoberg%26aufirst%3DR.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DPistillo%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DWells%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520highly%2520selective%2520thienopyridine%2520Janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8440%26epage%3D8450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taoka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zugay-Murphy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Discovery of 1-amino-5<i>H</i>-pyrido[4,3-<i>b</i>]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7334</span><span class="NLM_x">–</span> <span class="NLM_lpage">7349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200909u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7334-7349&author=J.+Limauthor=B.+Taokaauthor=R.+D.+Otteauthor=K.+Spencerauthor=C.+J.+Dinsmoreauthor=M.+D.+Altmanauthor=G.+Chanauthor=C.+Rosensteinauthor=S.+Sharmaauthor=H.+P.+Suauthor=A.+A.+Szewczakauthor=L.+Xuauthor=H.+Yinauthor=J.+Zugay-Murphyauthor=C.+G.+Marshallauthor=J.+R.+Young&title=Discovery+of+1-amino-5H-pyrido%5B4%2C3-b%5Dindol-4-carboxamide+inhibitors+of+Janus+kinase+2+%28JAK2%29+for+the+treatment+of+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1021%2Fjm200909u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200909u%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DTaoka%26aufirst%3DB.%26aulast%3DOtte%26aufirst%3DR.%2BD.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZugay-Murphy%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%25201-amino-5H-pyrido%255B4%252C3-b%255Dindol-4-carboxamide%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7334%26epage%3D7349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozina, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouthillette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: Hit to lead</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7421</span><span class="NLM_x">–</span> <span class="NLM_lpage">7425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7421-7425&author=T.+Siuauthor=E.+S.+Kozinaauthor=J.+Jungauthor=C.+Rosensteinauthor=A.+Mathurauthor=M.+D.+Altmanauthor=G.+Chanauthor=L.+Xuauthor=E.+Bachmanauthor=J.+R.+Moauthor=M.+Bouthilletteauthor=T.+Rushauthor=C.+J.+Dinsmoreauthor=C.+G.+Marshallauthor=J.+R.+Young&title=The+discovery+of+tricyclic+pyridone+JAK2+inhibitors.+Part+1%3A+Hit+to+lead"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DKozina%26aufirst%3DE.%2BS.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBachman%26aufirst%3DE.%26aulast%3DMo%26aufirst%3DJ.%2BR.%26aulast%3DBouthillette%26aufirst%3DM.%26aulast%3DRush%26aufirst%3DT.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520discovery%2520of%2520tricyclic%2520pyridone%2520JAK2%2520inhibitors.%2520Part%25201%253A%2520Hit%2520to%2520lead%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7421%26epage%3D7425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Discovery of 5-chloro-<i>N</i>2-[(1<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i>4-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.+J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0lhg-Fft6amPHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35fR"><div class="casContent"><span class="casTitleNuber">35f</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0ljPqu99CVndfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourke, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrugia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feutrill, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nero, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikanyika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treutlein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5887</span><span class="NLM_x">–</span> <span class="NLM_lpage">5892</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5887-5892&author=C.+J.+Burnsauthor=D.+G.+Bourkeauthor=L.+Andrauauthor=X.+Buauthor=S.+A.+Charmanauthor=A.+C.+Donohueauthor=E.+Fantinoauthor=M.+Farrugiaauthor=J.+T.+Feutrillauthor=M.+Joffeauthor=M.+R.+Klingauthor=M.+Kurekauthor=T.+L.+Neroauthor=T.+Nguyenauthor=J.+T.+Palmerauthor=I.+Phillipsauthor=D.+M.+Shacklefordauthor=H.+Sikanyikaauthor=M.+Stylesauthor=S.+Suauthor=H.+Treutleinauthor=J.+Zengauthor=A.+F.+Wilks&title=Phenylaminopyrimidines+as+inhibitors+of+Janus+kinases+%28JAKs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DBourke%26aufirst%3DD.%2BG.%26aulast%3DAndrau%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonohue%26aufirst%3DA.%2BC.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DFarrugia%26aufirst%3DM.%26aulast%3DFeutrill%26aufirst%3DJ.%2BT.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DKurek%26aufirst%3DM.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPhillips%26aufirst%3DI.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DPhenylaminopyrimidines%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520%2528JAKs%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5887%26epage%3D5892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit35h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Hexner, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdikoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swider, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span> </span><span class="NLM_article-title">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5663</span><span class="NLM_x">–</span> <span class="NLM_lpage">5671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5663-5671&author=E.+O.+Hexnerauthor=C.+Serdikoffauthor=M.+Janauthor=C.+R.+Swiderauthor=C.+Robinsonauthor=S.+Yangauthor=T.+Angelesauthor=S.+G.+Emersonauthor=M.+Carrollauthor=B.+Ruggeriauthor=P.+Dobrzanski&title=Lestaurtinib+%28CEP701%29+is+a+JAK2+inhibitor+that+suppresses+JAK2%2FSTAT5+signaling+and+the+proliferation+of+primary+erythroid+cells+from+patients+with+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DSwider%26aufirst%3DC.%2BR.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DEmerson%26aufirst%3DS.%2BG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDobrzanski%26aufirst%3DP.%26atitle%3DLestaurtinib%2520%2528CEP701%2529%2520is%2520a%2520JAK2%2520inhibitor%2520that%2520suppresses%2520JAK2%252FSTAT5%2520signaling%2520and%2520the%2520proliferation%2520of%2520primary%2520erythroid%2520cells%2520from%2520patients%2520with%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5663%26epage%3D5671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kulagowski, J. J.; Blair, W.; Bull, R. J.; Chang, C.; Deshmukh, G.; Dyke, H. J.; Eigenbrot, C.; Ghilardi, N.; Gibbons, P.; Harrison, T. K.; Hewitt, P. R.; Liimatta, M.; Hurley, C. A.; Johnson, A.; Johnson, T.; Kenny, J. R.; Bir Kohli, P.; Maxey, R. J.; Mendonca, R.; Mortara, K.; Murray, J.; Narukulla, R.; Shia, S.; Steffek, M.; Ubhayakar, S.; Ultsch, M.; van Abbema, A.; Ward, S. I.; Waszkowycz, B.; Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 Inhibitors</span>.  <span class="citation_source-journal">J. Med. Chem.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1021/jm300438j</span> . Published online: May 16,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+J.+Kulagowski&author=W.+Blair&author=R.+J.+Bull&author=C.+Chang&author=G.+Deshmukh&author=H.+J.+Dyke&author=C.+Eigenbrot&author=N.+Ghilardi&author=P.+Gibbons&author=T.+K.+Harrison&author=P.+R.+Hewitt&author=M.+Liimatta&author=C.+A.+Hurley&author=A.+Johnson&author=T.+Johnson&author=J.+R.+Kenny&author=P.+Bir+Kohli&author=R.+J.+Maxey&author=R.+Mendonca&author=K.+Mortara&author=J.+Murray&author=R.+Narukulla&author=S.+Shia&author=M.+Steffek&author=S.+Ubhayakar&author=M.+Ultsch&author=A.+van+Abbema&author=S.+I.+Ward&author=B.+Waszkowycz&author=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+Inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm300438j%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">Prior to commencement of our work, a series of related, imidazolone-containing compounds had been described as JAK3 inhibitors: </p></div><div class="NLM_citation" id="cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Inoue, T.; Tanaka, A.; Nakai, K.; Sasaki, H.; Takahashi, F.; Shirakami, S.; Hatanaka, K.; Nakajima, Y.; Mukoyoshi, K.; Hamaguchi, H.; Kunikawa, S.; Higashi, Y.</span><span> </span><span class="NLM_article-title">Heterocyclic Janus Kinase 3 Inhibitors</span>. WO2007077949,<span class="NLM_x"> </span><span class="NLM_year">2007</span>. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Inoue&author=A.+Tanaka&author=K.+Nakai&author=H.+Sasaki&author=F.+Takahashi&author=S.+Shirakami&author=K.+Hatanaka&author=Y.+Nakajima&author=K.+Mukoyoshi&author=H.+Hamaguchi&author=S.+Kunikawa&author=Y.+Higashi&title=Heterocyclic+Janus+Kinase+3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DHeterocyclic%2520Janus%2520Kinase%25203%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">More recently, during the course of or after completion of our work, patent applications have appeared describing other tricyclic azaindole-containing scaffolds as JAK inhibitors. These include azaindole annelated by pyrrole:</p></div><div class="NLM_citation" id="cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shirakami, S.; Nakajima, Y.; Maeda, J.; Tominaga, H.; Yamagishi, H.; Hondo, T.; Inami, M.; Morio, H.; Inoue, T.; Mizutani, T.; Ishioka, H.</span><span> </span><span class="NLM_article-title">Fused Pyrrolopyridine Derivative</span>. WO2010119875,<span class="NLM_x"> </span><span class="NLM_year">2010</span>. <div class="note"><p class="first last">Azaindole annelated by pyrrole, pyrazole, and isoxazole:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Shirakami&author=Y.+Nakajima&author=J.+Maeda&author=H.+Tominaga&author=H.+Yamagishi&author=T.+Hondo&author=M.+Inami&author=H.+Morio&author=T.+Inoue&author=T.+Mizutani&author=H.+Ishioka&title=Fused+Pyrrolopyridine+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShirakami%26aufirst%3DS.%26atitle%3DFused%2520Pyrrolopyridine%2520Derivative%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wishart, N.; Argiriadi, M.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R.</span><span> </span><span class="NLM_article-title">Novel Tricyclic Compounds</span>. WO2009152133,<span class="NLM_x"> </span><span class="NLM_year">2009</span>. <div class="note"><p class="first last">Azaindole annelated by isothiazole, triazole, and imidazole:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+Wishart&author=M.+Argiriadi&author=D.+J.+Calderwood&author=A.+M.+Ericsson&author=B.+A.+Fiamengo&author=K.+E.+Frank&author=M.+Friedman&author=D.+M.+George&author=E.+R.+Goedken&author=N.+S.+Josephsohn&author=B.+C.+Li&author=M.+J.+Morytko&author=K.+D.+Stewart&author=J.+W.+Voss&author=G.+A.+Wallace&author=L.+Wang&author=K.+R.+Woller&title=Novel+Tricyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DNovel%2520Tricyclic%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Wishart, N.; Argiriadi, M.; Breinlinger, E. C.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Mullen, K. D.; Somal, G.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R.</span><span> </span><span class="NLM_article-title">Novel Tricyclic Compounds</span>. WO2011068899,<span class="NLM_x"> </span><span class="NLM_year">2011</span>. <div class="note"><p class="first last">Tricyclic systems related to <b>3</b> but having distinct substitution on the core and probably employing an alternative hinge-binding mode have recently appeared as JAK2 inhibitors:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Wishart&author=M.+Argiriadi&author=E.+C.+Breinlinger&author=D.+J.+Calderwood&author=A.+M.+Ericsson&author=B.+A.+Fiamengo&author=K.+E.+Frank&author=M.+Friedman&author=D.+M.+George&author=E.+R.+Goedken&author=N.+S.+Josephsohn&author=B.+C.+Li&author=M.+J.+Morytko&author=K.+D.+Mullen&author=G.+Somal&author=K.+D.+Stewart&author=J.+W.+Voss&author=G.+A.+Wallace&author=L.+Wang&author=K.+R.+Woller&title=Novel+Tricyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DNovel%2520Tricyclic%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit37e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Purandare, A. V.; Grebinski, J. W.; Hart, A.; Inghrim, J.; Schroeder, G.; Wan, H.</span><span> </span><span class="NLM_article-title">JAK2 Inhibitors and Their Use for the Treatment of Myeloproliferative Diseases and Cancer</span>. WO2011028864,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+V.+Purandare&author=J.+W.+Grebinski&author=A.+Hart&author=J.+Inghrim&author=G.+Schroeder&author=H.+Wan&title=JAK2+Inhibitors+and+Their+Use+for+the+Treatment+of+Myeloproliferative+Diseases+and+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DJAK2%2520Inhibitors%2520and%2520Their%2520Use%2520for%2520the%2520Treatment%2520of%2520Myeloproliferative%2520Diseases%2520and%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="note"><p class="first last">EC<sub>50</sub> values for compounds that do not achieve at least 50% inhibition at the highest concentration tested (10000 nM) in the cell based assays are considered to be noncalculable and are reported as >10000 nM. Because of normal run-to-run variability, some weakly potent compounds achieve >50% inhibition in some, but not all, of the replicate runs. In these cases, we report EC<sub>50</sub> > <i>X</i>, where <i>X</i> is the arithmetic mean of all the individual EC<sub>50</sub> values, both calculable and noncalculable. For example, compound <b>3</b> displayed replicate EC<sub>50</sub> values of 6300, >10000, and >10000 nM in the EPO-pSTAT5 assay; thus, the average EC<sub>50</sub> is reported as >8800 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selzer, P.</span><span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3714</span><span class="NLM_x">–</span> <span class="NLM_lpage">3717</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0lglk0-XRgPsGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="note"><p class="first last">Prior to synthesis, predicted log <i>D</i> values were calculated using the MoKa sofware (<a href="http://www.moldiscovery.com" class="extLink">www.moldiscovery.com</a> (ref <a class="ref internalNav" href="#cit40a" aria-label="40a">40a</a>) and a custom p<i>K</i><sub>a</sub> model (ref <a class="ref internalNav" href="#cit40b" aria-label="40b">40b</a>). </p></div><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original p<i>K</i><sub>a</sub> prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0liF9hkjH7H-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending p<i>K</i><sub>a</sub> prediction accuracy: high-throughput p<i>K</i><sub>a</sub> measurements to understand p<i>K</i><sub>a</sub> modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0liF9hkjH7H-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="note"><p class="first last">The <i>t</i> tests were conducted on the JAK1 and JAK2 <i>K</i><sub>i</sub> values for <b>4</b>, <b>11</b>, <b>14</b>, and <b>20</b>. In each case, JAK1 biochemical activity was found to be inhibited to a greater extent than the corresponding JAK2 biochemical activity by a statistically significant margin (<i>p</i> < 0.02 for <b>14</b>, <i>p</i> < 0.001 for <b>4</b>, <b>11</b>, and <b>20</b>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Balague, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span> </span><span class="NLM_article-title">Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1320</span><span class="NLM_x">–</span> <span class="NLM_lpage">1332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1111%2Fj.1476-5381.2012.01836.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=22229697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1320-1332&author=C.+Balagueauthor=M.+Pontauthor=N.+Pratsauthor=N.+Godessart&title=Profiling+of+dihydroorotate+dehydrogenase%2C+p38+and+JAK+inhibitors+in+the+rat+adjuvant-induced+arthritis+model%3A+a+translational+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study</span></div><div class="casAuthors">Balague, C.; Pont, M.; Prats, N.; Godessart, N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1320-1332</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Translational animal models are essential in the prediction of the efficacy and side effects of new chem. entities.  We have carried out a thorough study of three distinct disease-modifying antirheumatic drugs (DMARDs) in an adjuvant-induced arthritis (AIA) model in the rat and critically appraised the results in the context of the reported clin. experience in rheumatoid arthritis (RA) patients.  Exptl. Approach Teriflunomide - a dihydroorotate dehydrogenase (DHODH) inhibitor; AL8697 - a selective p38 MAPK inhibitor; and tofacitinib - a Janus kinase (JAK) inhibitor; were selected as representatives of their class and dose-response studies carried out using a therapeutic 10-day administration scheme in arthritic rats.  Paw swelling and body wt. were periodically monitored, and joint radiol. and histol., lymph organ wt. and haematol. and biochem. parameters evaluated at study completion.  Key Results All three drugs demonstrated beneficial effects on paw swelling, bone lesions and splenomegalia, with p38 inhibition providing the best anti-inflammatory effect and JAK inhibition the best DMARD effect.  Leukopenia, body wt. loss and gastrointestinal toxicity were dose-dependently obsd. with teriflunomide treatment.  P38 MAPK inhibition induced leukocytosis and increased total plasma cholesterol.  JAK inhibition, normalized platelet, reticulocyte and neutrophil counts, and alanine aminotransferase (ALT) levels while inducing lymphopenia and cholesterolemia.  Conclusions and Implications This multiparametric approach can reveal specific drug properties and provide translational information.  Whereas the complex profile for p38 inhibition in AIA is not obsd. in human RA, immunosuppressants such as DHODH and JAK inhibitors show DMARD properties and side effects seen in both AIA and RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTidNBvH5aRrVg90H21EOLACvtfcHk0liF9hkjH7H-Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWmt7g%253D&md5=32eb083b1793cb1a23a0cc6539a31c2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01836.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01836.x%26sid%3Dliteratum%253Aachs%26aulast%3DBalague%26aufirst%3DC.%26aulast%3DPont%26aufirst%3DM.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DGodessart%26aufirst%3DN.%26atitle%3DProfiling%2520of%2520dihydroorotate%2520dehydrogenase%252C%2520p38%2520and%2520JAK%2520inhibitors%2520in%2520the%2520rat%2520adjuvant-induced%2520arthritis%2520model%253A%2520a%2520translational%2520study%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1320%26epage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><div class="note"><p class="first last">The maximum achievable oral bioavailability (<i>F</i><sub>max</sub>) is the product of the fraction absorbed (<i>F</i><sub>a</sub>), the fraction escaping intestinal metabolism (<i>F</i><sub>g</sub>), and the fraction escaping hepatic metabolism (<i>F</i><sub>h</sub>), as expressed by the equation <i>F</i><sub>max</sub> = <i>F</i><sub>a</sub><i>F</i><sub>g</sub><i>F</i><sub>h</sub>. Assuming a best case scenario of no intestinal wall metabolism and complete absorption of the oral dose (<i>F</i><sub>g</sub> and <i>F</i><sub>a</sub> are 1), the equation is simplified to <i>F</i><sub>max</sub> = <i>F</i><sub>h</sub>. Since <i>F</i><sub>h</sub> = 1 – CL/<i>Q</i><sub>h</sub>, where CL is clearance and <i>Q</i><sub>h</sub> is hepatic blood flow, it is apparent that the maximum achievable bioavailability should be controlled by clearance according to the equation <i>F</i><sub>max</sub> = 1 – CL/<i>Q</i><sub>h</sub>. Assuming a hepatic blood flow in the rat of 70 mL min<sup>–1</sup> kg<sup>–1</sup>, a compound with an iv clearance of 43 mL min<sup>–1</sup> kg<sup>–1</sup> should have an <i>F</i><sub>max</sub> of 39%. See the following: </p></div><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Järvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+J%C3%A4rvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0lhJ83WIDWYTpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bondi, D.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=D.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0lhJ83WIDWYTpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DD.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit44b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussinov, R.</span><span> </span><span class="NLM_article-title">A set of van der Waals and coulombic radii of protein atoms for molecular and solvent-accessible surface calculation, packing evaluation and docking</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=111-127&author=A.+Liauthor=R.+Nussinov&title=A+set+of+van+der+Waals+and+coulombic+radii+of+protein+atoms+for+molecular+and+solvent-accessible+surface+calculation%2C+packing+evaluation+and+docking"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DA%2520set%2520of%2520van%2520der%2520Waals%2520and%2520coulombic%2520radii%2520of%2520protein%2520atoms%2520for%2520molecular%2520and%2520solvent-accessible%2520surface%2520calculation%252C%2520packing%2520evaluation%2520and%2520docking%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1998%26volume%3D32%26spage%3D111%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="note"><p class="first last">Further details on the quantum mechanical calculations may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van Niel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locker, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. L.</span><span> </span><span class="NLM_article-title">Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2087</span><span class="NLM_x">–</span> <span class="NLM_lpage">2104</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm981133m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2087-2104&author=M.+B.+van+Nielauthor=I.+Collinsauthor=M.+S.+Beerauthor=H.+B.+Broughtonauthor=S.+K.+Chengauthor=S.+C.+Goodacreauthor=A.+Healdauthor=K.+L.+Lockerauthor=A.+M.+MacLeodauthor=D.+Morrisonauthor=C.+R.+Moyesauthor=D.+O%E2%80%99Connorauthor=A.+Pikeauthor=M.+Rowleyauthor=M.+G.+Russellauthor=B.+Sohalauthor=J.+A.+Stantonauthor=S.+Thomasauthor=H.+Verrierauthor=A.+P.+Wattauthor=J.+L.+Castro&title=Fluorination+of+3-%283-%28piperidin-1-yl%29propyl%29indoles+and+3-%283-%28piperazin-1-yl%29propyl%29indoles+gives+selective+human+5-HT1D+receptor+ligands+with+improved+pharmacokinetic+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1021%2Fjm981133m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981133m%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNiel%26aufirst%3DM.%2BB.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DBeer%26aufirst%3DM.%2BS.%26aulast%3DBroughton%26aufirst%3DH.%2BB.%26aulast%3DCheng%26aufirst%3DS.%2BK.%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26aulast%3DHeald%26aufirst%3DA.%26aulast%3DLocker%26aufirst%3DK.%2BL.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DD.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DM.%2BG.%26aulast%3DSohal%26aufirst%3DB.%26aulast%3DStanton%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DVerrier%26aufirst%3DH.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DCastro%26aufirst%3DJ.%2BL.%26atitle%3DFluorination%2520of%25203-%25283-%2528piperidin-1-yl%2529propyl%2529indoles%2520and%25203-%25283-%2528piperazin-1-yl%2529propyl%2529indoles%2520gives%2520selective%2520human%25205-HT1D%2520receptor%2520ligands%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2087%26epage%3D2104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Basarab, G.; Ni, H.; Sherer, B; Zhou, F.</span><span> </span><span class="NLM_article-title">Chemical Compounds</span>. WO2007071965,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=G.+Basarab&author=H.+Ni&author=B+Sherer&author=F.+Zhou&title=Chemical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%26atitle%3DChemical%2520Compounds%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shirakami, S.; Takayuki, I.; Mukoyoshi, K.; Nakajima, Y.; Usuda, H.; Hamaguchi, H.; Higashi, Y.; Hatanaka, K.</span><span> </span><span class="NLM_article-title">Condensed Pyridine Compounds</span>. EP2123651,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+Shirakami&author=I.+Takayuki&author=K.+Mukoyoshi&author=Y.+Nakajima&author=H.+Usuda&author=H.+Hamaguchi&author=Y.+Higashi&author=K.+Hatanaka&title=Condensed+Pyridine+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShirakami%26aufirst%3DS.%26atitle%3DCondensed%2520Pyridine%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Remen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezencon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard-Bildstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corminboeuf, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisostomi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sifferlen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delahaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span> </span><span class="NLM_article-title">New classes of potent and bioavailable human renin inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6762</span><span class="NLM_x">–</span> <span class="NLM_lpage">6765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6762-6765&author=L.+Remenauthor=O.+Bezenconauthor=S.+Richard-Bildsteinauthor=D.+Burauthor=L.+Pradeauthor=O.+Corminboeufauthor=C.+Bossauthor=C.+Grisostomiauthor=T.+Sifferlenauthor=P.+Stricknerauthor=P.+Hessauthor=S.+Delahayeauthor=A.+Treiberauthor=T.+Wellerauthor=C.+Binkertauthor=B.+Steinerauthor=W.+Fischli&title=New+classes+of+potent+and+bioavailable+human+renin+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRemen%26aufirst%3DL.%26aulast%3DBezencon%26aufirst%3DO.%26aulast%3DRichard-Bildstein%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DPrade%26aufirst%3DL.%26aulast%3DCorminboeuf%26aufirst%3DO.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DGrisostomi%26aufirst%3DC.%26aulast%3DSifferlen%26aufirst%3DT.%26aulast%3DStrickner%26aufirst%3DP.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DDelahaye%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DFischli%26aufirst%3DW.%26atitle%3DNew%2520classes%2520of%2520potent%2520and%2520bioavailable%2520human%2520renin%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6762%26epage%3D6765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Brocklehurst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laumen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Vecchia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vögtle, M.</span><span> </span><span class="NLM_article-title">Diastereoisomeric salt formation and enzyme-catalyzed kinetic resolution as complementary methods for the chiral separation of <i>cis</i>-/<i>trans</i>-enantiomers of 3-aminocyclohexanol</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/doi/10.1021/op1002424" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=294-300&author=C.+E.+Brocklehurstauthor=K.+Laumenauthor=L.+La+Vecchiaauthor=D.+Shawauthor=M.+V%C3%B6gtle&title=Diastereoisomeric+salt+formation+and+enzyme-catalyzed+kinetic+resolution+as+complementary+methods+for+the+chiral+separation+of+cis-%2Ftrans-enantiomers+of+3-aminocyclohexanol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fop1002424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop1002424%26sid%3Dliteratum%253Aachs%26aulast%3DBrocklehurst%26aufirst%3DC.%2BE.%26aulast%3DLaumen%26aufirst%3DK.%26aulast%3DLa%2BVecchia%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DV%25C3%25B6gtle%26aufirst%3DM.%26atitle%3DDiastereoisomeric%2520salt%2520formation%2520and%2520enzyme-catalyzed%2520kinetic%2520resolution%2520as%2520complementary%2520methods%2520for%2520the%2520chiral%2520separation%2520of%2520cis-%252Ftrans-enantiomers%2520of%25203-aminocyclohexanol%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Erickson, S. D.; Qian, Y.; Tilley, J. W.</span><span> </span><span class="NLM_article-title">Diaminocyclohexane and Diaminocyclopentane Derivatives</span>. WO2008065021,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+D.+Erickson&author=Y.+Qian&author=J.+W.+Tilley&title=Diaminocyclohexane+and+Diaminocyclopentane+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DS.%2BD.%26atitle%3DDiaminocyclohexane%2520and%2520Diaminocyclopentane%2520Derivatives%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3a','cit3b'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c','cit7d'],'ref8':['cit8a','cit8b'],'ref9':['cit9a','cit9b'],'ref10':['cit10'],'ref11':['cit11a','cit11b','cit11c'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':[],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24a','cit24b','cit24c'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b'],'ref34':['cit34'],'ref35':['cit35a','cit35b','cit35c','cit35d','cit35e','cit35f','cit35g','cit35h'],'ref36':['cit36'],'ref37':['cit37a','cit37b','cit37c','cit37d','cit37e'],'ref38':[],'ref39':['cit39'],'ref40':['cit40a','cit40b'],'ref41':[],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44a','cit44b'],'ref45':[],'ref46':['cit46a','cit46b'],'ref47':['cit47a','cit47b'],'ref48':['cit48'],'ref49':['cit49']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 38 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ryan R. Davis, Baoli Li, Sang Y. Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, <span class="NLM_string-name hlFld-ContribAuthor">Ernst Schönbrunn</span>. </span><span class="cited-content_cbyCitation_article-title">Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (4)
                                     , 2228-2241. <a href="https://doi.org/10.1021/acs.jmedchem.0c01952" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01952%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252BInsights%252Binto%252BJAK2%252BInhibition%252Bby%252BRuxolitinib%25252C%252BFedratinib%25252C%252Band%252BDerivatives%252BThereof%26aulast%3DDavis%26aufirst%3DRyan%2BR.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D17112020%26date%3D11022021%26volume%3D64%26issue%3D4%26spage%3D2228%26epage%3D2241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Minjian Yang, Bingzhong Tao, Chengjuan Chen, Wenqiang Jia, Shaolei Sun, Tiantai Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Xiaojian Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (12)
                                     , 5002-5012. <a href="https://doi.org/10.1021/acs.jcim.9b00798" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00798%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DMachine%252BLearning%252BModels%252BBased%252Bon%252BMolecular%252BFingerprints%252Band%252Ban%252BExtreme%252BGradient%252BBoosting%252BMethod%252BLead%252Bto%252Bthe%252BDiscovery%252Bof%252BJAK2%252BInhibitors%26aulast%3DYang%26aufirst%3DMinjian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15092019%26date%3D04122019%26date%3D20112019%26volume%3D59%26issue%3D12%26spage%3D5002%26epage%3D5012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mohamed
S. A. Elsayed, Jeffery J. Nielsen, Sungtae Park, Jeongho Park, Qingyang Liu, Chang H. Kim, Yves Pommier, Keli Agama, Philip S. Low, <span class="NLM_string-name hlFld-ContribAuthor">Mark Cushman</span>. </span><span class="cited-content_cbyCitation_article-title">Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) Series. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (23)
                                     , 10440-10462. <a href="https://doi.org/10.1021/acs.jmedchem.8b00510" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00510</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00510%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DApplication%252Bof%252BSequential%252BPalladium%252BCatalysis%252Bfor%252Bthe%252BDiscovery%252Bof%252BJanus%252BKinase%252BInhibitors%252Bin%252Bthe%252BBenzo%25255Bc%25255Dpyrrolo%25255B2%25252C3-h%25255D%25255B1%25252C6%25255Dnaphthyridin-5-one%252B%252528BPN%252529%252BSeries%26aulast%3DElsayed%26aufirst%3DMohamed%2BS.%2BA.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D31032018%26date%3D21112018%26volume%3D61%26issue%3D23%26spage%3D10440%26epage%3D10462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tony  Siu</span>, <span class="hlFld-ContribAuthor ">Jason  Brubaker</span>, <span class="hlFld-ContribAuthor ">Peter  Fuller</span>, <span class="hlFld-ContribAuthor ">Luis  Torres</span>, <span class="hlFld-ContribAuthor ">Hongbo  Zeng</span>, <span class="hlFld-ContribAuthor ">Joshua  Close</span>, <span class="hlFld-ContribAuthor ">Dawn M.  Mampreian</span>, <span class="hlFld-ContribAuthor ">Feng  Shi</span>, <span class="hlFld-ContribAuthor ">Duan  Liu</span>, <span class="hlFld-ContribAuthor ">Xavier  Fradera</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Nathan  Bays</span>, <span class="hlFld-ContribAuthor ">Elma  Kadic</span>, <span class="hlFld-ContribAuthor ">Fang  He</span>, <span class="hlFld-ContribAuthor ">Peter  Goldenblatt</span>, <span class="hlFld-ContribAuthor ">Lynsey  Shaffer</span>, <span class="hlFld-ContribAuthor ">Sangita B.  Patel</span>, <span class="hlFld-ContribAuthor ">Charles A.  Lesburg</span>, <span class="hlFld-ContribAuthor ">Carla  Alpert</span>, <span class="hlFld-ContribAuthor ">Lauren  Dorosh</span>, <span class="hlFld-ContribAuthor ">Sujal V.  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Hongshi  Yu</span>, <span class="hlFld-ContribAuthor ">Joel  Klappenbach</span>, <span class="hlFld-ContribAuthor ">Fiona  Elwood</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Dinsmore</span>, <span class="hlFld-ContribAuthor ">Rafael  Fernandez</span>, <span class="hlFld-ContribAuthor ">Lily  Moy</span>, and <span class="hlFld-ContribAuthor ">Jonathan R.  Young</span>  . </span><span class="cited-content_cbyCitation_article-title">The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (23)
                                     , 9676-9690. <a href="https://doi.org/10.1021/acs.jmedchem.7b01135" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01135</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01135%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BDiscovery%252Bof%252B3-%252528%2525284-Chloro-3-methoxyphenyl%252529amino%252529-1-%252528%2525283R%25252C4S%252529-4-cyanotetrahydro-2H-pyran-3-yl%252529-1H-pyrazole-4-carboxamide%25252C%252Ba%252BHighly%252BLigand%252BEfficient%252Band%252BEfficacious%252BJanus%252BKinase%252B1%252BSelective%252BInhibitor%252Bwith%252BFavorable%252BPharmacokinetic%252BProperties%26aulast%3DSiu%26aufirst%3DTony%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D04082017%26date%3D04122017%26date%3D14122017%26date%3D20112017%26volume%3D60%26issue%3D23%26spage%3D9676%26epage%3D9690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Raphaëlle  Berger</span>, <span class="hlFld-ContribAuthor ">Kristin  Goldberg</span>, <span class="hlFld-ContribAuthor ">Rachel T.  Nishimura</span>, <span class="hlFld-ContribAuthor ">John  Reilly</span>, <span class="hlFld-ContribAuthor ">Paul  Richardson</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Edward C.  Sherer</span>, <span class="hlFld-ContribAuthor ">Brian A.  Sparling</span>, and <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>  . </span><span class="cited-content_cbyCitation_article-title">Sustainable Practices in Medicinal Chemistry Part 2: Green by Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (14)
                                     , 5955-5968. <a href="https://doi.org/10.1021/acs.jmedchem.6b01837" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01837%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSustainable%252BPractices%252Bin%252BMedicinal%252BChemistry%252BPart%252B2%25253A%252BGreen%252Bby%252BDesign%26aulast%3DAliagas%26aufirst%3DIgnacio%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D14122016%26date%3D12042017%26date%3D27072017%26date%3D04042017%26volume%3D60%26issue%3D14%26spage%3D5955%26epage%3D5968" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dávid  Bajusz</span>, <span class="hlFld-ContribAuthor ">György G.  Ferenczy</span>, and <span class="hlFld-ContribAuthor ">György M.  Keserű</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (1)
                                     , 234-247. <a href="https://doi.org/10.1021/acs.jcim.5b00634" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00634</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00634%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDiscovery%252Bof%252BSubtype%252BSelective%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bby%252BStructure-Based%252BVirtual%252BScreening%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26date%3D2015%26date%3D2015%26date%3D18102015%26date%3D31122015%26date%3D25012016%26date%3D18122015%26volume%3D56%26issue%3D1%26spage%3D234%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atli  Thorarensen</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Banker</span>, <span class="hlFld-ContribAuthor ">Andrew  Fensome</span>, <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>, <span class="hlFld-ContribAuthor ">Brian  Juba</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Robert M.  Czerwinski</span>, and <span class="hlFld-ContribAuthor ">Agustin  Casimiro-Garcia</span>  . </span><span class="cited-content_cbyCitation_article-title">ATP-Mediated Kinome Selectivity: The Missing Link in Understanding the Contribution of Individual JAK Kinase Isoforms to Cellular Signaling. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2014,</strong> <em>9 </em>
                                    (7)
                                     , 1552-1558. <a href="https://doi.org/10.1021/cb5002125" title="DOI URL">https://doi.org/10.1021/cb5002125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb5002125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb5002125%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DATP-Mediated%252BKinome%252BSelectivity%25253A%252BThe%252BMissing%252BLink%252Bin%252BUnderstanding%252Bthe%252BContribution%252Bof%252BIndividual%252BJAK%252BKinase%252BIsoforms%252Bto%252BCellular%252BSignaling%26aulast%3DThorarensen%26aufirst%3DAtli%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D19032014%26date%3D12052014%26date%3D28052014%26date%3D18072014%26date%3D12052014%26volume%3D9%26issue%3D7%26spage%3D1552%26epage%3D1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James D.  Clark</span>, <span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, and <span class="hlFld-ContribAuthor ">Jean-Baptiste  Telliez</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5023-5038. <a href="https://doi.org/10.1021/jm401490p" title="DOI URL">https://doi.org/10.1021/jm401490p</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401490p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401490p%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BJanus%252BKinase%252B%252528JAK%252529%252BInhibitors%252Bfor%252BInflammatory%252BDiseases%26aulast%3DClark%26aufirst%3DJames%2BD.%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D25092013%26date%3D23012014%26date%3D26062014%26date%3D13012014%26volume%3D57%26issue%3D12%26spage%3D5023%26epage%3D5038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon J.  Shaw</span>, <span class="hlFld-ContribAuthor ">Dane A.  Goff</span>, <span class="hlFld-ContribAuthor ">Luke A.  Boralsky</span>, <span class="hlFld-ContribAuthor ">Mark  Irving</span>, and <span class="hlFld-ContribAuthor ">Rajinder  Singh</span>  . </span><span class="cited-content_cbyCitation_article-title">Enantioselective Synthesis of cis-3-Fluoropiperidin-4-ol, a Building Block for Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>78 </em>
                                    (17)
                                     , 8892-8897. <a href="https://doi.org/10.1021/jo401352z" title="DOI URL">https://doi.org/10.1021/jo401352z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo401352z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo401352z%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DEnantioselective%252BSynthesis%252Bof%252Bcis-3-Fluoropiperidin-4-ol%25252C%252Ba%252BBuilding%252BBlock%252Bfor%252BMedicinal%252BChemistry%26aulast%3DShaw%26aufirst%3DSimon%2BJ.%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D24062013%26date%3D19082013%26date%3D06092013%26volume%3D78%26issue%3D17%26spage%3D8892%26epage%3D8897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Stuart I.  Ward</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Mercedesz  Balazs</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Richard  Bull</span>, <span class="hlFld-ContribAuthor ">Paroma  Chakravarty</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Peter  Crackett</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Jason  DeVoss</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Charles  Ellwood</span>, <span class="hlFld-ContribAuthor ">Simon  Gaines</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Stefan  Gradl</span>, <span class="hlFld-ContribAuthor ">Peter  Gribling</span>, <span class="hlFld-ContribAuthor ">Chris  Hamman</span>, <span class="hlFld-ContribAuthor ">Eric  Harstad</span>, <span class="hlFld-ContribAuthor ">Peter  Hewitt</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Tony  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Michael F. T.  Koehler</span>, <span class="hlFld-ContribAuthor ">Pawan  Bir Kohli</span>, <span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Jiangpeng  Liao</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Raman  Narukulla</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Austin  Reeve</span>, <span class="hlFld-ContribAuthor ">Scott  Savage</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Barbara  Avitabile-Woo</span>, <span class="hlFld-ContribAuthor ">Yisong  Xiao</span>, <span class="hlFld-ContribAuthor ">Jing  Yang</span>, and <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (11)
                                     , 4764-4785. <a href="https://doi.org/10.1021/jm4004895" title="DOI URL">https://doi.org/10.1021/jm4004895</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm4004895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm4004895%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252BC-2%252BHydroxyethyl%252BImidazopyrrolopyridines%252Bas%252BPotent%252BJAK1%252BInhibitors%252Bwith%252BFavorable%252BPhysicochemical%252BProperties%252Band%252BHigh%252BSelectivity%252Bover%252BJAK2%26aulast%3DZak%26aufirst%3DMark%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D04042013%26date%3D31052013%26date%3D13062013%26date%3D09052013%26volume%3D56%26issue%3D11%26spage%3D4764%26epage%3D4785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily J.  Hanan</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Jeff  Blaney</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Sean  Flynn</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Janusz  Kulagowski</span>, <span class="hlFld-ContribAuthor ">Leslie  Lee</span>, <span class="hlFld-ContribAuthor ">Steven R.  Magnuson</span>, <span class="hlFld-ContribAuthor ">Claire  Morris</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Richard M.  Pastor</span>, <span class="hlFld-ContribAuthor ">Tom  Rawson</span>, <span class="hlFld-ContribAuthor ">Michael  Siu</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Aihe  Zhou</span>, <span class="hlFld-ContribAuthor ">Deepak  Sampath</span>, and <span class="hlFld-ContribAuthor ">Joseph P.  Lyssikatos</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Selective Pyrazolopyrimidine Janus Kinase 2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2012,</strong> <em>55 </em>
                                    (22)
                                     , 10090-10107. <a href="https://doi.org/10.1021/jm3012239" title="DOI URL">https://doi.org/10.1021/jm3012239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm3012239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm3012239%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BSelective%252BPyrazolopyrimidine%252BJanus%252BKinase%252B2%252BInhibitors%26aulast%3DHanan%26aufirst%3DEmily%2BJ.%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D22082012%26date%3D24102012%26date%3D26112012%26date%3D12102012%26volume%3D55%26issue%3D22%26spage%3D10090%26epage%3D10107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Xu</span>, <span class="hlFld-ContribAuthor ">Pei  Shen</span>, <span class="hlFld-ContribAuthor ">Hai  Wang</span>, <span class="hlFld-ContribAuthor ">Lian  Qin</span>, <span class="hlFld-ContribAuthor ">Jie  Ren</span>, <span class="hlFld-ContribAuthor ">Qiushuang  Sun</span>, <span class="hlFld-ContribAuthor ">Raoling  Ge</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>, <span class="hlFld-ContribAuthor ">Yi  Zhong</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">JuBo  Wang</span>, <span class="hlFld-ContribAuthor ">Zhixia  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113394. <a href="https://doi.org/10.1016/j.ejmech.2021.113394" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113394</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113394%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bimidazopyrrolopyridines%252Bderivatives%252Bas%252Bnovel%252Band%252Bselective%252Binhibitors%252Bof%252BJAK2%26aulast%3DXu%26aufirst%3DPengfei%26date%3D2021%26volume%3D218%26spage%3D113394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Safa  Daoud</span>, <span class="hlFld-ContribAuthor ">Mutasem O.  Taha</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore modeling of JAK1: A target infested with activity-cliffs. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>99 </em>, 107615. <a href="https://doi.org/10.1016/j.jmgm.2020.107615" title="DOI URL">https://doi.org/10.1016/j.jmgm.2020.107615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2020.107615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2020.107615%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DPharmacophore%252Bmodeling%252Bof%252BJAK1%25253A%252BA%252Btarget%252Binfested%252Bwith%252Bactivity-cliffs%26aulast%3DDaoud%26aufirst%3DSafa%26date%3D2020%26volume%3D99%26spage%3D107615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yifan  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiao  Liu</span>, <span class="hlFld-ContribAuthor ">Youzhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Long  Peng</span>, <span class="hlFld-ContribAuthor ">John Z. H.  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Residue-specific free energy analysis in ligand bindings to JAK2. </span><span class="cited-content_cbyCitation_journal-name">Molecular Physics</span><span> <strong>2018,</strong> <em>116 </em>
                                    (19-20)
                                     , 2633-2641. <a href="https://doi.org/10.1080/00268976.2018.1442596" title="DOI URL">https://doi.org/10.1080/00268976.2018.1442596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00268976.2018.1442596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00268976.2018.1442596%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Physics%26atitle%3DResidue-specific%252Bfree%252Benergy%252Banalysis%252Bin%252Bligand%252Bbindings%252Bto%252BJAK2%26aulast%3DZhou%26aufirst%3DYifan%26date%3D2018%26date%3D2018%26volume%3D116%26issue%3D19-20%26spage%3D2633%26epage%3D2641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haneesh  Jasuja</span>, <span class="hlFld-ContribAuthor ">Navriti  Chadha</span>, <span class="hlFld-ContribAuthor ">Pankaj Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Maninder  Kaur</span>, <span class="hlFld-ContribAuthor ">Malkeet Singh  Bahia</span>, <span class="hlFld-ContribAuthor ">Om  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Putative dual inhibitors of Janus kinase 1 and 3 (JAK1/3): Pharmacophore based hierarchical virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2018,</strong> <em>76 </em>, 109-117. <a href="https://doi.org/10.1016/j.compbiolchem.2018.07.009" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.07.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.07.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.07.009%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DPutative%252Bdual%252Binhibitors%252Bof%252BJanus%252Bkinase%252B1%252Band%252B3%252B%252528JAK1%25252F3%252529%25253A%252BPharmacophore%252Bbased%252Bhierarchical%252Bvirtual%252Bscreening%26aulast%3DJasuja%26aufirst%3DHaneesh%26date%3D2018%26volume%3D76%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fumi  Okabe-Nakahara</span>, <span class="hlFld-ContribAuthor ">Eiichi  Masumoto</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Maruoka</span>, <span class="hlFld-ContribAuthor ">Kenji  Yamagata</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Novel Angular and Linear Fused [5-6-5] Heterocycles by the Reaction of Methyl Cyano-(3-cyano-4,5-dihydro-2(3H)-furanylidene)acetate with Hydrazines and Dimethylformamide Dimethyl Acetal. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2018,</strong> <em>96 </em>
                                    (4)
                                     , 664. <a href="https://doi.org/10.3987/COM-17-13861" title="DOI URL">https://doi.org/10.3987/COM-17-13861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-17-13861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-17-13861%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252BNovel%252BAngular%252Band%252BLinear%252BFused%252B%25255B5-6-5%25255D%252BHeterocycles%252Bby%252Bthe%252BReaction%252Bof%252BMethyl%252BCyano-%2525283-cyano-4%25252C5-dihydro-2%2525283H%252529-furanylidene%252529acetate%252Bwith%252BHydrazines%252Band%252BDimethylformamide%252BDimethyl%252BAcetal%26aulast%3DOkabe-Nakahara%26aufirst%3DFumi%26date%3D2018%26volume%3D96%26issue%3D4%26spage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramesh  Itteboina</span>, <span class="hlFld-ContribAuthor ">Srilata  Ballu</span>, <span class="hlFld-ContribAuthor ">Sree Kanth  Sivan</span>, <span class="hlFld-ContribAuthor ">Vijjulatha  Manga</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modeling-driven approach for identification of Janus kinase 1 inhibitors through 3D-QSAR, docking and molecular dynamics simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Receptors and Signal Transduction</span><span> <strong>2017,</strong> <em>37 </em>
                                    (5)
                                     , 453-469. <a href="https://doi.org/10.1080/10799893.2017.1328442" title="DOI URL">https://doi.org/10.1080/10799893.2017.1328442</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/10799893.2017.1328442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F10799893.2017.1328442%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Receptors%2520and%2520Signal%2520Transduction%26atitle%3DMolecular%252Bmodeling-driven%252Bapproach%252Bfor%252Bidentification%252Bof%252BJanus%252Bkinase%252B1%252Binhibitors%252Bthrough%252B3D-QSAR%25252C%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bsimulations%26aulast%3DItteboina%26aufirst%3DRamesh%26date%3D2017%26date%3D2017%26volume%3D37%26issue%3D5%26spage%3D453%26epage%3D469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dávid  Bajusz</span>, <span class="hlFld-ContribAuthor ">György G.  Ferenczy</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2016,</strong> <em>70 </em>, 275-283. <a href="https://doi.org/10.1016/j.jmgm.2016.10.014" title="DOI URL">https://doi.org/10.1016/j.jmgm.2016.10.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2016.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2016.10.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DEnsemble%252Bdocking-based%252Bvirtual%252Bscreening%252Byields%252Bnovel%252Bspirocyclic%252BJAK1%252Binhibitors%26aulast%3DBajusz%26aufirst%3DD%25C3%25A1vid%26date%3D2016%26volume%3D70%26spage%3D275%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramesh  Itteboina</span>, <span class="hlFld-ContribAuthor ">Srilata  Ballu</span>, <span class="hlFld-ContribAuthor ">Sree Kanth  Sivan</span>, <span class="hlFld-ContribAuthor ">Vijjulatha  Manga</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2016,</strong> <em>64 </em>, 33-46. <a href="https://doi.org/10.1016/j.compbiolchem.2016.04.009" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2016.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2016.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2016.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DMolecular%252Bdocking%25252C%252B3D%252BQSAR%252Band%252Bdynamics%252Bsimulation%252Bstudies%252Bof%252Bimidazo-pyrrolopyridines%252Bas%252Bjanus%252Bkinase%252B1%252B%252528JAK%252B1%252529%252Binhibitors%26aulast%3DItteboina%26aufirst%3DRamesh%26date%3D2016%26volume%3D64%26spage%3D33%26epage%3D46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyungmi  Kim</span>, <span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Hyunah  Choo</span>, <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (14)
                                     , 3213-3215. <a href="https://doi.org/10.1016/j.bmcl.2016.05.078" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.05.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.05.078%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252BJAK1-selective%252Bbenzimidazole%252Binhibitors%252Bwith%252Benhanced%252Bmembrane%252Bpermeability%26aulast%3DKim%26aufirst%3DHyungmi%26date%3D2016%26volume%3D26%26issue%3D14%26spage%3D3213%26epage%3D3215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroaki  Yamagishi</span>, <span class="hlFld-ContribAuthor ">Shohei  Shirakami</span>, <span class="hlFld-ContribAuthor ">Yutaka  Nakajima</span>, <span class="hlFld-ContribAuthor ">Akira  Tanaka</span>, <span class="hlFld-ContribAuthor ">Fumie  Takahashi</span>, <span class="hlFld-ContribAuthor ">Hisao  Hamaguchi</span>, <span class="hlFld-ContribAuthor ">Keiko  Hatanaka</span>, <span class="hlFld-ContribAuthor ">Ayako  Moritomo</span>, <span class="hlFld-ContribAuthor ">Masamichi  Inami</span>, <span class="hlFld-ContribAuthor ">Yasuyuki  Higashi</span>, <span class="hlFld-ContribAuthor ">Takayuki  Inoue</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (15)
                                     , 4846-4859. <a href="https://doi.org/10.1016/j.bmc.2015.05.028" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.05.028</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.05.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.05.028%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3%25252C6-dihydroimidazo%25255B4%25252C5-d%25255Dpyrrolo%25255B2%25252C3-b%25255Dpyridin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bnovel%252BJAK%252Binhibitors%26aulast%3DYamagishi%26aufirst%3DHiroaki%26date%3D2015%26volume%3D23%26issue%3D15%26spage%3D4846%26epage%3D4859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ignacio  Aliagas</span>, <span class="hlFld-ContribAuthor ">Alberto  Gobbi</span>, <span class="hlFld-ContribAuthor ">Timothy  Heffron</span>, <span class="hlFld-ContribAuthor ">Man-Ling  Lee</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>, <span class="hlFld-ContribAuthor ">S. Cyrus  Khojasteh</span>. </span><span class="cited-content_cbyCitation_article-title">A probabilistic method to report predictions from a human liver microsomes stability QSAR model: a practical tool for drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2015,</strong> <em>29 </em>
                                    (4)
                                     , 327-338. <a href="https://doi.org/10.1007/s10822-015-9838-3" title="DOI URL">https://doi.org/10.1007/s10822-015-9838-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-015-9838-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-015-9838-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DA%252Bprobabilistic%252Bmethod%252Bto%252Breport%252Bpredictions%252Bfrom%252Ba%252Bhuman%252Bliver%252Bmicrosomes%252Bstability%252BQSAR%252Bmodel%25253A%252Ba%252Bpractical%252Btool%252Bfor%252Bdrug%252Bdiscovery%26aulast%3DAliagas%26aufirst%3DIgnacio%26date%3D2015%26date%3D2015%26volume%3D29%26issue%3D4%26spage%3D327%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J  Menet</span>, <span class="hlFld-ContribAuthor ">Oscar  Mammoliti</span>, <span class="hlFld-ContribAuthor ">Miriam  López-Ramos</span>. </span><span class="cited-content_cbyCitation_article-title">Progress toward JAK1-selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2015,</strong> <em>7 </em>
                                    (2)
                                     , 203-235. <a href="https://doi.org/10.4155/fmc.14.149" title="DOI URL">https://doi.org/10.4155/fmc.14.149</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.14.149&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.14.149%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DProgress%252Btoward%252BJAK1-selective%252Binhibitors%26aulast%3DMenet%26aufirst%3DChristel%2BJ%26date%3D2015%26volume%3D7%26issue%3D2%26spage%3D203%26epage%3D235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung Do  Kim</span>, <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">De Novo Design of 2-Amino-4-Alkylaminoquinazoline-7-Carboxamides as Potential Scaffold for JAK1-Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2014,</strong> <em>35 </em>
                                    (11)
                                     , 3377-3380. <a href="https://doi.org/10.5012/bkcs.2014.35.11.3377" title="DOI URL">https://doi.org/10.5012/bkcs.2014.35.11.3377</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5012/bkcs.2014.35.11.3377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5012%2Fbkcs.2014.35.11.3377%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DDe%252BNovo%252BDesign%252Bof%252B2-Amino-4-Alkylaminoquinazoline-7-Carboxamides%252Bas%252BPotential%252BScaffold%252Bfor%252BJAK1-Selective%252BInhibitors%26aulast%3DKim%26aufirst%3DMi%2BKyoung%26date%3D2014%26volume%3D35%26issue%3D11%26spage%3D3377%26epage%3D3380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javier  de Vicente</span>, <span class="hlFld-ContribAuthor ">Remy  Lemoine</span>, <span class="hlFld-ContribAuthor ">Mark  Bartlett</span>, <span class="hlFld-ContribAuthor ">Johannes C.  Hermann</span>, <span class="hlFld-ContribAuthor ">Mohammad  Hekmat-Nejad</span>, <span class="hlFld-ContribAuthor ">Robert  Henningsen</span>, <span class="hlFld-ContribAuthor ">Sue  Jin</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Hongju  Li</span>, <span class="hlFld-ContribAuthor ">Allen J.  Lovey</span>, <span class="hlFld-ContribAuthor ">John  Menke</span>, <span class="hlFld-ContribAuthor ">Linghao  Niu</span>, <span class="hlFld-ContribAuthor ">Vaishali  Patel</span>, <span class="hlFld-ContribAuthor ">Ann  Petersen</span>, <span class="hlFld-ContribAuthor ">Lina  Setti</span>, <span class="hlFld-ContribAuthor ">Ada  Shao</span>, <span class="hlFld-ContribAuthor ">Parcharee  Tivitmahaisoon</span>, <span class="hlFld-ContribAuthor ">Minh Diem  Vu</span>, <span class="hlFld-ContribAuthor ">Michael  Soth</span>. </span><span class="cited-content_cbyCitation_article-title">Scaffold hopping towards potent and selective JAK3 inhibitors: Discovery of novel C-5 substituted pyrrolopyrazines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (21)
                                     , 4969-4975. <a href="https://doi.org/10.1016/j.bmcl.2014.09.031" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.09.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.09.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DScaffold%252Bhopping%252Btowards%252Bpotent%252Band%252Bselective%252BJAK3%252Binhibitors%25253A%252BDiscovery%252Bof%252Bnovel%252BC-5%252Bsubstituted%252Bpyrrolopyrazines%26aulast%3Dde%2BVicente%26aufirst%3DJavier%26date%3D2014%26volume%3D24%26issue%3D21%26spage%3D4969%26epage%3D4975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Onnuri  Bae</span>, <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Molecular Docking Study of Flavonol Derivatives as Selective JAK1 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2014,</strong> <em>35 </em>
                                    (8)
                                     , 2581-2584. <a href="https://doi.org/10.5012/bkcs.2014.35.8.2581" title="DOI URL">https://doi.org/10.5012/bkcs.2014.35.8.2581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5012/bkcs.2014.35.8.2581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5012%2Fbkcs.2014.35.8.2581%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BMolecular%252BDocking%252BStudy%252Bof%252BFlavonol%252BDerivatives%252Bas%252BSelective%252BJAK1%252BInhibitors%26aulast%3DKim%26aufirst%3DMi%2BKyoung%26date%3D2014%26volume%3D35%26issue%3D8%26spage%3D2581%26epage%3D2584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H.  Jasuja</span>, <span class="hlFld-ContribAuthor ">N.  Chadha</span>, <span class="hlFld-ContribAuthor ">M.  Kaur</span>, <span class="hlFld-ContribAuthor ">O.  Silakari</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2. </span><span class="cited-content_cbyCitation_journal-name">SAR and QSAR in Environmental Research</span><span> <strong>2014,</strong> <em>25 </em>
                                    (8)
                                     , 617-636. <a href="https://doi.org/10.1080/1062936X.2014.884163" title="DOI URL">https://doi.org/10.1080/1062936X.2014.884163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/1062936X.2014.884163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F1062936X.2014.884163%26sid%3Dliteratum%253Aachs%26jtitle%3DSAR%2520and%2520QSAR%2520in%2520Environmental%2520Research%26atitle%3DPharmacophore%252Band%252Bdocking-based%252Bvirtual%252Bscreening%252Bapproach%252Bfor%252Bthe%252Bdesign%252Bof%252Bnew%252Bdual%252Binhibitors%252Bof%252BJanus%252Bkinase%252B1%252Band%252BJanus%252Bkinase%252B2%26aulast%3DJasuja%26aufirst%3DH.%26date%3D2014%26date%3D2014%26volume%3D25%26issue%3D8%26spage%3D617%26epage%3D636" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yasutaka  Hoashi</span>, <span class="hlFld-ContribAuthor ">Takafumi  Takai</span>, <span class="hlFld-ContribAuthor ">Tatsuki  Koike</span>, <span class="hlFld-ContribAuthor ">Osamu  Uchikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of a novel tricyclic 1,6,7,8-tetrahydro-2H-cyclopenta[b]furo[3,2-d]pyridine derivative, the 5-aza analog of ramelteon. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (29)
                                     , 4014-4016. <a href="https://doi.org/10.1016/j.tetlet.2014.05.036" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.05.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.05.036%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252Ba%252Bnovel%252Btricyclic%252B1%25252C6%25252C7%25252C8-tetrahydro-2H-cyclopenta%25255Bb%25255Dfuro%25255B3%25252C2-d%25255Dpyridine%252Bderivative%25252C%252Bthe%252B5-aza%252Banalog%252Bof%252Bramelteon%26aulast%3DHoashi%26aufirst%3DYasutaka%26date%3D2014%26volume%3D55%26issue%3D29%26spage%3D4014%26epage%3D4016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J  Menet</span>. </span><span class="cited-content_cbyCitation_article-title">Toward selective TYK2 inhibitors as therapeutic agents for the treatment of inflammatory diseases. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Patent Analyst</span><span> <strong>2014,</strong> <em>3 </em>
                                    (4)
                                     , 449-466. <a href="https://doi.org/10.4155/ppa.14.23" title="DOI URL">https://doi.org/10.4155/ppa.14.23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/ppa.14.23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fppa.14.23%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Patent%2520Analyst%26atitle%3DToward%252Bselective%252BTYK2%252Binhibitors%252Bas%252Btherapeutic%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Binflammatory%252Bdiseases%26aulast%3DMenet%26aufirst%3DChristel%2BJ%26date%3D2014%26volume%3D3%26issue%3D4%26spage%3D449%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>, <span class="hlFld-ContribAuthor ">Ellen  Pfaffenrot</span>, <span class="hlFld-ContribAuthor ">Silke  Bauer</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Tricyclic JAK3 Inhibitors with Picomolar Affinities as Novel Molecular Probes. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2014,</strong> <em>9 </em>
                                    (2)
                                     , 277-281. <a href="https://doi.org/10.1002/cmdc.201300520" title="DOI URL">https://doi.org/10.1002/cmdc.201300520</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201300520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201300520%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BTricyclic%252BJAK3%252BInhibitors%252Bwith%252BPicomolar%252BAffinities%252Bas%252BNovel%252BMolecular%252BProbes%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2014%26date%3D2014%26volume%3D9%26issue%3D2%26spage%3D277%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mi Kyoung  Kim</span>, <span class="hlFld-ContribAuthor ">Heerim  Shin</span>, <span class="hlFld-ContribAuthor ">Seo Young  Cho</span>, <span class="hlFld-ContribAuthor ">Youhoon  Chong</span>. </span><span class="cited-content_cbyCitation_article-title">Linear propargylic alcohol functionality attached to the indazole-7-carboxamide as a JAK1-specific linear probe group. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (3)
                                     , 1156-1162. <a href="https://doi.org/10.1016/j.bmc.2013.12.033" title="DOI URL">https://doi.org/10.1016/j.bmc.2013.12.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2013.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2013.12.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DLinear%252Bpropargylic%252Balcohol%252Bfunctionality%252Battached%252Bto%252Bthe%252Bindazole-7-carboxamide%252Bas%252Ba%252BJAK1-specific%252Blinear%252Bprobe%252Bgroup%26aulast%3DKim%26aufirst%3DMi%2BKyoung%26date%3D2014%26volume%3D22%26issue%3D3%26spage%3D1156%26epage%3D1162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark E.  McDonnell</span>, <span class="hlFld-ContribAuthor ">Haiyan  Bian</span>, <span class="hlFld-ContribAuthor ">Jay  Wrobel</span>, <span class="hlFld-ContribAuthor ">Garry R.  Smith</span>, <span class="hlFld-ContribAuthor ">Shuguang  Liang</span>, <span class="hlFld-ContribAuthor ">Haiching  Ma</span>, <span class="hlFld-ContribAuthor ">Allen B.  Reitz</span>. </span><span class="cited-content_cbyCitation_article-title">Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (4)
                                     , 1116-1121. <a href="https://doi.org/10.1016/j.bmcl.2014.01.001" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.01.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.01.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAnilino-monoindolylmaleimides%252Bas%252Bpotent%252Band%252Bselective%252BJAK3%252Binhibitors%26aulast%3DMcDonnell%26aufirst%3DMark%2BE.%26date%3D2014%26volume%3D24%26issue%3D4%26spage%3D1116%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Lupardus</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Anne van  Abbema</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>. </span><span class="cited-content_cbyCitation_article-title">Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (21)
                                     , 5923-5930. <a href="https://doi.org/10.1016/j.bmcl.2013.08.082" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.08.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.08.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.08.082%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bevaluation%252Bof%252Bnovel%252B8-oxo-pyridopyrimidine%252BJak1%25252F2%252Binhibitors%26aulast%3DLabadie%26aufirst%3DSharada%26date%3D2013%26volume%3D23%26issue%3D21%26spage%3D5923%26epage%3D5930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro
              and
              In Vivo
              Assays. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 67-98. <a href="https://doi.org/10.1002/9781118354483.ch3" title="DOI URL">https://doi.org/10.1002/9781118354483.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118354483.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118354483.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DIn%252BVitro%252Band%252BIn%252BVivo%252BAssays%26aulast%3DJohnson%26aufirst%3DAdam%2BR.%26date%3D2013%26date%3D2013%26spage%3D67%26epage%3D98%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DDrug%252BDiscovery%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2013%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stacy  Van Epps</span>, <span class="hlFld-ContribAuthor ">Bryan  Fiamengo</span>, <span class="hlFld-ContribAuthor ">Jeremy  Edmunds</span>, <span class="hlFld-ContribAuthor ">Anna  Ericsson</span>, <span class="hlFld-ContribAuthor ">Kristine  Frank</span>, <span class="hlFld-ContribAuthor ">Michael  Friedman</span>, <span class="hlFld-ContribAuthor ">Dawn  George</span>, <span class="hlFld-ContribAuthor ">Jonathan  George</span>, <span class="hlFld-ContribAuthor ">Eric  Goedken</span>, <span class="hlFld-ContribAuthor ">Brian  Kotecki</span>, <span class="hlFld-ContribAuthor ">Gloria  Martinez</span>, <span class="hlFld-ContribAuthor ">Philip  Merta</span>, <span class="hlFld-ContribAuthor ">Michael  Morytko</span>, <span class="hlFld-ContribAuthor ">Shashank  Shekhar</span>, <span class="hlFld-ContribAuthor ">Barbara  Skinner</span>, <span class="hlFld-ContribAuthor ">Kent  Stewart</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Voss</span>, <span class="hlFld-ContribAuthor ">Grier  Wallace</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Lu  Wang</span>, <span class="hlFld-ContribAuthor ">Neil  Wishart</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of tricyclic cores for kinase inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (3)
                                     , 693-698. <a href="https://doi.org/10.1016/j.bmcl.2012.11.108" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.11.108</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.11.108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.11.108%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Btricyclic%252Bcores%252Bfor%252Bkinase%252Binhibition%26aulast%3DVan%2BEpps%26aufirst%3DStacy%26date%3D2013%26volume%3D23%26issue%3D3%26spage%3D693%26epage%3D698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christel J.  Menet</span>, <span class="hlFld-ContribAuthor ">Luc Van  Rompaey</span>, <span class="hlFld-ContribAuthor ">Raphaël  Geney</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in the Discovery of Selective JAK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 153-223. <a href="https://doi.org/10.1016/B978-0-444-62652-3.00004-1" title="DOI URL">https://doi.org/10.1016/B978-0-444-62652-3.00004-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-444-62652-3.00004-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-444-62652-3.00004-1%26sid%3Dliteratum%253Aachs%26atitle%3DAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BSelective%252BJAK%252BInhibitors%26aulast%3DMenet%26aufirst%3DChristel%2BJ.%26date%3D2013%26spage%3D153%26epage%3D223%26pub%3DElsevier%26date%3D2013%26volume%3D52" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sharada  Labadie</span>, <span class="hlFld-ContribAuthor ">Peter S.  Dragovich</span>, <span class="hlFld-ContribAuthor ">Kathy  Barrett</span>, <span class="hlFld-ContribAuthor ">Wade S.  Blair</span>, <span class="hlFld-ContribAuthor ">Philippe  Bergeron</span>, <span class="hlFld-ContribAuthor ">Christine  Chang</span>, <span class="hlFld-ContribAuthor ">Gauri  Deshmukh</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Christopher A.  Hurley</span>, <span class="hlFld-ContribAuthor ">Adam  Johnson</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Pawan Bir  Kohli</span>, <span class="hlFld-ContribAuthor ">Janusz J.  Kulagowski</span>, <span class="hlFld-ContribAuthor ">Marya  Liimatta</span>, <span class="hlFld-ContribAuthor ">Patrick J.  Lupardus</span>, <span class="hlFld-ContribAuthor ">Rohan  Mendonca</span>, <span class="hlFld-ContribAuthor ">Jeremy M.  Murray</span>, <span class="hlFld-ContribAuthor ">Rebecca  Pulk</span>, <span class="hlFld-ContribAuthor ">Steven  Shia</span>, <span class="hlFld-ContribAuthor ">Micah  Steffek</span>, <span class="hlFld-ContribAuthor ">Savita  Ubhayakar</span>, <span class="hlFld-ContribAuthor ">Mark  Ultsch</span>, <span class="hlFld-ContribAuthor ">Anne  van Abbema</span>, <span class="hlFld-ContribAuthor ">Stuart  Ward</span>, <span class="hlFld-ContribAuthor ">Mark  Zak</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2012,</strong> <em>22 </em>
                                    (24)
                                     , 7627-7633. <a href="https://doi.org/10.1016/j.bmcl.2012.10.008" title="DOI URL">https://doi.org/10.1016/j.bmcl.2012.10.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2012.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2012.10.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bdiscovery%252Bof%252BC-2%252Bsubstituted%252Bimidazo-pyrrolopyridine%252BJAK1%252Binhibitors%252Bwith%252Bimproved%252Bselectivity%252Bover%252BJAK2%26aulast%3DLabadie%26aufirst%3DSharada%26date%3D2012%26volume%3D22%26issue%3D24%26spage%3D7627%26epage%3D7633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter  Norman</span>. </span><span class="cited-content_cbyCitation_article-title">Selective JAK1 inhibitor and selective Tyk2 inhibitor patents. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2012,</strong> <em>22 </em>
                                    (10)
                                     , 1233-1249. <a href="https://doi.org/10.1517/13543776.2012.723693" title="DOI URL">https://doi.org/10.1517/13543776.2012.723693</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2012.723693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2012.723693%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DSelective%252BJAK1%252Binhibitor%252Band%252Bselective%252BTyk2%252Binhibitor%252Bpatents%26aulast%3DNorman%26aufirst%3DPeter%26date%3D2012%26date%3D2012%26volume%3D22%26issue%3D10%26spage%3D1233%26epage%3D1249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0007.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inhibition of biochemical and cell-based JAK activity by <b>1</b> and <b>2</b>. Superscript letters indicate the following: (a) biochemical assays; (b) arithmetic mean of at least three separate runs (<i>n</i> ≥ 3), where on average, the coefficients of variation were less than 0.3 times the mean for biochemical assays and less than 0.5 times the mean for cell-based assays; (c) cell-based measure of JAK1 inhibition; (d) cell-based measure of JAK2 inhibition.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structure of compound <b>3</b> and inhibition of biochemical and cell-based JAK1/JAK2 activity. Superscript letters indicate the following: (a) biochemical assays; (b) arithmetic mean of eight separate runs (<i>n</i> = 8), where on average, the coefficients of variation were less than 0.3 times the mean for biochemical assays; (c) <i>K</i><sub>i</sub>(JAK2)/<i>K</i><sub>i</sub>(JAK1); (d) cell-based measure of JAK1 inhibition; (e) arithmetic mean of three separate runs (<i>n</i> = 3), where on average, the coefficients of variation were less than 0.5 times the mean for cell-based assays; (f) cell-based measure of JAK2 inhibition; (g) see ref <a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">38</a>; (h) EC<sub>50</sub>(EPO-pSTAT5)/EC<sub>50</sub>(IL6-pSTAT3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Exposure vs time profiles after iv and oral doses of compound <b>20</b> in the dog and relevant in vitro and in vivo parameters. Superscript letters indicate the following: (a) total plasma concentration of <b>20</b> after intravenous dosing (0.4 mg/kg), where the sample formulated is as a solution in PEG400/citrate buffer (pH<sub>5.0</sub>) and data are the average from three separate animals; (b) total plasma concentration of <b>20</b> after oral dosing (2 mg/kg), where the sample is formulated as a suspension in MCT and data are the average from three separate animals; (c) unbound plasma concentration of <b>20</b> after oral dosing (2 mg/kg), [<b>20</b>]<sub>unbound</sub> = [<b>20</b>]<sub>total</sub>(1 – (PPB/100)); (d) in vitro IL6-pSTAT3 EC<sub>50</sub> measured in TF-1 cells (87 nM); (e) dog plasma protein binding; (f) in vitro stability in cryopreserved dog hepatocytes; (g) theoretical maximum of achievable oral bioavailability (see ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">43</a> for calculation, and a hepatic blood flow of 30.9 mL min<sup>–1</sup> kg<sup>–1</sup> in the dog is assumed); (h) amount of time unbound drug plasma concentration following 2 mg/kg po dose remains in excess of in vitro IL6-pSTAT3 EC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0013.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Design and results of an IL-6 induced pSTAT3 PK/PD study of compound <b>20</b> in the mouse<sup> </sup>(c). (a) Measured 1 h after dosing of <b>20</b>. (b) Measured 30 min after dosing of IL-6. (c) Five animals were used in each of the control and dosing arms.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of <b>3</b> in complex with JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F08">4F08</a>). The ligand <b>3</b> is shown in orange. Hydrogen-bond interactions with the hinge residues L932 and E930 are shown as dashed black lines. The side chains differing between JAK1 and JAK2 are highlighted in green. The corresponding JAK1 side chains are noted in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>a. The structure is of insufficient resolution (2.8 Å) to observe bound waters around the ligand.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0002.jpeg" id="rightTab-GRAPHIC-d4516e2552-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) X-ray structure of <b>4</b> in complex with JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EHZ">4EHZ</a>). (b) X-ray structure of <b>4</b> in complex with JAK2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F09">4F09</a>). Compound <b>4</b> is depicted in orange. Hydrogen bonds to the ligand are depicted as dashed black lines. Backbone hinge atoms contacting <b>4</b> are highlighted (E957 and L959 for JAK1; E930 and L932 for JAK2). Notable crystallographic waters are denoted as red spheres (waters modeled into electron density peaks of >1.5σ). A molecule of ethylene glycol (teal) is observed in part a. The double-headed black arrows highlight the proximity of the <i>C</i>-2 methyl group of the ligand to a key residue difference between JAK1 (E966) and JAK2 (D939). The resolutions of the X-ray structures are 2.2 Å for JAK1 (a) and 2.4 Å for JAK2 (b).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0003.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Bound conformations of <b>3</b> in complex with JAK2 (green) and of <b>4</b> in complex with JAK1 (pink) and JAK2 (yellow) determined by X-ray crystallography. For clarity, the structures of the proteins have been omitted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0004.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Relative energies of <b>out</b> vs <b>in</b> conformations of compounds <b>3</b> and <b>4</b> calculated with aqueous solvent models.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0005.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. X-ray structure of <b>20</b> in complex with JAK1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EI4">4EI4</a>). Compound <b>20</b> is depicted in orange. Hydrogen bonds to the ligand are depicted as dashed black lines. The backbone hinge atoms contacting <b>20</b> are highlighted (E957 and L959). An additional residue (R1007) forming a hydrogen bond with <b>20</b> is shown in white. Notable crystallographic waters are denoted as red spheres (waters modeled into electron density peaks of >1.5σ). The double-headed black arrow highlights the proximity of the <i>C</i>-2 methyl group of the ligand to a key residue difference between JAK1 (E966) and JAK2 (D939). The resolution of the X-ray structure is 2.2 Å.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/medium/jm-2012-00628c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0006.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of <i>C</i>-2 Methylimidazopyrrolopyridine Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-13/jm300628c/production/images/large/jm-2012-00628c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300628c&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (i) DIPEA, <i>i</i>-PrOH, 65–120 °C; (ii) Fe, NH<sub>4</sub>Cl, MeOH, H<sub>2</sub>O, reflux; (ii′) H<sub>2</sub>, Pd/C, EtOH, THF, 50 °C; (iii) triethyl orthoacetate, <i>p</i>-TsOH, toluene, reflux; (iii′) acetamide, Et<sub>3</sub>(O<sup>+</sup>)BF<sub>4</sub><sup>–</sup>, THF, EtOH, 25 → 70 °C; (iv) NaOH, H<sub>2</sub>O, MeOH or EtOH, 50 °C; (v) Pd(OH)<sub>2</sub>, ammonium formate, MeOH, 75 °C; (v′) H-Cube, Pd(OH)<sub>2</sub> cartridge, 50 psi, 80 °C; (vi) TFA, H<sub>2</sub>O, 25 °C; (vii) acrylonitrile, EtOH, 75 °C; (viii) MsCl, DIPEA, THF, 25 °C; (ix) Ac<sub>2</sub>O, DIPEA, THF, 25 °C (x) methyl chloroformate, DIPEA, THF, 25 °C.</p><p><span class="fn-label">Scheme b</span>Relative stereochemistry between substituents on piperidine, cyclohexane, or cyclopentane rings.</p><p><span class="fn-label">Scheme c</span>Not applicable.</p><p><span class="fn-label">Scheme d</span>Racemic mixture.</p><p><span class="fn-label">Scheme e</span>Single enantiomer, (<i>S</i>)-stereochemistry.</p><p><span class="fn-label">Scheme f</span>Single enantiomer, (<i>R</i>,<i>R</i>)-stereochemistry</p><p class="last"><span class="fn-label">Scheme g</span>Enantiomers separated by preparative chiral SFC.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i52">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 49 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Wilks, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurban, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ralph, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zurcher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span> </span><span class="NLM_article-title">Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2057</span><span class="NLM_x">–</span> <span class="NLM_lpage">2065</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1128%2FMCB.11.4.2057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=1848670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK3MXlslyju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=2057-2065&author=A.+F.+Wilksauthor=A.+G.+Harpurauthor=R.+R.+Kurbanauthor=S.+J.+Ralphauthor=G.+Zurcherauthor=A.+Ziemiecki&title=Two+novel+protein-tyrosine+kinases%2C+each+with+a+second+phosphotransferase-related+catalytic+domain%2C+define+a+new+class+of+protein+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase</span></div><div class="casAuthors">Wilks, Andrew F.; Harpur, Ailsa G.; Kurban, R. R.; Ralph, Stephen J.; Zuercher, Gisela; Ziemiecki, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2057-65</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The protein tyrosine kinases (PTKs) are a burgeoning family of proteins, each of which bears a conserved domain of 250-300 amino acids capable of phosphorylating substrate proteins on tyrosine residues.  Recently, the existence of 2 highly conserved sequence elements within the catalytic domain was exploited to generate PTK-specific degenerate oligonucleotide primers.  By application of the polymerase chain reaction, portions of the catalytic domains of several novel PTKs were amplified.  Here, the primary sequence is reported of one of these new PTKs, JAK1 (from Janus kinase), a member of a new class of PTK characterized by the presence of a 2nd phosphotransferase-related domain immediately N-terminal to the PTK domain.  The sequence was derived from the cDNA sequence of a human fibroblast clone.  The 2nd phosphotransferase domain bears all the hallmarks of a protein kinase, although its structure differed significantly from that of the PTK and threonine/serine kinase family members.  A 2nd member of this family (JAK2) was partially characterized and exhibited a similar array of kinase-related domains.  JAK1 is a large, widely expressed membrane-assocd. phosphoprotein of ∼130 kDa.  The PTK activity of JAK1 was located in the C-terminal PTK-like domain.  The role of the 2nd kinase-like domain is unknown.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8XPv7ZSQ7kbVg90H21EOLACvtfcHk0ljwCOPCIG69RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlslyju7s%253D&md5=7094cf98426dbe3ed5470ced76dc839b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.4.2057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.4.2057%26sid%3Dliteratum%253Aachs%26aulast%3DWilks%26aufirst%3DA.%2BF.%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DKurban%26aufirst%3DR.%2BR.%26aulast%3DRalph%26aufirst%3DS.%2BJ.%26aulast%3DZurcher%26aufirst%3DG.%26aulast%3DZiemiecki%26aufirst%3DA.%26atitle%3DTwo%2520novel%2520protein-tyrosine%2520kinases%252C%2520each%2520with%2520a%2520second%2520phosphotransferase-related%2520catalytic%2520domain%252C%2520define%2520a%2520new%2520class%2520of%2520protein%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D2057%26epage%3D2065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Harpur, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziemiecki, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">JAK2, a third member of the JAK family of protein tyrosine kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1347</span><span class="NLM_x">–</span> <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=1620548" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK38XmtVOrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1992&pages=1347-1353&author=A.+G.+Harpurauthor=A.+C.+Andresauthor=A.+Ziemieckiauthor=R.+R.+Astonauthor=A.+F.+Wilks&title=JAK2%2C+a+third+member+of+the+JAK+family+of+protein+tyrosine+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">JAK2, a third member of the JAK family of protein tyrosine kinases</span></div><div class="casAuthors">Harpur, Ailsa G.; Andres, Anne Catherine; Ziemiecki, Andrew; Aston, Raja R.; Wilks, Andrew F.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1347-53</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">CDNA clones encoding a third, widely expressed, member of the JAK family of protein tyrosine kinases (PTKs) were isolated.  The anticipated amino acid sequence of JAK2 predicts the presence of two kinase-related domains, a feature characteristic of this family of PTKs.  The structural similarity of JAK2 to the other members of this family extends towards their N-termini, beyond the two kinase-related domains, and reveals five further domains of substantial amino acid similarity.  The C-terminal portion of one of these domains, the JH4 domain, bears an intriguing, albeit tenuous, similarity to the core element of the SH2 domain, whereas the remaining JAK homol. domains do not appear to be a feature of other known proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquGgx2uwGEN7Vg90H21EOLACvtfcHk0liBCCxwpm5aYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XmtVOrtLc%253D&md5=db385133406115942157615e9c56b47f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHarpur%26aufirst%3DA.%2BG.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26aulast%3DZiemiecki%26aufirst%3DA.%26aulast%3DAston%26aufirst%3DR.%2BR.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DJAK2%252C%2520a%2520third%2520member%2520of%2520the%2520JAK%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DOncogene%26date%3D1992%26volume%3D7%26spage%3D1347%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Johnston, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamura, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirken, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibuya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortaldo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McVicar, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">151</span><span class="NLM_x">–</span> <span class="NLM_lpage">153</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=151-153&author=J.+A.+Johnstonauthor=M.+Kawamuraauthor=R.+A.+Kirkenauthor=Y.+Q.+Chenauthor=T.+B.+Blakeauthor=K.+Shibuyaauthor=J.+R.+Ortaldoauthor=D.+W.+McVicarauthor=J.+J.+O%E2%80%99Shea&title=Phosphorylation+and+activation+of+the+Jak-3+Janus+kinase+in+response+to+interleukin-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BA.%26aulast%3DKawamura%26aufirst%3DM.%26aulast%3DKirken%26aufirst%3DR.%2BA.%26aulast%3DChen%26aufirst%3DY.%2BQ.%26aulast%3DBlake%26aufirst%3DT.%2BB.%26aulast%3DShibuya%26aufirst%3DK.%26aulast%3DOrtaldo%26aufirst%3DJ.%2BR.%26aulast%3DMcVicar%26aufirst%3DD.%2BW.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DPhosphorylation%2520and%2520activation%2520of%2520the%2520Jak-3%2520Janus%2520kinase%2520in%2520response%2520to%2520interleukin-2%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D151%26epage%3D153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cwik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=1994&pages=153-157&author=B.+A.+Witthuhnauthor=O.+Silvennoinenauthor=O.+Miuraauthor=K.+S.+Laiauthor=C.+Cwikauthor=E.+T.+Liuauthor=J.+N.+Ihle&title=Involvement+of+the+Jak-3+Janus+kinase+in+signalling+by+interleukins+2+and+4+in+lymphoid+and+myeloid+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DK.%2BS.%26aulast%3DCwik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DInvolvement%2520of%2520the%2520Jak-3%2520Janus%2520kinase%2520in%2520signalling%2520by%2520interleukins%25202%2520and%25204%2520in%2520lymphoid%2520and%2520myeloid%2520cells%26jtitle%3DNature%26date%3D1994%26volume%3D370%26spage%3D153%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Firmbach-Kraft, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shows, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalla-Favera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krolewski, J. J.</span><span> </span><span class="NLM_article-title">tyk2, prototype of a novel class of non-receptor tyrosine kinase genes</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1329</span><span class="NLM_x">–</span> <span class="NLM_lpage">1336</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=2216457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1990&pages=1329-1336&author=I.+Firmbach-Kraftauthor=M.+Byersauthor=T.+Showsauthor=R.+Dalla-Faveraauthor=J.+J.+Krolewski&title=tyk2%2C+prototype+of+a+novel+class+of+non-receptor+tyrosine+kinase+genes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">tyk2, Prototype of a novel class of non-receptor tyrosine kinase genes</span></div><div class="casAuthors">Firmbach-Kraft, Iris; Byers, Mary; Shows, Thomas; Dalla-Favera, Riccardo; Krolewski, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1329-36</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    </div><div class="casAbstract">The authors previously identified a novel protein tyrosine kinase gene, tyk2, by screening a human lymphoid cDNA library with a tyrosine kinase domain specific c-fms restriction fragment under low stringency hybridization conditions.  They now isolated and sequenced a full length tyk2 cDNA clone; demonstrated that this gene is widely expressed in hematopoietic and non-hematopoietic cell lines; and mapped it to chromosome 19p13.2.  The cDNA clone is 4176 nucleotides long and codes for a putative protein with a mol. wt. of 134 kilodaltons.  Hydrophobicity anal. of the sequence does not identify a transmembrane domain, which is found in all members of the receptor class of protein tyrosine kinases; nor can the authors detect an SH2 domain, found in all previously identified non-receptor protein kinases.  They propose that tyk2 is the prototype of a new class of non-receptor protein tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhLoFCW2FDWrVg90H21EOLACvtfcHk0liBCCxwpm5aYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXhsFyjuro%253D&md5=c7a4180a140f0bcdc98140a265fb4cb4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFirmbach-Kraft%26aufirst%3DI.%26aulast%3DByers%26aufirst%3DM.%26aulast%3DShows%26aufirst%3DT.%26aulast%3DDalla-Favera%26aufirst%3DR.%26aulast%3DKrolewski%26aufirst%3DJ.%2BJ.%26atitle%3Dtyk2%252C%2520prototype%2520of%2520a%2520novel%2520class%2520of%2520non-receptor%2520tyrosine%2520kinase%2520genes%26jtitle%3DOncogene%26date%3D1990%26volume%3D5%26spage%3D1329%26epage%3D1336" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Huising, M. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruiswijk, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flik, G.</span><span> </span><span class="NLM_article-title">Phylogeny and evolution of class-I helical cytokines</span> <span class="citation_source-journal">J. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1677%2Fjoe.1.06591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=16614377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkslaqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2006&pages=1-25&author=M.+O.+Huisingauthor=C.+P.+Kruiswijkauthor=G.+Flik&title=Phylogeny+and+evolution+of+class-I+helical+cytokines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Phylogeny and evolution of class-I helical cytokines</span></div><div class="casAuthors">Huising, Mark O.; Kruiswijk, Corine P.; Flik, Gert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Endocrinology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">189</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-25</span>CODEN:
                <span class="NLM_cas:coden">JOENAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-0795</span>.
    
            (<span class="NLM_cas:orgname">Society for Endocrinology</span>)
        </div><div class="casAbstract">A review.  The class-I helical cytokines constitute a large group of signaling mols. that play key roles in a plethora of physiol. processes including host defense, immune regulation, somatic growth, reprodn., food intake and energy metab., regulation of neural growth and many more.  Despite little primary amino acid sequence similarity, the view that all contemporary class-I helical cytokines have expanded from a single ancestor is widely accepted, as all class-I helical cytokines share a similar three-dimensional fold, signal via related class-I helical cytokine receptors and activate similar intracellular signaling cascades.  Virtually all of our knowledge on class-I helical cytokine signaling derives from research on primate and rodent species.  Information on the presence, structure and function of class-I helical cytokines in non-mammalian vertebrates and non-vertebrates is fragmentary.  Consequently, our ideas about the evolution of this versatile multigene family are often based on a limited comparison of human and murine orthologs.  In the last 5 years, whole genome sequencing projects have yielded draft genomes of the early vertebrates, pufferfish (Takifugu rubripes), spotted green pufferfish (Tetraodon nigroviridis) and zebrafish (Danio rerio).  Fuelled by this development, fish orthologs of a no. of mammalian class-I helical cytokines have recently been discovered.  In this review, we have characterised the mammalian class-I helical cytokine family and compared it with the emerging class-I helical cytokine repertoire of teleost fish.  This approach offers important insights into cytokine evolution as it identifies the helical cytokines shared by fish and mammals that, consequently, existed before the divergence of teleosts and tetrapods.  A 'fish-mammalian' comparison will identify the class-I helical cytokines that still await discovery in fish or, alternatively, may have been evolutionarily recent addns. to the mammalian cytokine repertoire.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOL7tSlCn0fbVg90H21EOLACvtfcHk0lix--_8acSwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkslaqsb0%253D&md5=624f0cc6441665e8cd0ecb4559ba6fe8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1677%2Fjoe.1.06591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1677%252Fjoe.1.06591%26sid%3Dliteratum%253Aachs%26aulast%3DHuising%26aufirst%3DM.%2BO.%26aulast%3DKruiswijk%26aufirst%3DC.%2BP.%26aulast%3DFlik%26aufirst%3DG.%26atitle%3DPhylogeny%2520and%2520evolution%2520of%2520class-I%2520helical%2520cytokines%26jtitle%3DJ.%2520Endocrinol.%26date%3D2006%26volume%3D189%26spage%3D1%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Bazan, J. F.</span><span> </span><span class="NLM_article-title">Structural design and molecular evolution of a cytokine receptor superfamily</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">6934</span><span class="NLM_x">–</span> <span class="NLM_lpage">6938</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=1990&pages=6934-6938&author=J.+F.+Bazan&title=Structural+design+and+molecular+evolution+of+a+cytokine+receptor+superfamily"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBazan%26aufirst%3DJ.%2BF.%26atitle%3DStructural%2520design%2520and%2520molecular%2520evolution%2520of%2520a%2520cytokine%2520receptor%2520superfamily%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1990%26volume%3D87%26spage%3D6934%26epage%3D6938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr.</span><span> </span><span class="NLM_article-title">STATs and gene regulation</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">1630</span><span class="NLM_x">–</span> <span class="NLM_lpage">1635</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1997&pages=1630-1635&author=J.+E.+Darnell&title=STATs+and+gene+regulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26atitle%3DSTATs%2520and%2520gene%2520regulation%26jtitle%3DScience%26date%3D1997%26volume%3D277%26spage%3D1630%26epage%3D1635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Darnell, J. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stark, G. R.</span><span> </span><span class="NLM_article-title">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">264</span><span class="NLM_x">, </span> <span class="NLM_fpage">1415</span><span class="NLM_x">–</span> <span class="NLM_lpage">1421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1126%2Fscience.8197455" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=8197455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=264&publication_year=1994&pages=1415-1421&author=J.+E.+Darnellauthor=I.+M.+Kerrauthor=G.+R.+Stark&title=Jak-STAT+pathways+and+transcriptional+activation+in+response+to+IFNs+and+other+extracellular+signaling+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins</span></div><div class="casAuthors">Darnell, James E., Jr.; Kerr, Ian M.; Stark, George R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">264</span>
        (<span class="NLM_cas:issue">5164</span>),
    <span class="NLM_cas:pages">1415-21</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">A review with 97 refs.  Through the study of transcriptional activation in response to interferon α (IFN-α) and interferon γ (IFN-γ), a previously unrecognized direct signal transduction pathway to the nucleus has been uncovered: IFN-receptor interaction at the cell surface leads to the activation of kinases of the Jak family that then phosphorylate substrate proteins called STATs (signal transducers and activators of transcription).  The phosphorylated STAT proteins move to the nucleus, bind specific DNA elements, and direct transcription.  Recognition of the mols. involved in the IFN-α and IFN-γ pathway has led to discoveries that a no. of STAT family members exist and that other polypeptide ligands also use the Jak-STAT mols. in signal transduction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo64rvN_qWlmLVg90H21EOLACvtfcHk0lix--_8acSwxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlalsL4%253D&md5=f63d2c7bb3c1aeca6f36fef38aff713c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1126%2Fscience.8197455&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8197455%26sid%3Dliteratum%253Aachs%26aulast%3DDarnell%26aufirst%3DJ.%2BE.%26aulast%3DKerr%26aufirst%3DI.%2BM.%26aulast%3DStark%26aufirst%3DG.%2BR.%26atitle%3DJak-STAT%2520pathways%2520and%2520transcriptional%2520activation%2520in%2520response%2520to%2520IFNs%2520and%2520other%2520extracellular%2520signaling%2520proteins%26jtitle%3DScience%26date%3D1994%26volume%3D264%26spage%3D1415%26epage%3D1421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">O’shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Cytokine signaling in 2002: new surprises in the Jak/Stat pathway</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl.</span><span class="NLM_x">) </span> <span class="NLM_fpage">S121</span><span class="NLM_x">–</span> <span class="NLM_lpage">S131</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2002&pages=S121-S131&issue=Suppl.&author=J.+J.+O%E2%80%99sheaauthor=M.+Gadinaauthor=R.+D.+Schreiber&title=Cytokine+signaling+in+2002%3A+new+surprises+in+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599shea%26aufirst%3DJ.%2BJ.%26aulast%3DGadina%26aufirst%3DM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DCytokine%2520signaling%2520in%25202002%253A%2520new%2520surprises%2520in%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DCell%26date%3D2002%26volume%3D109%26issue%3DSuppl%26spage%3DS121%26epage%3DS131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Schindler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Decker, T.</span><span> </span><span class="NLM_article-title">JAK-STAT signaling: from interferons to cytokines</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">20059</span><span class="NLM_x">–</span> <span class="NLM_lpage">20063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=20059-20063&author=C.+Schindlerauthor=D.+E.+Levyauthor=T.+Decker&title=JAK-STAT+signaling%3A+from+interferons+to+cytokines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DC.%26aulast%3DLevy%26aufirst%3DD.%2BE.%26aulast%3DDecker%26aufirst%3DT.%26atitle%3DJAK-STAT%2520signaling%253A%2520from%2520interferons%2520to%2520cytokines%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D20059%26epage%3D20063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">STATs: signal transducers and activators of transcription</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=1996&pages=331-334&author=J.+N.+Ihle&title=STATs%3A+signal+transducers+and+activators+of+transcription"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DSTATs%253A%2520signal%2520transducers%2520and%2520activators%2520of%2520transcription%26jtitle%3DCell%26date%3D1996%26volume%3D84%26spage%3D331%26epage%3D334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rane, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Hematopoietic cytokine receptor signaling</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">6724</span><span class="NLM_x">–</span> <span class="NLM_lpage">6737</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fsj.onc.1210757" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=17934481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=6724-6737&author=S.+J.+Bakerauthor=S.+G.+Raneauthor=E.+P.+Reddy&title=Hematopoietic+cytokine+receptor+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Hematopoietic cytokine receptor signaling</span></div><div class="casAuthors">Baker, S. J.; Rane, S. G.; Reddy, E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">6724-6737</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors.  Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types.  Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription).  Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders.  This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCBFLj3Gs4BrVg90H21EOLACvtfcHk0lh2Si5rzuX0yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFKhsLbN&md5=b003dc7def939f23f5acb98fb79d39de</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210757&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210757%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DHematopoietic%2520cytokine%2520receptor%2520signaling%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D6724%26epage%3D6737" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Jaks, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">11</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1997&pages=1-11&author=J.+J.+O%E2%80%99Shea&title=Jaks%2C+STATs%2C+cytokine+signal+transduction%2C+and+immunoregulation%3A+Are+we+there+yet%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DJaks%252C%2520STATs%252C%2520cytokine%2520signal%2520transduction%252C%2520and%2520immunoregulation%253A%2520Are%2520we%2520there%2520yet%253F%26jtitle%3DImmunity%26date%3D1997%26volume%3D7%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurence, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span> </span><span class="NLM_article-title">Therapeutic targeting of Janus kinases</span> <span class="citation_source-journal">Immunol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">223</span><span class="NLM_x">, </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">142</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1111%2Fj.1600-065X.2008.00644.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18613833" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=223&publication_year=2008&pages=132-142&author=M.+Pesuauthor=A.+Laurenceauthor=N.+Kishoreauthor=S.+H.+Zwillichauthor=G.+Chanauthor=J.+J.+O%E2%80%99Shea&title=Therapeutic+targeting+of+Janus+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of Janus kinases</span></div><div class="casAuthors">Pesu, Marko; Laurence, Arian; Kishore, Nandini; Zwillich, Samuel H.; Chan, Gary; O'Shea, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">223</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">132-142</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">A review.  Cytokines play pivotal roles in immunity and inflammation, and targeting cytokines and their receptors is an effective means of treating such disorders.  Type I and II cytokine receptors assoc. with Janus family kinases (JAKs) to effect intracellular signaling.  These structurally unique protein kinases play essential and specific roles in immune cell development and function.  One JAK, JAK3, has particularly selective functions.  Mutations of this kinase underlie severe combined immunodeficiency, indicative of its crit. role in the development and function of lymphocytes.  Because JAK3 appears not to have functions outside of hematopoietic cells, this kinase has been viewed as an excellent therapeutic target for the development of a new class of immunosuppressive drugs.  In fact, several companies are developing JAK3 inhibitors, and Phase II studies are underway.  Mutations of Tyk2 cause autosomal recessive hyperIgE syndrome, and in principle, Tyk2 inhibitors might also be useful as immunosuppressive drugs.  JAK2 gain-of-function mutations (V617F) underlie a subset of disorders collectively referred to as myeloproliferative diseases and phase 2 trials using JAK inhibitors are underway in this setting.  Thus, we are learning a great deal about the feasibility and effectiveness of targeting Janus kinases, and it appears likely that this will be a fruitful strategy in a variety of settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-VTmlwlhcv7Vg90H21EOLACvtfcHk0lh2Si5rzuX0yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlGls7c%253D&md5=73dc15932d0eaa312bc2588bdbce404c</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2008.00644.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2008.00644.x%26sid%3Dliteratum%253Aachs%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DLaurence%26aufirst%3DA.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26atitle%3DTherapeutic%2520targeting%2520of%2520Janus%2520kinases%26jtitle%3DImmunol.%2520Rev.%26date%3D2008%26volume%3D223%26spage%3D132%26epage%3D142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pesu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">A new modality for immunosuppression: targeting the JAK/STAT pathway</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">555</span><span class="NLM_x">–</span> <span class="NLM_lpage">564</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=555-564&author=J.+J.+O%E2%80%99Sheaauthor=M.+Pesuauthor=D.+C.+Borieauthor=P.+S.+Changelian&title=A+new+modality+for+immunosuppression%3A+targeting+the+JAK%2FSTAT+pathway"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DA%2520new%2520modality%2520for%2520immunosuppression%253A%2520targeting%2520the%2520JAK%252FSTAT%2520pathway%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D555%26epage%3D564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Clark, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamen, R.</span><span> </span><span class="NLM_article-title">The human hematopoietic colony-stimulating factors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1987</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">1229</span><span class="NLM_x">–</span> <span class="NLM_lpage">1237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1987&pages=1229-1237&author=S.+C.+Clarkauthor=R.+Kamen&title=The+human+hematopoietic+colony-stimulating+factors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DS.%2BC.%26aulast%3DKamen%26aufirst%3DR.%26atitle%3DThe%2520human%2520hematopoietic%2520colony-stimulating%2520factors%26jtitle%3DScience%26date%3D1987%26volume%3D236%26spage%3D1229%26epage%3D1237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Metcalf, D.</span><span> </span><span class="NLM_article-title">The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1989</span><span class="NLM_x">, </span> <span class="NLM_volume">339</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">30</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=339&publication_year=1989&pages=27-30&author=D.+Metcalf&title=The+molecular+control+of+cell+division%2C+differentiation+commitment+and+maturation+in+haemopoietic+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMetcalf%26aufirst%3DD.%26atitle%3DThe%2520molecular%2520control%2520of%2520cell%2520division%252C%2520differentiation%2520commitment%2520and%2520maturation%2520in%2520haemopoietic%2520cells%26jtitle%3DNature%26date%3D1989%26volume%3D339%26spage%3D27%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quelle, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miura, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=1993&pages=227-236&author=B.+A.+Witthuhnauthor=F.+W.+Quelleauthor=O.+Silvennoinenauthor=T.+Yiauthor=B.+Tangauthor=O.+Miuraauthor=J.+N.+Ihle&title=JAK2+associates+with+the+erythropoietin+receptor+and+is+tyrosine+phosphorylated+and+activated+following+stimulation+with+erythropoietin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DQuelle%26aufirst%3DF.%2BW.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DYi%26aufirst%3DT.%26aulast%3DTang%26aufirst%3DB.%26aulast%3DMiura%26aufirst%3DO.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJAK2%2520associates%2520with%2520the%2520erythropoietin%2520receptor%2520and%2520is%2520tyrosine%2520phosphorylated%2520and%2520activated%2520following%2520stimulation%2520with%2520erythropoietin%26jtitle%3DCell%26date%3D1993%26volume%3D74%26spage%3D227%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Rochman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spolski, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">New insights into the regulation of T cells by gamma(c) family cytokines</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">480</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fnri2580" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=19543225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=480-490&author=Y.+Rochmanauthor=R.+Spolskiauthor=W.+J.+Leonard&title=New+insights+into+the+regulation+of+T+cells+by+gamma%28c%29+family+cytokines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into the regulation of T cells by γc family cytokines</span></div><div class="casAuthors">Rochman, Yrina; Spolski, Rosanne; Leonard, Warren J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">480-490</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Common cytokine receptor γ-chain (γc) family cytokines have crucial roles in the development, proliferation, survival and differentiation of multiple cell lineages of both the innate and adaptive immune systems.  In this Review, the authors focus on the current understanding of the distinct and overlapping effects of interleukin-2 (IL-2), IL-7, IL-9, IL-15 and IL-21, as well as the IL-7-related cytokine thymic stromal lymphopoietin (TSLP), on the survival and proliferation of conventional αβ T cells, γδ T cells and regulatory T cells.  This knowledge potentially allows for the therapeutic manipulation of immune responses for the treatment of cancer, autoimmunity, allergic diseases and immunodeficiency, as well as for vaccine development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6GBlSyD8_NLVg90H21EOLACvtfcHk0lhSjR3QlSTuIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsVylu78%253D&md5=a6c7285b05193002b89be7233d11f271</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnri2580&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2580%26sid%3Dliteratum%253Aachs%26aulast%3DRochman%26aufirst%3DY.%26aulast%3DSpolski%26aufirst%3DR.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DNew%2520insights%2520into%2520the%2520regulation%2520of%2520T%2520cells%2520by%2520gamma%2528c%2529%2520family%2520cytokines%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2009%26volume%3D9%26spage%3D480%26epage%3D490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Noguchi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenblatt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filipovich, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adelstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, O. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leonard, W. J.</span><span> </span><span class="NLM_article-title">Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">147</span><span class="NLM_x">–</span> <span class="NLM_lpage">157</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1993&pages=147-157&author=M.+Noguchiauthor=H.+Yiauthor=H.+M.+Rosenblattauthor=A.+H.+Filipovichauthor=S.+Adelsteinauthor=W.+S.+Modiauthor=O.+W.+McBrideauthor=W.+J.+Leonard&title=Interleukin-2+receptor+gamma+chain+mutation+results+in+X-linked+severe+combined+immunodeficiency+in+humans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNoguchi%26aufirst%3DM.%26aulast%3DYi%26aufirst%3DH.%26aulast%3DRosenblatt%26aufirst%3DH.%2BM.%26aulast%3DFilipovich%26aufirst%3DA.%2BH.%26aulast%3DAdelstein%26aufirst%3DS.%26aulast%3DModi%26aufirst%3DW.%2BS.%26aulast%3DMcBride%26aufirst%3DO.%2BW.%26aulast%3DLeonard%26aufirst%3DW.%2BJ.%26atitle%3DInterleukin-2%2520receptor%2520gamma%2520chain%2520mutation%2520results%2520in%2520X-linked%2520severe%2520combined%2520immunodeficiency%2520in%2520humans%26jtitle%3DCell%26date%3D1993%26volume%3D73%26spage%3D147%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Stahl, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boulton, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farruggella, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ip, N. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witthuhn, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quelle, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silvennoinen, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegrini, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yancopulos, G. D.</span><span> </span><span class="NLM_article-title">Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 β receptor components</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">95</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=92-95&author=N.+Stahlauthor=T.+G.+Boultonauthor=T.+Farruggellaauthor=N.+Y.+Ipauthor=S.+Davisauthor=B.+A.+Witthuhnauthor=F.+W.+Quelleauthor=O.+Silvennoinenauthor=G.+Barbieriauthor=S.+Pellegriniauthor=J.+N.+Ihleauthor=G.+D.+Yancopulos&title=Association+and+activation+of+Jak-Tyk+kinases+by+CNTF-LIF-OSM-IL-6+%CE%B2+receptor+components"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStahl%26aufirst%3DN.%26aulast%3DBoulton%26aufirst%3DT.%2BG.%26aulast%3DFarruggella%26aufirst%3DT.%26aulast%3DIp%26aufirst%3DN.%2BY.%26aulast%3DDavis%26aufirst%3DS.%26aulast%3DWitthuhn%26aufirst%3DB.%2BA.%26aulast%3DQuelle%26aufirst%3DF.%2BW.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DBarbieri%26aufirst%3DG.%26aulast%3DPellegrini%26aufirst%3DS.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26aulast%3DYancopulos%26aufirst%3DG.%2BD.%26atitle%3DAssociation%2520and%2520activation%2520of%2520Jak-Tyk%2520kinases%2520by%2520CNTF-LIF-OSM-IL-6%2520%25CE%25B2%2520receptor%2520components%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D92%26epage%3D95" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishimoto, T.</span><span> </span><span class="NLM_article-title">Immunotherapeutic implication of IL-6 blockade</span> <span class="citation_source-journal">Immunotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=T.+Tanakaauthor=T.+Kishimoto&title=Immunotherapeutic+implication+of+IL-6+blockade"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKishimoto%26aufirst%3DT.%26atitle%3DImmunotherapeutic%2520implication%2520of%2520IL-6%2520blockade%26jtitle%3DImmunotherapy%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gouilleux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haldosen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norstedt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groner, B.</span><span> </span><span class="NLM_article-title">Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">2005</span><span class="NLM_x">–</span> <span class="NLM_lpage">2013</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=2005-2013&author=F.+Gouilleuxauthor=C.+Pallardauthor=I.+Dusanter-Fourtauthor=H.+Wakaoauthor=L.+A.+Haldosenauthor=G.+Norstedtauthor=D.+Levyauthor=B.+Groner&title=Prolactin%2C+growth+hormone%2C+erythropoietin+and+granulocyte-macrophage+colony+stimulating+factor+induce+MGF-Stat5+DNA+binding+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGouilleux%26aufirst%3DF.%26aulast%3DPallard%26aufirst%3DC.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26aulast%3DWakao%26aufirst%3DH.%26aulast%3DHaldosen%26aufirst%3DL.%2BA.%26aulast%3DNorstedt%26aufirst%3DG.%26aulast%3DLevy%26aufirst%3DD.%26aulast%3DGroner%26aufirst%3DB.%26atitle%3DProlactin%252C%2520growth%2520hormone%252C%2520erythropoietin%2520and%2520granulocyte-macrophage%2520colony%2520stimulating%2520factor%2520induce%2520MGF-Stat5%2520DNA%2520binding%2520activity%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26spage%3D2005%26epage%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pallard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gouilleux, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Groner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gisselbrecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dusanter-Fourt, I.</span><span> </span><span class="NLM_article-title">Interleukin-3, erythropoietin, and prolactin activate a STAT5-like factor in lymphoid cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">15942</span><span class="NLM_x">–</span> <span class="NLM_lpage">15945</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=15942-15945&author=C.+Pallardauthor=F.+Gouilleuxauthor=M.+Charonauthor=B.+Gronerauthor=S.+Gisselbrechtauthor=I.+Dusanter-Fourt&title=Interleukin-3%2C+erythropoietin%2C+and+prolactin+activate+a+STAT5-like+factor+in+lymphoid+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPallard%26aufirst%3DC.%26aulast%3DGouilleux%26aufirst%3DF.%26aulast%3DCharon%26aufirst%3DM.%26aulast%3DGroner%26aufirst%3DB.%26aulast%3DGisselbrecht%26aufirst%3DS.%26aulast%3DDusanter-Fourt%26aufirst%3DI.%26atitle%3DInterleukin-3%252C%2520erythropoietin%252C%2520and%2520prolactin%2520activate%2520a%2520STAT5-like%2520factor%2520in%2520lymphoid%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D15942%26epage%3D15945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Skoda, R. C.</span><span> </span><span class="NLM_article-title">Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects</span> <span class="citation_source-journal">J. Recept. Signal. Transduction Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">741</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.3109%2F10799899909036684" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=10071797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1999&pages=741-772&author=R.+C.+Skoda&title=Specificity+of+signaling+by+hematopoietic+cytokine+receptors%3A+instructive+versus+permissive+effects"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Specificity of signaling by hematopoietic cytokine receptors: instructive versus permissive effects</span></div><div class="casAuthors">Skoda, Radek C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Receptor and Signal Transduction Research</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1-4</span>),
    <span class="NLM_cas:pages">741-772</span>CODEN:
                <span class="NLM_cas:coden">JRETET</span>;
        ISSN:<span class="NLM_cas:issn">1079-9893</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A review with 163 refs.  The helical cytokines constitute a family of proteins with a common three-dimensional structure.  They exert a wide variety of biol. effects with a preference for the hematopoietic system.  The effects of helical cytokines are mediated by cell surface receptors, which belong to the cytokine receptor superfamily and signal by activating cytoplasmic tyrosine kinases of the Janus kinase (Jak) family and other downstream signaling pathways.  The relevance of each of these pathways for eliciting a specific cellular response remains to be detd.  This review will focus on cytokine receptors which play a role in the regulation of hematopoiesis and summarize data that address the question how specificity of signaling is achieved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquBbee9L17arVg90H21EOLACvtfcHk0liK_fEL3j6G-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWgsL0%253D&md5=65b9b15109627fbac2586c29f8086102</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.3109%2F10799899909036684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F10799899909036684%26sid%3Dliteratum%253Aachs%26aulast%3DSkoda%26aufirst%3DR.%2BC.%26atitle%3DSpecificity%2520of%2520signaling%2520by%2520hematopoietic%2520cytokine%2520receptors%253A%2520instructive%2520versus%2520permissive%2520effects%26jtitle%3DJ.%2520Recept.%2520Signal.%2520Transduction%2520Res.%26date%3D1999%26volume%3D19%26spage%3D741%26epage%3D772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenisch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodish, H. F.</span><span> </span><span class="NLM_article-title">Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">67</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1995&pages=59-67&author=H.+Wuauthor=X.+Liuauthor=R.+Jaenischauthor=H.+F.+Lodish&title=Generation+of+committed+erythroid+BFU-E+and+CFU-E+progenitors+does+not+require+erythropoietin+or+the+erythropoietin+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJaenisch%26aufirst%3DR.%26aulast%3DLodish%26aufirst%3DH.%2BF.%26atitle%3DGeneration%2520of%2520committed%2520erythroid%2520BFU-E%2520and%2520CFU-E%2520progenitors%2520does%2520not%2520require%2520erythropoietin%2520or%2520the%2520erythropoietin%2520receptor%26jtitle%3DCell%26date%3D1995%26volume%3D83%26spage%3D59%26epage%3D67" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Changelian, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzuti, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklyn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koslov, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milici, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckius, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaweco, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beals, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Littman, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagouras, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magna, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saltarelli, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelms, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Des Etages, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawabata, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finco-Kent, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paniagua, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Shea, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borie, D. C.</span><span> </span><span class="NLM_article-title">Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">875</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1126%2Fscience.1087061" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=14593182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2003&pages=875-878&author=P.+S.+Changelianauthor=M.+E.+Flanaganauthor=D.+J.+Ballauthor=C.+R.+Kentauthor=K.+S.+Magnusonauthor=W.+H.+Martinauthor=B.+J.+Rizzutiauthor=P.+S.+Sawyerauthor=B.+D.+Perryauthor=W.+H.+Brissetteauthor=S.+P.+McCurdyauthor=E.+M.+Kudlaczauthor=M.+J.+Conklynauthor=E.+A.+Elliottauthor=E.+R.+Koslovauthor=M.+B.+Fisherauthor=T.+J.+Strelevitzauthor=K.+Yoonauthor=D.+A.+Whippleauthor=J.+Sunauthor=M.+J.+Munchhofauthor=J.+L.+Dotyauthor=J.+M.+Casavantauthor=T.+A.+Blumenkopfauthor=M.+Hinesauthor=M.+F.+Brownauthor=B.+M.+Lillieauthor=C.+Subramanyamauthor=C.+Shang-Poaauthor=A.+J.+Miliciauthor=G.+E.+Beckiusauthor=J.+D.+Moyerauthor=C.+Suauthor=T.+G.+Woodworthauthor=A.+S.+Gawecoauthor=C.+R.+Bealsauthor=B.+H.+Littmanauthor=D.+A.+Fisherauthor=J.+F.+Smithauthor=P.+Zagourasauthor=H.+A.+Magnaauthor=M.+J.+Saltarelliauthor=K.+S.+Johnsonauthor=L.+F.+Nelmsauthor=S.+G.+Des+Etagesauthor=L.+S.+Hayesauthor=T.+T.+Kawabataauthor=D.+Finco-Kentauthor=D.+L.+Bakerauthor=M.+Larsonauthor=M.+S.+Siauthor=R.+Paniaguaauthor=J.+Higginsauthor=B.+Holmauthor=B.+Reitzauthor=Y.+J.+Zhouauthor=R.+E.+Morrisauthor=J.+J.+O%E2%80%99Sheaauthor=D.+C.+Borie&title=Prevention+of+organ+allograft+rejection+by+a+specific+Janus+kinase+3+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor</span></div><div class="casAuthors">Changelian, Paul S.; Flanagan, Mark E.; Ball, Douglas J.; Kent, Craig R.; Magnuson, Kelly S.; Martin, William H.; Rizzuti, Bonnie J.; Sawyer, Perry S.; Perry, Bret D.; Brissette, William H.; McCurdy, Sandra P.; Kudlacz, Elizabeth M.; Conklyn, Maryrose J.; Elliott, Eileen A.; Koslov, Erika R.; Fisher, Michael B.; Strelevitz, Timothy J.; Yoon, Kwansik; Whipple, David A.; Sun, Jianmin; Munchhof, Michael J.; Doty, John L.; Casavant, Jeffrey M.; Blumenkopf, Todd A.; Hines, Michael; Brown, Matthew F.; Lillie, Brett M.; Subramanyam, Chakrapani; Chang, Shang-Poa; Milici, Anthony J.; Beckius, Gretchen E.; Moyer, James D.; Su, Chunyan; Woodworth, Thasia G.; Gaweco, Anderson S.; Beals, Chan R.; Littman, Bruce H.; Fisher, Douglas A.; Smith, James F.; Zagouras, Panayiotis; Magna, Holly A.; Saltarelli, Mary J.; Johnson, Kimberly S.; Nelms, Linda F.; Des Etages, Shelley G.; Hayes, Lisa S.; Kawabata, Thomas T.; Finco-Kent, Deborah; Baker, Deanna L.; Larson, Michael; Si, Ming-Sing; Paniagua, Ricardo; Higgins, John; Holm, Bari; Reitz, Bruce; Zhou, Yong-Jie; Morris, Randall E.; O'Shea, John J.; Borie, Dominic C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">5646</span>),
    <span class="NLM_cas:pages">875-878</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Because of its requirement for signaling by multiple cytokines, Janus kinase 3 (JAK3) is an excellent target for clin. immunosuppression.  The authors report the development of a specific, orally active inhibitor of JAK3, CP-690,550, that significantly prolonged survival in a murine model of heart transplantation and in cynomolgus monkeys receiving kidney transplants.  CP-690,550 treatment was not assocd. with hypertension, hyperlipidemia, or lymphoproliferative disease.  On the basis of these preclin. results, the authors believe JAK3 blockade by CP-690,550 has potential for therapeutically desirable immunosuppression in human organ transplantation and in other clin. settings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNoo8qryWWkbVg90H21EOLACvtfcHk0liK_fEL3j6G-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1Cmtrg%253D&md5=85b6ea64a6711f95fc28408d42ce9c49</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1126%2Fscience.1087061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1087061%26sid%3Dliteratum%253Aachs%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBall%26aufirst%3DD.%2BJ.%26aulast%3DKent%26aufirst%3DC.%2BR.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMartin%26aufirst%3DW.%2BH.%26aulast%3DRizzuti%26aufirst%3DB.%2BJ.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DConklyn%26aufirst%3DM.%2BJ.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DKoslov%26aufirst%3DE.%2BR.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DYoon%26aufirst%3DK.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DMilici%26aufirst%3DA.%2BJ.%26aulast%3DBeckius%26aufirst%3DG.%2BE.%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DSu%26aufirst%3DC.%26aulast%3DWoodworth%26aufirst%3DT.%2BG.%26aulast%3DGaweco%26aufirst%3DA.%2BS.%26aulast%3DBeals%26aufirst%3DC.%2BR.%26aulast%3DLittman%26aufirst%3DB.%2BH.%26aulast%3DFisher%26aufirst%3DD.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BF.%26aulast%3DZagouras%26aufirst%3DP.%26aulast%3DMagna%26aufirst%3DH.%2BA.%26aulast%3DSaltarelli%26aufirst%3DM.%2BJ.%26aulast%3DJohnson%26aufirst%3DK.%2BS.%26aulast%3DNelms%26aufirst%3DL.%2BF.%26aulast%3DDes%2BEtages%26aufirst%3DS.%2BG.%26aulast%3DHayes%26aufirst%3DL.%2BS.%26aulast%3DKawabata%26aufirst%3DT.%2BT.%26aulast%3DFinco-Kent%26aufirst%3DD.%26aulast%3DBaker%26aufirst%3DD.%2BL.%26aulast%3DLarson%26aufirst%3DM.%26aulast%3DSi%26aufirst%3DM.%2BS.%26aulast%3DPaniagua%26aufirst%3DR.%26aulast%3DHiggins%26aufirst%3DJ.%26aulast%3DHolm%26aufirst%3DB.%26aulast%3DReitz%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DY.%2BJ.%26aulast%3DMorris%26aufirst%3DR.%2BE.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DJ.%2BJ.%26aulast%3DBorie%26aufirst%3DD.%2BC.%26atitle%3DPrevention%2520of%2520organ%2520allograft%2520rejection%2520by%2520a%2520specific%2520Janus%2520kinase%25203%2520inhibitor%26jtitle%3DScience%26date%3D2003%26volume%3D302%26spage%3D875%26epage%3D878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+a+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0li3QsUj4oGtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520a%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Fleischmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cutolo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">Phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">617</span><span class="NLM_x">–</span> <span class="NLM_lpage">629</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1002%2Fart.33383" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=21952978" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2012&pages=617-629&author=R.+Fleischmannauthor=M.+Cutoloauthor=M.+C.+Genoveseauthor=E.+B.+Leeauthor=K.+S.+Kanikauthor=S.+Sadisauthor=C.+A.+Connellauthor=D.+Grubenauthor=S.+Krishnaswamiauthor=G.+Wallensteinauthor=B.+E.+Wilkinsonauthor=S.+H.+Zwillich&title=Phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+or+adalimumab+monotherapy+versus+placebo+in+patients+with+active+rheumatoid+arthritis+with+an+inadequate+response+to+DMARDs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20aR"><div class="casContent"><span class="casTitleNuber">20a</span><div class="casTitle"><span class="NLM_cas:atitle">Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs</span></div><div class="casAuthors">Fleischmann, Roy; Cutolo, Maurizio; Genovese, Mark C.; Lee, Eun Bong; Kanik, Keith S.; Sadis, Seth; Connell, Carol A.; Gruben, David; Krishnaswami, Sriram; Wallenstein, Gene; Wilkinson, Bethanie E.; Zwillich, Samuel H.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">617-629</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : To compare the efficacy, safety, and tolerability of 5 doses of oral tofacitinib (CP-690,550) or adalimumab monotherapy with placebo for the treatment of active rheumatoid arthritis (RA) in patients with an inadequate response to disease-modifying antirheumatic drugs.  Methods : In this 24-wk, double-blind, phase IIb study, patients with RA (n = 384) were randomized to receive placebo, tofacitinib at 1, 3, 5, 10, or 15 mg administered orally twice a day, or adalimumab at 40 mg injected s.c. every 2 wk (total of 6 injections) followed by oral tofacitinib at 5 mg twice a day for 12 wk.  The primary end point was the responder rate according to the American College of Rheumatol. 20% improvement criteria (ACR20) at week 12.  Results : Treatment with tofacitinib at a dose of ≥3 mg twice a day resulted in a rapid response with significant efficacy when compared to placebo, as indicated by the primary end point (ACR20 response at week 12), achieved in 39.2% (3 mg; P ≤ 0.05), 59.2% (5 mg; P < 0.0001), 70.5% (10 mg; P < 0.0001), and 71.9% (15 mg; P < 0.0001) in the tofacitinib group and 35.9% of patients in the adalimumab group (P = 0.105), compared with 22.0% of patients receiving placebo.  Improvements were sustained at week 24, according to the ACR20, ACR50, and ACR70 response rates as well as classifications of remission according to the 3-variable Disease Activity Score in 28 joints (DAS28) using C-reactive protein and the 4-variable DAS28 using the erythrocyte sedimentation rate.  The most common treatment-emergent adverse events (AEs) in patients across all tofacitinib treatment arms (n = 272) were urinary tract infection (7.7%), diarrhea (4.8%), headache (4.8%), and bronchitis (4.8%).  Conclusion : Tofacitinib monotherapy at ≥3 mg twice a day was efficacious in the treatment of patients with active RA over 24 wk and demonstrated a manageable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuu7Uf_SwBXbVg90H21EOLACvtfcHk0li3QsUj4oGtrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XivVGjurs%253D&md5=99d7be4fd115ffa87410dcbd6c6ea860</span></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=10.1002%2Fart.33383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33383%26sid%3Dliteratum%253Aachs%26aulast%3DFleischmann%26aufirst%3DR.%26aulast%3DCutolo%26aufirst%3DM.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DSadis%26aufirst%3DS.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DPhase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520or%2520adalimumab%2520monotherapy%2520versus%2520placebo%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520with%2520an%2520inadequate%2520response%2520to%2520DMARDs%26jtitle%3DArthritis%2520Rheum.%26date%3D2012%26volume%3D64%26spage%3D617%26epage%3D629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Kremer, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkinson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connell, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">French, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomez-Reino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruben, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanik, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnaswami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pascual-Ramos, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwillich, S. H.</span><span> </span><span class="NLM_article-title">A phase 2B dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate alone</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">970</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1002%2Fart.33419" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=22006202" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=970-981&author=J.+M.+Kremerauthor=S.+Cohenauthor=B.+E.+Wilkinsonauthor=C.+A.+Connellauthor=J.+L.+Frenchauthor=J.+Gomez-Reinoauthor=D.+Grubenauthor=K.+S.+Kanikauthor=S.+Krishnaswamiauthor=V.+Pascual-Ramosauthor=G.+Wallensteinauthor=S.+H.+Zwillich&title=A+phase+2B+dose-ranging+study+of+the+oral+JAK+inhibitor+tofacitinib+%28CP-690%2C550%29+versus+placebo+in+combination+with+background+methotrexate+in+patients+with+active+rheumatoid+arthritis+and+inadequate+response+to+methotrexate+alone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1002%2Fart.33419&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.33419%26sid%3Dliteratum%253Aachs%26aulast%3DKremer%26aufirst%3DJ.%2BM.%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DWilkinson%26aufirst%3DB.%2BE.%26aulast%3DConnell%26aufirst%3DC.%2BA.%26aulast%3DFrench%26aufirst%3DJ.%2BL.%26aulast%3DGomez-Reino%26aufirst%3DJ.%26aulast%3DGruben%26aufirst%3DD.%26aulast%3DKanik%26aufirst%3DK.%2BS.%26aulast%3DKrishnaswami%26aufirst%3DS.%26aulast%3DPascual-Ramos%26aufirst%3DV.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DZwillich%26aufirst%3DS.%2BH.%26atitle%3DA%2520phase%25202B%2520dose-ranging%2520study%2520of%2520the%2520oral%2520JAK%2520inhibitor%2520tofacitinib%2520%2528CP-690%252C550%2529%2520versus%2520placebo%2520in%2520combination%2520with%2520background%2520methotrexate%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%2520and%2520inadequate%2520response%2520to%2520methotrexate%2520alone%26jtitle%3DArthritis%2520Rheum.%26date%3D2011%26volume%3D64%26spage%3D970%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">Tofacitinib has completed several late stage clinical trials and recently received a recommendation for approval in RA from the FDA Advisory Committee.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Lin, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meloni, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galya, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, J.</span><span> </span><span class="NLM_article-title">Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1999</span><span class="NLM_x">–</span> <span class="NLM_lpage">2002</span></span><div class="citationLinks">[<a href="/doi/10.1021/ol900350k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=1999-2002&author=Q.+Linauthor=D.+Meloniauthor=Y.+Panauthor=M.+Xiaauthor=J.+Rodgersauthor=S.+Shepardauthor=M.+Liauthor=L.+Galyaauthor=B.+Metcalfauthor=T.+Y.+Yueauthor=P.+Liuauthor=J.+Zhou&title=Enantioselective+synthesis+of+Janus+kinase+inhibitor+INCB018424+via+an+organocatalytic+aza-Michael+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol900350k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol900350k%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DMeloni%26aufirst%3DD.%26aulast%3DPan%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DM.%26aulast%3DRodgers%26aufirst%3DJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DGalya%26aufirst%3DL.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DYue%26aufirst%3DT.%2BY.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DJ.%26atitle%3DEnantioselective%2520synthesis%2520of%2520Janus%2520kinase%2520inhibitor%2520INCB018424%2520via%2520an%2520organocatalytic%2520aza-Michael%2520reaction%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D1999%26epage%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Williams, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeever, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreland, L.</span><span> </span><span class="NLM_article-title">Initial efficacy of INCB018424, a selective janus kinase 1 & 2 (JAK1&2) inhibitor in rheumatoid arthritis (RA)</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">Supp.l 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=62&issue=Supp.l+2&author=W.+V.+Williamsauthor=P.+Scherleauthor=J.+Shiauthor=R.+Newtonauthor=E.+McKeeverauthor=J.+Fridmanauthor=K.+Vaddiauthor=R.+Levyauthor=L.+Moreland&title=Initial+efficacy+of+INCB018424%2C+a+selective+janus+kinase+1+%26+2+%28JAK1%262%29+inhibitor+in+rheumatoid+arthritis+%28RA%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DScherle%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DNewton%26aufirst%3DR.%26aulast%3DMcKeever%26aufirst%3DE.%26aulast%3DFridman%26aufirst%3DJ.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DMoreland%26aufirst%3DL.%26atitle%3DInitial%2520efficacy%2520of%2520INCB018424%252C%2520a%2520selective%2520janus%2520kinase%25201%2520%2526%25202%2520%2528JAK1%25262%2529%2520inhibitor%2520in%2520rheumatoid%2520arthritis%2520%2528RA%2529%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26issue%3DSupp.l%25202%26spage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last"> The abstract is online at <a href="http://www.abstracts2view.com/eular/view.php?nu=EULAR08L_OP-0044" class="extLink">http://www.abstracts2view.com/eular/view.php?nu=EULAR08L_OP-0044</a> (accessed May 30, 2012).</p></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span> A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects with Active Rheumatoid Arthritis. <a href="http://www.clinicaltrials.gov/ct2/show/NCT00550043?term=incb018424&amp;rank=19" class="extLink">http://www.clinicaltrials.gov/ct2/show/NCT00550043?term=incb018424&rank=19</a> (accessed June 5,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+A+Study+Exploring+the+Safety%2C+Tolerability+and+Efficacy+of+a+4+Week+Course+of+INCB018424+in+Subjects+with+Active+Rheumatoid+Arthritis.+http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00550043%3Fterm%3Dincb018424%26rank%3D19+%28accessed+June+5%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24a"><span><span class="NLM_label">(a) </span> In addition to being studied in early stage trials for RA, ruxolitinib has also been extensively evaluated as a treatment for myelofibrosis (MF). Recently, the Food and Drug Administration (FDA) granted marketing approval to ruxolitinib as a treatment for patients with MF. Incyte Press Release. <a href="http://investor.incyte.com/phoenix.zhtml?c=69764&amp;p=irol-newsArticle&amp;ID=1631201&amp;highlight" class="extLink">http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1631201&highlight</a> (accessed May 30,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+In+addition+to+being+studied+in+early+stage+trials+for+RA%2C+ruxolitinib+has+also+been+extensively+evaluated+as+a+treatment+for+myelofibrosis+%28MF%29.+Recently%2C+the+Food+and+Drug+Administration+%28FDA%29+granted+marketing+approval+to+ruxolitinib+as+a+treatment+for+patients+with+MF.+Incyte+Press+Release.+http%3A%2F%2Finvestor.incyte.com%2Fphoenix.zhtml%3Fc%3D69764%26p%3Dirol-newsArticle%26ID%3D1631201%26highlight+%28accessed+May+30%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24b"><span><span class="NLM_label">(b) </span><div class="note"><p class="first last">Incyte and Eli Lilly have progressed another small molecule JAK1/2 inhibitor (INCB028050/LY3009104) into clinical trials for rheumatoid arthritis. </p></div><span class="NLM_contrib-group">Greenwald, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidelus-Gort, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, W. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, R.</span><span> </span><span class="NLM_article-title">A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl. 10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=2172&issue=Suppl.+10&author=M.+W.+Greenwaldauthor=R.+Fidelus-Gortauthor=R.+Levyauthor=J.+Liangauthor=K.+Vaddiauthor=W.+V.+Williamsauthor=R.+Newton&title=A+randomized+dose-ranging%2C+placebo-controlled+study+of+INCB028050%2C+a+selective+JAK1+and+JAK2+inhibitor+in+subjects+with+active+rheumatoid+arthritis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenwald%26aufirst%3DM.%2BW.%26aulast%3DFidelus-Gort%26aufirst%3DR.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DWilliams%26aufirst%3DW.%2BV.%26aulast%3DNewton%26aufirst%3DR.%26atitle%3DA%2520randomized%2520dose-ranging%252C%2520placebo-controlled%2520study%2520of%2520INCB028050%252C%2520a%2520selective%2520JAK1%2520and%2520JAK2%2520inhibitor%2520in%2520subjects%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26issue%3DSuppl.%252010%26spage%3D2172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit24c"><span><span class="NLM_label">(c) </span> Further information on a phase 2a clinical trial of INCB028050/LY3009104 may be found in an Incyte press release: <a href="http://investor.incyte.com/phoenix.zhtml?c=69764&amp;p=irol-newsArticle&amp;ID=1494997&amp;highlight=" class="extLink">http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1494997&highlight=</a> (accessed June 6,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Further+information+on+a+phase+2a+clinical+trial+of+INCB028050%2FLY3009104+may+be+found+in+an+Incyte+press+release%3A+http%3A%2F%2Finvestor.incyte.com%2Fphoenix.zhtml%3Fc%3D69764%26p%3Dirol-newsArticle%26ID%3D1494997%26highlight%3D+%28accessed+June+6%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Meyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jesson, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elrick, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funckes-Shippy, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gross, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowty, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramaiah, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saabye, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kishore, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, D. L.</span><span> </span><span class="NLM_article-title">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span> <span class="citation_source-journal">J. Inflammation (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">41</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1186%2F1476-9255-7-41" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20701804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2010&pages=41&author=D.+M.+Meyerauthor=M.+I.+Jessonauthor=X.+Liauthor=M.+M.+Elrickauthor=C.+L.+Funckes-Shippyauthor=J.+D.+Warnerauthor=C.+J.+Grossauthor=M.+E.+Dowtyauthor=S.+K.+Ramaiahauthor=J.+L.+Hirschauthor=M.+J.+Saabyeauthor=J.+L.+Barksauthor=N.+Kishoreauthor=D.+L.+Morris&title=Anti-inflammatory+activity+and+neutrophil+reductions+mediated+by+the+JAK1%2FJAK3+inhibitor%2C+CP-690%2C550%2C+in+rat+adjuvant-induced+arthritis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis</span></div><div class="casAuthors">Meyer Debra M; Jesson Michael I; Li Xiong; Elrick Mollisa M; Funckes-Shippy Christie L; Warner James D; Gross Cindy J; Dowty Martin E; Ramaiah Shashi K; Hirsch Jeffrey L; Saabye Matthew J; Barks Jennifer L; Kishore Nandini; Morris Dale L</div><div class="citationInfo"><span class="NLM_cas:title">Journal of inflammation (London, England)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">41</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The Janus kinase (JAK) family of tyrosine kinases includes JAK1, JAK2, JAK3 and TYK2, and is required for signaling through Type I and Type II cytokine receptors.  CP-690,550 is a potent and selective JAK inhibitor currently in clinical trials for rheumatoid arthritis (RA) and other autoimmune disease indications.  In RA trials, dose-dependent decreases in neutrophil counts (PBNC) were observed with CP-690,550 treatment.  These studies were undertaken to better understand the relationship between JAK selectivity and PBNC decreases observed with CP-690,550 treatment.  METHODS:  Potency and selectivity of CP-690,550 for mouse, rat and human JAKs was evaluated in a panel of in vitro assays.  The effect of CP-690,550 on granulopoiesis from progenitor cells was also assessed in vitro using colony forming assays.  In vivo the potency of orally administered CP-690,550 on arthritis (paw edema), plasma cytokines, PBNC and bone marrow differentials were evaluated in the rat adjuvant-induced arthritis (AIA) model.  RESULTS:  CP-690,550 potently inhibited signaling through JAK1 and JAK3 with 5-100 fold selectivity over JAK2 in cellular assays, despite inhibiting all four JAK isoforms with nM potency in in vitro enzyme assays.  Dose-dependent inhibition of paw edema was observed in vivo with CP-690,550 treatment.  Plasma cytokines (IL-6 and IL-17), PBNC, and bone marrow myeloid progenitor cells were elevated in the context of AIA disease.  At efficacious exposures, CP-690,550 returned all of these parameters to pre-disease levels.  The plasma concentration of CP-690,550 at efficacious doses was above the in vitro whole blood IC50 of JAK1 and JAK3 inhibition, but not that of JAK2.  CONCLUSION:  Results from this investigation suggest that CP-690,550 is a potent inhibitor of JAK1 and JAK3 with potentially reduced cellular potency for JAK2.  In rat AIA, as in the case of human RA, PBNC were decreased at efficacious exposures of CP-690,550.  Inflammatory end points were similarly reduced, as judged by attenuation of paw edema and cytokines IL-6 and IL-17.  Plasma concentration at these exposures was consistent with inhibition of JAK1 and JAK3 but not JAK2.  Decreases in PBNC following CP-690,550 treatment may thus be related to attenuation of inflammation and are likely not due to suppression of granulopoiesis through JAK2 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR-l9vqy6452oNpW7w2tapOfW6udTcc2eagRJ2G-E5mJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjnsVWktA%253D%253D&md5=1190d7c5509fde79a7b56024a3aec9d9</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1186%2F1476-9255-7-41&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-9255-7-41%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DD.%2BM.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DElrick%26aufirst%3DM.%2BM.%26aulast%3DFunckes-Shippy%26aufirst%3DC.%2BL.%26aulast%3DWarner%26aufirst%3DJ.%2BD.%26aulast%3DGross%26aufirst%3DC.%2BJ.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DHirsch%26aufirst%3DJ.%2BL.%26aulast%3DSaabye%26aufirst%3DM.%2BJ.%26aulast%3DBarks%26aufirst%3DJ.%2BL.%26aulast%3DKishore%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26atitle%3DAnti-inflammatory%2520activity%2520and%2520neutrophil%2520reductions%2520mediated%2520by%2520the%2520JAK1%252FJAK3%2520inhibitor%252C%2520CP-690%252C550%252C%2520in%2520rat%2520adjuvant-induced%2520arthritis%26jtitle%3DJ.%2520Inflammation%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2010%26volume%3D7%26spage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nuninger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falchetto, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hermes, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tavares, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vangrevelinghe, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">284</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm101157q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=284-288&author=G.+Thomaauthor=F.+Nuningerauthor=R.+Falchettoauthor=E.+Hermesauthor=G.+A.+Tavaresauthor=E.+Vangrevelingheauthor=H.+G.+Zerwes&title=Identification+of+a+potent+Janus+kinase+3+inhibitor+with+high+selectivity+within+the+Janus+kinase+family"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=10.1021%2Fjm101157q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101157q%26sid%3Dliteratum%253Aachs%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DNuninger%26aufirst%3DF.%26aulast%3DFalchetto%26aufirst%3DR.%26aulast%3DHermes%26aufirst%3DE.%26aulast%3DTavares%26aufirst%3DG.%2BA.%26aulast%3DVangrevelinghe%26aufirst%3DE.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DIdentification%2520of%2520a%2520potent%2520Janus%2520kinase%25203%2520inhibitor%2520with%2520high%2520selectivity%2520within%2520the%2520Janus%2520kinase%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D284%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manshouri, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scherle, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulder, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waeltz, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rupar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burn, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Covington, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodgers, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verstovsek, S.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">3109</span><span class="NLM_x">–</span> <span class="NLM_lpage">3117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quintas-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0liUOzvnBFO7mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Van Abbema, A.; Kanada, H.; Chang, C.; Bir Kohli, P.; Smith, J.; Barrett, K.; Lewin-Koh, N.; Johnson, A. R.; Ghilardi, N.; Blair, W.</span><span> </span><span class="NLM_article-title">Determination of the JAK-dependence of cytokine pathways using small molecule inhibitors</span>. Unpublished results. Experimental details of the biochemical and cell-based assays reported herein may be found in the <span class="NLM_xref">Supporting Information</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Van+Abbema%2C+A.%3B+Kanada%2C+H.%3B+Chang%2C+C.%3B+Bir+Kohli%2C+P.%3B+Smith%2C+J.%3B+Barrett%2C+K.%3B+Lewin-Koh%2C+N.%3B+Johnson%2C+A.+R.%3B+Ghilardi%2C+N.%3B+Blair%2C+W.+Determination+of+the+JAK-dependence+of+cytokine+pathways+using+small+molecule+inhibitors.+Unpublished+results.+Experimental+details+of+the+biochemical+and+cell-based+assays+reported+herein+may+be+found+in+the+Supporting+Information."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BAbbema%26aufirst%3DA.%26atitle%3DDetermination%2520of%2520the%2520JAK-dependence%2520of%2520cytokine%2520pathways%2520using%2520small%2520molecule%2520inhibitors" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Rodig, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meraz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampe, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pennica, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schreiber, R. D.</span><span> </span><span class="NLM_article-title">Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">373</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=373-383&author=S.+J.+Rodigauthor=M.+A.+Merazauthor=J.+M.+Whiteauthor=P.+A.+Lampeauthor=J.+K.+Rileyauthor=C.+D.+Arthurauthor=K.+L.+Kingauthor=K.+C.+Sheehanauthor=L.+Yinauthor=D.+Pennicaauthor=E.+M.+Johnsonauthor=R.+D.+Schreiber&title=Disruption+of+the+Jak1+gene+demonstrates+obligatory+and+nonredundant+roles+of+the+Jaks+in+cytokine-induced+biologic+responses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRodig%26aufirst%3DS.%2BJ.%26aulast%3DMeraz%26aufirst%3DM.%2BA.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DLampe%26aufirst%3DP.%2BA.%26aulast%3DRiley%26aufirst%3DJ.%2BK.%26aulast%3DArthur%26aufirst%3DC.%2BD.%26aulast%3DKing%26aufirst%3DK.%2BL.%26aulast%3DSheehan%26aufirst%3DK.%2BC.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DPennica%26aufirst%3DD.%26aulast%3DJohnson%26aufirst%3DE.%2BM.%26aulast%3DSchreiber%26aufirst%3DR.%2BD.%26atitle%3DDisruption%2520of%2520the%2520Jak1%2520gene%2520demonstrates%2520obligatory%2520and%2520nonredundant%2520roles%2520of%2520the%2520Jaks%2520in%2520cytokine-induced%2520biologic%2520responses%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D373%26epage%3D383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Shimoda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kouji, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyamoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibamori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamashita, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Numata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takase, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Asano, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gondo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sekiguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niho, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakayama, K.</span><span> </span><span class="NLM_article-title">Tyk2 plays a restricted role in IFNα signaling, although it is required for IL-12-mediated T cell function</span> <span class="citation_source-journal">Immunity</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">561</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2000&pages=561-571&author=K.+Shimodaauthor=K.+Koujiauthor=K.+Aokiauthor=T.+Matsudaauthor=A.+Miyamotoauthor=M.+Shibamoriauthor=M.+Yamashitaauthor=A.+Numataauthor=K.+Takaseauthor=S.+Kobayashiauthor=S.+Shibataauthor=Y.+Asanoauthor=H.+Gondoauthor=K.+Sekiguchiauthor=K.+Nakayamaauthor=T.+Nakayamaauthor=T.+Okamuraauthor=S.+Okamuraauthor=Y.+Nihoauthor=K.+Nakayama&title=Tyk2+plays+a+restricted+role+in+IFN%CE%B1+signaling%2C+although+it+is+required+for+IL-12-mediated+T+cell+function"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShimoda%26aufirst%3DK.%26aulast%3DKouji%26aufirst%3DK.%26aulast%3DAoki%26aufirst%3DK.%26aulast%3DMatsuda%26aufirst%3DT.%26aulast%3DMiyamoto%26aufirst%3DA.%26aulast%3DShibamori%26aufirst%3DM.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DNumata%26aufirst%3DA.%26aulast%3DTakase%26aufirst%3DK.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DShibata%26aufirst%3DS.%26aulast%3DAsano%26aufirst%3DY.%26aulast%3DGondo%26aufirst%3DH.%26aulast%3DSekiguchi%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DK.%26aulast%3DNakayama%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DT.%26aulast%3DOkamura%26aufirst%3DS.%26aulast%3DNiho%26aufirst%3DY.%26aulast%3DNakayama%26aufirst%3DK.%26atitle%3DTyk2%2520plays%2520a%2520restricted%2520role%2520in%2520IFN%25CE%25B1%2520signaling%252C%2520although%2520it%2520is%2520required%2520for%2520IL-12-mediated%2520T%2520cell%2520function%26jtitle%3DImmunity%26date%3D2000%26volume%3D13%26spage%3D561%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Parganas, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stravopodis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topham, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marine, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teglund, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanin, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bodner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colamonici, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Deursen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosveld, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ihle, J. N.</span><span> </span><span class="NLM_article-title">Jak2 is essential for signaling through a variety of cytokine receptors</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">395</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=385-395&author=E.+Parganasauthor=D.+Wangauthor=D.+Stravopodisauthor=D.+J.+Tophamauthor=J.+C.+Marineauthor=S.+Teglundauthor=E.+F.+Vaninauthor=S.+Bodnerauthor=O.+R.+Colamoniciauthor=J.+M.+van+Deursenauthor=G.+Grosveldauthor=J.+N.+Ihle&title=Jak2+is+essential+for+signaling+through+a+variety+of+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParganas%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DStravopodis%26aufirst%3DD.%26aulast%3DTopham%26aufirst%3DD.%2BJ.%26aulast%3DMarine%26aufirst%3DJ.%2BC.%26aulast%3DTeglund%26aufirst%3DS.%26aulast%3DVanin%26aufirst%3DE.%2BF.%26aulast%3DBodner%26aufirst%3DS.%26aulast%3DColamonici%26aufirst%3DO.%2BR.%26aulast%3Dvan%2BDeursen%26aufirst%3DJ.%2BM.%26aulast%3DGrosveld%26aufirst%3DG.%26aulast%3DIhle%26aufirst%3DJ.%2BN.%26atitle%3DJak2%2520is%2520essential%2520for%2520signaling%2520through%2520a%2520variety%2520of%2520cytokine%2520receptors%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D385%26epage%3D395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Smolen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubbert-Roth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramos-Remus, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rovensky, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alecock, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodworth, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alten, R.</span><span> </span><span class="NLM_article-title">Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">371</span><span class="NLM_x">, </span> <span class="NLM_fpage">987</span><span class="NLM_x">–</span> <span class="NLM_lpage">997</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2008&pages=987-997&author=J.+S.+Smolenauthor=A.+Beaulieuauthor=A.+Rubbert-Rothauthor=C.+Ramos-Remusauthor=J.+Rovenskyauthor=E.+Alecockauthor=T.+Woodworthauthor=R.+Alten&title=Effect+of+interleukin-6+receptor+inhibition+with+tocilizumab+in+patients+with+rheumatoid+arthritis+%28OPTION+study%29%3A+a+double-blind%2C+placebo-controlled%2C+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmolen%26aufirst%3DJ.%2BS.%26aulast%3DBeaulieu%26aufirst%3DA.%26aulast%3DRubbert-Roth%26aufirst%3DA.%26aulast%3DRamos-Remus%26aufirst%3DC.%26aulast%3DRovensky%26aufirst%3DJ.%26aulast%3DAlecock%26aufirst%3DE.%26aulast%3DWoodworth%26aufirst%3DT.%26aulast%3DAlten%26aufirst%3DR.%26atitle%3DEffect%2520of%2520interleukin-6%2520receptor%2520inhibition%2520with%2520tocilizumab%2520in%2520patients%2520with%2520rheumatoid%2520arthritis%2520%2528OPTION%2520study%2529%253A%2520a%2520double-blind%252C%2520placebo-controlled%252C%2520randomised%2520trial%26jtitle%3DLancet%26date%3D2008%26volume%3D371%26spage%3D987%26epage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Haan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolvering, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapp, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druckes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thoma, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrmann, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zerwes, H. G.</span><span> </span><span class="NLM_article-title">Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">323</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.chembiol.2011.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=21439476" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFSrtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=314-323&author=C.+Haanauthor=C.+Rolveringauthor=F.+Raulfauthor=M.+Kappauthor=P.+Druckesauthor=G.+Thomaauthor=I.+Behrmannauthor=H.+G.+Zerwes&title=Jak1+has+a+dominant+role+over+Jak3+in+signal+transduction+through+%CE%B3c-containing+cytokine+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Jak1 Has a Dominant Role over Jak3 in Signal Transduction through γc-Containing Cytokine Receptors</span></div><div class="casAuthors">Haan, Claude; Rolvering, Catherine; Raulf, Friedrich; Kapp, Manuela; Drueckes, Peter; Thoma, Gebhard; Behrmann, Iris; Zerwes, Hans-Guenter</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-323</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Genetic deficiency of Jak3 leads to abrogation of signal transduction through the common gamma chain (γc) and thus to immunodeficiency suggesting that specific inhibition of Jak3 kinase may result in immunosuppression.  Jak1 cooperates with Jak3 in signaling through γc-contg. receptors.  Unexpectedly, a Jak3-selective inhibitor was less efficient in abolishing STAT5 phosphorylation than pan-Jak inhibitors.  We therefore explored the roles of Jak1 and Jak3 kinase functionality in signaling using a reconstituted system.  The presence of kinase-inactive Jak1 but not kinase-inactive Jak3 resulted in complete abolishment of STAT5 phosphorylation.  Specific inhibition of the "analog-sensitive" mutant AS-Jak1 but not AS-Jak3 by the ATP-competitive analog 1NM-PP1 abrogated IL-2 signaling, corroborating the data with the selective Jak3 inhibitor.  Jak1 thus plays a dominant role over Jak3 and these data challenge the notion that selective ATP-competitive Jak3 kinase inhibitors will be effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUv04vX29Zk7Vg90H21EOLACvtfcHk0lgdksOKt3KHrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFSrtrw%253D&md5=0109f316cfe0bee40f80a79f244e6ba5</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2011.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2011.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHaan%26aufirst%3DC.%26aulast%3DRolvering%26aufirst%3DC.%26aulast%3DRaulf%26aufirst%3DF.%26aulast%3DKapp%26aufirst%3DM.%26aulast%3DDruckes%26aufirst%3DP.%26aulast%3DThoma%26aufirst%3DG.%26aulast%3DBehrmann%26aufirst%3DI.%26aulast%3DZerwes%26aufirst%3DH.%2BG.%26atitle%3DJak1%2520has%2520a%2520dominant%2520role%2520over%2520Jak3%2520in%2520signal%2520transduction%2520through%2520%25CE%25B3c-containing%2520cytokine%2520receptors%26jtitle%3DChem.%2520Biol.%26date%3D2011%26volume%3D18%26spage%3D314%26epage%3D323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Frenzel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallace, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDoom, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capecchi, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sayeski, P. P.</span><span> </span><span class="NLM_article-title">A functional Jak2 tyrosine kinase domain is essential for mouse development</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">312</span><span class="NLM_x">, </span> <span class="NLM_fpage">2735</span><span class="NLM_x">–</span> <span class="NLM_lpage">2744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.yexcr.2006.05.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=16887119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=312&publication_year=2006&pages=2735-2744&author=K.+Frenzelauthor=T.+A.+Wallaceauthor=I.+McDoomauthor=H.+D.+Xiaoauthor=M.+R.+Capecchiauthor=K.+E.+Bernsteinauthor=P.+P.+Sayeski&title=A+functional+Jak2+tyrosine+kinase+domain+is+essential+for+mouse+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">A functional Jak2 tyrosine kinase domain is essential for mouse development</span></div><div class="casAuthors">Frenzel, Kristen; Wallace, Tiffany A.; McDoom, Issam; Xiao, Hong D.; Capecchi, Mario R.; Bernstein, Kenneth E.; Sayeski, Peter P.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">312</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2735-2744</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Jak2 is a member of the Janus family of tyrosine kinases and is involved in cytokine signaling.  As a part of a study to det. biol. functions of Jak2, we used mol. modeling to identify W1038 as a residue that is crit. for tyrosine kinase function.  Mutation of W1038, in tandem with E1046, generates a dominant-neg. form of the Jak2 protein.  Mice that were engineered to express two copies of this dominant-neg. Jak2 protein died in utero.  Addnl., heterozygous mice expressing Jak2 with kinase activity that is moderately reduced when compared to wild-type activity appear phenotypically normal.  Collectively, these data suggest that Jak2 kinase activity is essential for normal mammalian development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_eBTfkGGF3rVg90H21EOLACvtfcHk0lgdksOKt3KHrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWqtbg%253D&md5=347e54bb72e8fdb6cce0563020c5656e</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2006.05.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2006.05.004%26sid%3Dliteratum%253Aachs%26aulast%3DFrenzel%26aufirst%3DK.%26aulast%3DWallace%26aufirst%3DT.%2BA.%26aulast%3DMcDoom%26aufirst%3DI.%26aulast%3DXiao%26aufirst%3DH.%2BD.%26aulast%3DCapecchi%26aufirst%3DM.%2BR.%26aulast%3DBernstein%26aufirst%3DK.%2BE.%26aulast%3DSayeski%26aufirst%3DP.%2BP.%26atitle%3DA%2520functional%2520Jak2%2520tyrosine%2520kinase%2520domain%2520is%2520essential%2520for%2520mouse%2520development%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2006%26volume%3D312%26spage%3D2735%26epage%3D2744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Neubauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cumano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huffstadt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfeffer, K.</span><span> </span><span class="NLM_article-title">Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">397</span><span class="NLM_x">–</span> <span class="NLM_lpage">409</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1998&pages=397-409&author=H.+Neubauerauthor=A.+Cumanoauthor=M.+Mullerauthor=H.+Wuauthor=U.+Huffstadtauthor=K.+Pfeffer&title=Jak2+deficiency+defines+an+essential+developmental+checkpoint+in+definitive+hematopoiesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNeubauer%26aufirst%3DH.%26aulast%3DCumano%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DHuffstadt%26aufirst%3DU.%26aulast%3DPfeffer%26aufirst%3DK.%26atitle%3DJak2%2520deficiency%2520defines%2520an%2520essential%2520developmental%2520checkpoint%2520in%2520definitive%2520hematopoiesis%26jtitle%3DCell%26date%3D1998%26volume%3D93%26spage%3D397%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Verstovsek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesa, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pardanani, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes-Franco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Estrov, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fridman, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradley, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erickson-Viitanen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaddi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span> </span><span class="NLM_article-title">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1117</span><span class="NLM_x">–</span> <span class="NLM_lpage">1127</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1056%2FNEJMoa1002028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20843246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1117-1127&author=S.+Verstovsekauthor=H.+Kantarjianauthor=R.+A.+Mesaauthor=A.+D.+Pardananiauthor=J.+Cortes-Francoauthor=D.+A.+Thomasauthor=Z.+Estrovauthor=J.+S.+Fridmanauthor=E.+C.+Bradleyauthor=S.+Erickson-Viitanenauthor=K.+Vaddiauthor=R.+Levyauthor=A.+Tefferi&title=Safety+and+efficacy+of+INCB018424%2C+a+JAK1+and+JAK2+inhibitor%2C+in+myelofibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis</span></div><div class="casAuthors">Verstovsek, Srdan; Kantarjian, Hagop; Mesa, Ruben A.; Pardanani, Animesh D.; Cortes-Franco, Jorge; Thomas, Deborah A.; Estrov, Zeev; Fridman, Jordan S.; Bradley, Edward C.; Erickson-Viitanen, Susan; Vaddi, Kris; Levy, Richard; Tefferi, Ayalew</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1117-1127</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Myelofibrosis is a Philadelphia chromosome-neg. myeloproliferative neoplasm assocd. with cytopenias, splenomegaly, poor quality of life, and shortened survival.  About half of patients with myelofibrosis carry a gain-of-function mutation in the Janus kinase 2 gene (JAK2 V617F) that contributes to the pathophysiol. of the disease.  INCB018424 is a potent and selective Janus kinase 1 (JAK1) and JAK2 inhibitor.  Methods: We conducted a phase 1-2 trial of INCB018424 in patients with JAK2 V617F-pos. or JAK2 V617F-neg. primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis.  Results: A total of 153 patients received INCB018424 for a median duration of more than 14.7 mo.  The initial dose-escalation phase established 25 mg twice daily or 100 mg once daily as max. tolerated doses, on the basis of reversible thrombocytopenia.  A dose-dependent suppression of phosphorylated signal transducer and activator of transcription 3 (STAT3), a marker of JAK signaling, was demonstrated in patients with wild-type JAK2 and in patients with the JAK2 V617F mutation.  We studied addnl. doses and established that a 15-mg twice-daily starting dose, followed by individualized dose titrn., was the most effective and safest dosing regimen.  At this dose, 17 of 33 patients (52%) had a rapid objective response (>50% redn. of splenomegaly) lasting for 12 mo or more, and this therapy was assocd. with grade 3 or grade 4 adverse events (mainly myelosuppression) in less than 10% of patients.  Patients with debilitating symptoms, including wt. loss, fatigue, night sweats, and pruritus, had rapid improvement.  Clin. benefits were assocd. with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myelofibrosis.  Conclusions: INCB018424 was assocd. with marked and durable clin. benefits in patients with myelofibrosis for whom no approved therapies existed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUi05ApP1FLrVg90H21EOLACvtfcHk0li9Vqt-e60C2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFOltrjJ&md5=ba6fe766323a10a1508c686fdb3720b1</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1002028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1002028%26sid%3Dliteratum%253Aachs%26aulast%3DVerstovsek%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DPardanani%26aufirst%3DA.%2BD.%26aulast%3DCortes-Franco%26aufirst%3DJ.%26aulast%3DThomas%26aufirst%3DD.%2BA.%26aulast%3DEstrov%26aufirst%3DZ.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DBradley%26aufirst%3DE.%2BC.%26aulast%3DErickson-Viitanen%26aufirst%3DS.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLevy%26aufirst%3DR.%26aulast%3DTefferi%26aufirst%3DA.%26atitle%3DSafety%2520and%2520efficacy%2520of%2520INCB018424%252C%2520a%2520JAK1%2520and%2520JAK2%2520inhibitor%252C%2520in%2520myelofibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1117%26epage%3D1127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="note"><p class="first last">A summary of previous disclosures of compounds exhibiting JAK1 vs JAK2 selectivity is presented in ref <a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">36</a>. Additionally, a number of publications describing JAK2 inhibitors with varying JAK family and other kinase selectivity profiles have appeared recently. These include the following: </p></div><div class="NLM_citation" id="rightTab-cit35a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schenkel, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deak, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emkey, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunaydin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loberg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pistillo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geuns-Meyer, S.</span><span> </span><span class="NLM_article-title">Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8440</span><span class="NLM_x">–</span> <span class="NLM_lpage">8450</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200911r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8440-8450&author=L.+B.+Schenkelauthor=X.+Huangauthor=A.+Chengauthor=H.+L.+Deakauthor=E.+Dohertyauthor=R.+Emkeyauthor=Y.+Guauthor=H.+Gunaydinauthor=J.+L.+Kimauthor=J.+Leeauthor=R.+Lobergauthor=P.+Olivieriauthor=J.+Pistilloauthor=J.+Tangauthor=Q.+Wanauthor=H.+L.+Wangauthor=S.+W.+Wangauthor=M.+C.+Wellsauthor=B.+Wuauthor=V.+Yuauthor=L.+Liuauthor=S.+Geuns-Meyer&title=Discovery+of+potent+and+highly+selective+thienopyridine+Janus+kinase+2+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35a&amp;dbid=16384&amp;doi=10.1021%2Fjm200911r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200911r%26sid%3Dliteratum%253Aachs%26aulast%3DSchenkel%26aufirst%3DL.%2BB.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DA.%26aulast%3DDeak%26aufirst%3DH.%2BL.%26aulast%3DDoherty%26aufirst%3DE.%26aulast%3DEmkey%26aufirst%3DR.%26aulast%3DGu%26aufirst%3DY.%26aulast%3DGunaydin%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DLoberg%26aufirst%3DR.%26aulast%3DOlivieri%26aufirst%3DP.%26aulast%3DPistillo%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%2BL.%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DWells%26aufirst%3DM.%2BC.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DV.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGeuns-Meyer%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520potent%2520and%2520highly%2520selective%2520thienopyridine%2520Janus%2520kinase%25202%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8440%26epage%3D8450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taoka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otte, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zugay-Murphy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">Discovery of 1-amino-5<i>H</i>-pyrido[4,3-<i>b</i>]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7334</span><span class="NLM_x">–</span> <span class="NLM_lpage">7349</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200909u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7334-7349&author=J.+Limauthor=B.+Taokaauthor=R.+D.+Otteauthor=K.+Spencerauthor=C.+J.+Dinsmoreauthor=M.+D.+Altmanauthor=G.+Chanauthor=C.+Rosensteinauthor=S.+Sharmaauthor=H.+P.+Suauthor=A.+A.+Szewczakauthor=L.+Xuauthor=H.+Yinauthor=J.+Zugay-Murphyauthor=C.+G.+Marshallauthor=J.+R.+Young&title=Discovery+of+1-amino-5H-pyrido%5B4%2C3-b%5Dindol-4-carboxamide+inhibitors+of+Janus+kinase+2+%28JAK2%29+for+the+treatment+of+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35b&amp;dbid=16384&amp;doi=10.1021%2Fjm200909u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200909u%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DTaoka%26aufirst%3DB.%26aulast%3DOtte%26aufirst%3DR.%2BD.%26aulast%3DSpencer%26aufirst%3DK.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSu%26aufirst%3DH.%2BP.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DZugay-Murphy%26aufirst%3DJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DDiscovery%2520of%25201-amino-5H-pyrido%255B4%252C3-b%255Dindol-4-carboxamide%2520inhibitors%2520of%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7334%26epage%3D7349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Siu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozina, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jung, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachman, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mo, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouthillette, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J. R.</span><span> </span><span class="NLM_article-title">The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: Hit to lead</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">7421</span><span class="NLM_x">–</span> <span class="NLM_lpage">7425</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=7421-7425&author=T.+Siuauthor=E.+S.+Kozinaauthor=J.+Jungauthor=C.+Rosensteinauthor=A.+Mathurauthor=M.+D.+Altmanauthor=G.+Chanauthor=L.+Xuauthor=E.+Bachmanauthor=J.+R.+Moauthor=M.+Bouthilletteauthor=T.+Rushauthor=C.+J.+Dinsmoreauthor=C.+G.+Marshallauthor=J.+R.+Young&title=The+discovery+of+tricyclic+pyridone+JAK2+inhibitors.+Part+1%3A+Hit+to+lead"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSiu%26aufirst%3DT.%26aulast%3DKozina%26aufirst%3DE.%2BS.%26aulast%3DJung%26aufirst%3DJ.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DChan%26aufirst%3DG.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DBachman%26aufirst%3DE.%26aulast%3DMo%26aufirst%3DJ.%2BR.%26aulast%3DBouthillette%26aufirst%3DM.%26aulast%3DRush%26aufirst%3DT.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DYoung%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520discovery%2520of%2520tricyclic%2520pyridone%2520JAK2%2520inhibitors.%2520Part%25201%253A%2520Hit%2520to%2520lead%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D7421%26epage%3D7425" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">William, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulsen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagaraj, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goh, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hart, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayaraman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasha, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ethirajulu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dymock, B. W.</span><span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/Fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4638</span><span class="NLM_x">–</span> <span class="NLM_lpage">4658</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2FFms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35d&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.1%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252FFms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Ioannidis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamb, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almeida, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Block, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffmann, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivard, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollard, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alimzhanov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bebernitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huszar, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinda, M.</span><span> </span><span class="NLM_article-title">Discovery of 5-chloro-<i>N</i>2-[(1<i>S</i>)-1-(5-fluoropyrimidin-2-yl)ethyl]-<i>N</i>4-(5-methyl-1<i>H</i>-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">262</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011319" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35e&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=262-276&author=S.+Ioannidisauthor=M.+L.+Lambauthor=T.+Wangauthor=L.+Almeidaauthor=M.+H.+Blockauthor=A.+M.+Daviesauthor=B.+Pengauthor=M.+Suauthor=H.+J.+Zhangauthor=E.+Hoffmannauthor=C.+Rivardauthor=I.+Greenauthor=T.+Howardauthor=H.+Pollardauthor=J.+Readauthor=M.+Alimzhanovauthor=G.+Bebernitzauthor=K.+Bellauthor=M.+Yeauthor=D.+Huszarauthor=M.+Zinda&title=Discovery+of+5-chloro-N2-%5B%281S%29-1-%285-fluoropyrimidin-2-yl%29ethyl%5D-N4-%285-methyl-1H-pyrazol-3-yl%29pyrimidine-2%2C4-diamine+%28AZD1480%29+as+a+novel+inhibitor+of+the+Jak%2FStat+pathway"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35eR"><div class="casContent"><span class="casTitleNuber">35e</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 5-Chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a Novel Inhibitor of the Jak/Stat Pathway</span></div><div class="casAuthors">Ioannidis, Stephanos; Lamb, Michelle L.; Wang, Tao; Almeida, Lynsie; Block, Michael H.; Davies, Audrey M.; Peng, Bo; Su, Mei; Zhang, Hai-Jun; Hoffmann, Ethan; Rivard, Caroline; Green, Isabelle; Howard, Tina; Pollard, Hannah; Read, Jon; Alimzhanov, Marat; Bebernitz, Geraldine; Bell, Kirsten; Ye, Min-Wei; Huszar, Dennis; Zinda, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">262-276</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematol. malignancies characterized by clonal expansion of one or more myeloid lineages.  The discovery of the Jak2 V617F gain of function mutation highlighted Jak2 as a potential therapeutic target in the MPNs.  Herein, we disclose the discovery of a series of pyrazol-3-yl pyrimidin-4-amines and the identification of 9e (AZD1480) as a potent Jak2 inhibitor.  9E inhibits signaling and proliferation of Jak2 V617F cell lines in vitro, demonstrates in vivo efficacy in a TEL-Jak2 model, has excellent phys. properties and preclin. pharmacokinetics, and is currently being evaluated in Phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMG6RQUv4HqbVg90H21EOLACvtfcHk0ljbPTOU_cyAfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFarsr%252FN&md5=c8141c5b0e25a007e68b6e2567a576fe</span></div><a href="/servlet/linkout?suffix=cit35e&amp;dbid=16384&amp;doi=10.1021%2Fjm1011319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011319%26sid%3Dliteratum%253Aachs%26aulast%3DIoannidis%26aufirst%3DS.%26aulast%3DLamb%26aufirst%3DM.%2BL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DAlmeida%26aufirst%3DL.%26aulast%3DBlock%26aufirst%3DM.%2BH.%26aulast%3DDavies%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DH.%2BJ.%26aulast%3DHoffmann%26aufirst%3DE.%26aulast%3DRivard%26aufirst%3DC.%26aulast%3DGreen%26aufirst%3DI.%26aulast%3DHoward%26aufirst%3DT.%26aulast%3DPollard%26aufirst%3DH.%26aulast%3DRead%26aufirst%3DJ.%26aulast%3DAlimzhanov%26aufirst%3DM.%26aulast%3DBebernitz%26aufirst%3DG.%26aulast%3DBell%26aufirst%3DK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DHuszar%26aufirst%3DD.%26aulast%3DZinda%26aufirst%3DM.%26atitle%3DDiscovery%2520of%25205-chloro-N2-%255B%25281S%2529-1-%25285-fluoropyrimidin-2-yl%2529ethyl%255D-N4-%25285-methyl-1H-pyrazol-3-yl%2529pyrimidine-2%252C4-diamine%2520%2528AZD1480%2529%2520as%2520a%2520novel%2520inhibitor%2520of%2520the%2520Jak%252FStat%2520pathway%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D262%26epage%3D276" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Wernig, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kharas, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leeman, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gozo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDowell, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doukas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, B. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soll, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tefferi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span> </span><span class="NLM_article-title">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">320</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.ccr.2008.02.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18394554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35f&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=311-320&author=G.+Wernigauthor=M.+G.+Kharasauthor=R.+Okabeauthor=S.+A.+Mooreauthor=D.+S.+Leemanauthor=D.+E.+Cullenauthor=M.+Gozoauthor=E.+P.+McDowellauthor=R.+L.+Levineauthor=J.+Doukasauthor=C.+C.+Makauthor=G.+Noronhaauthor=M.+Martinauthor=Y.+D.+Koauthor=B.+H.+Leeauthor=R.+M.+Sollauthor=A.+Tefferiauthor=J.+D.+Hoodauthor=D.+G.+Gilliland&title=Efficacy+of+TG101348%2C+a+selective+JAK2+inhibitor%2C+in+treatment+of+a+murine+model+of+JAK2V617F-induced+polycythemia+vera"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35fR"><div class="casContent"><span class="casTitleNuber">35f</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera</span></div><div class="casAuthors">Wernig, Gerlinde; Kharas, Michael G.; Okabe, Rachel; Moore, Sandra A.; Leeman, Dena S.; Cullen, Dana E.; Gozo, Maricel; McDowell, Elizabeth P.; Levine, Ross L.; Doukas, John; Mak, Chi Ching; Noronha, Glenn; Martin, Michael; Ko, Yon D.; Lee, Benjamin H.; Soll, Richard M.; Tefferi, Ayalew; Hood, John D.; Gilliland, D. Gary</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-320</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">We report that TG101348, a selective small-mol. inhibitor of JAK2 with an in vitro IC50 of ∼3 nM, shows therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617F mutation.  In treated animals, there was a statistically significant redn. in hematocrit and leukocyte count, a dose-dependent redn./elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for attenuation of myelofibrosis.  There were no apparent toxicities and no effect on T cell no.  In vivo responses were correlated with surrogate endpoints, including redn./elimination of JAK2V617F disease burden assessed by quant. genomic PCR, suppression of endogenous erythroid colony formation, and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phosphorylated Stat5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSJOc4cS_lO7Vg90H21EOLACvtfcHk0lh96MQbHenSlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkslSjtrs%253D&md5=3dd923595cafebb6439dd67f026735be</span></div><a href="/servlet/linkout?suffix=cit35f&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2008.02.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2008.02.009%26sid%3Dliteratum%253Aachs%26aulast%3DWernig%26aufirst%3DG.%26aulast%3DKharas%26aufirst%3DM.%2BG.%26aulast%3DOkabe%26aufirst%3DR.%26aulast%3DMoore%26aufirst%3DS.%2BA.%26aulast%3DLeeman%26aufirst%3DD.%2BS.%26aulast%3DCullen%26aufirst%3DD.%2BE.%26aulast%3DGozo%26aufirst%3DM.%26aulast%3DMcDowell%26aufirst%3DE.%2BP.%26aulast%3DLevine%26aufirst%3DR.%2BL.%26aulast%3DDoukas%26aufirst%3DJ.%26aulast%3DMak%26aufirst%3DC.%2BC.%26aulast%3DNoronha%26aufirst%3DG.%26aulast%3DMartin%26aufirst%3DM.%26aulast%3DKo%26aufirst%3DY.%2BD.%26aulast%3DLee%26aufirst%3DB.%2BH.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DHood%26aufirst%3DJ.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26atitle%3DEfficacy%2520of%2520TG101348%252C%2520a%2520selective%2520JAK2%2520inhibitor%252C%2520in%2520treatment%2520of%2520a%2520murine%2520model%2520of%2520JAK2V617F-induced%2520polycythemia%2520vera%26jtitle%3DCancer%2520Cell%26date%3D2008%26volume%3D13%26spage%3D311%26epage%3D320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Burns, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bourke, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrau, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donohue, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fantino, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrugia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feutrill, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joffe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nero, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phillips, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shackleford, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sikanyika, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Styles, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treutlein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilks, A. F.</span><span> </span><span class="NLM_article-title">Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5887</span><span class="NLM_x">–</span> <span class="NLM_lpage">5892</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=5887-5892&author=C.+J.+Burnsauthor=D.+G.+Bourkeauthor=L.+Andrauauthor=X.+Buauthor=S.+A.+Charmanauthor=A.+C.+Donohueauthor=E.+Fantinoauthor=M.+Farrugiaauthor=J.+T.+Feutrillauthor=M.+Joffeauthor=M.+R.+Klingauthor=M.+Kurekauthor=T.+L.+Neroauthor=T.+Nguyenauthor=J.+T.+Palmerauthor=I.+Phillipsauthor=D.+M.+Shacklefordauthor=H.+Sikanyikaauthor=M.+Stylesauthor=S.+Suauthor=H.+Treutleinauthor=J.+Zengauthor=A.+F.+Wilks&title=Phenylaminopyrimidines+as+inhibitors+of+Janus+kinases+%28JAKs%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26aulast%3DBourke%26aufirst%3DD.%2BG.%26aulast%3DAndrau%26aufirst%3DL.%26aulast%3DBu%26aufirst%3DX.%26aulast%3DCharman%26aufirst%3DS.%2BA.%26aulast%3DDonohue%26aufirst%3DA.%2BC.%26aulast%3DFantino%26aufirst%3DE.%26aulast%3DFarrugia%26aufirst%3DM.%26aulast%3DFeutrill%26aufirst%3DJ.%2BT.%26aulast%3DJoffe%26aufirst%3DM.%26aulast%3DKling%26aufirst%3DM.%2BR.%26aulast%3DKurek%26aufirst%3DM.%26aulast%3DNero%26aufirst%3DT.%2BL.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26aulast%3DPhillips%26aufirst%3DI.%26aulast%3DShackleford%26aufirst%3DD.%2BM.%26aulast%3DSikanyika%26aufirst%3DH.%26aulast%3DStyles%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DTreutlein%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DJ.%26aulast%3DWilks%26aufirst%3DA.%2BF.%26atitle%3DPhenylaminopyrimidines%2520as%2520inhibitors%2520of%2520Janus%2520kinases%2520%2528JAKs%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D5887%26epage%3D5892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit35h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Hexner, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Serdikoff, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swider, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Emerson, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrzanski, P.</span><span> </span><span class="NLM_article-title">Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x">, </span> <span class="NLM_fpage">5663</span><span class="NLM_x">–</span> <span class="NLM_lpage">5671</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2008&pages=5663-5671&author=E.+O.+Hexnerauthor=C.+Serdikoffauthor=M.+Janauthor=C.+R.+Swiderauthor=C.+Robinsonauthor=S.+Yangauthor=T.+Angelesauthor=S.+G.+Emersonauthor=M.+Carrollauthor=B.+Ruggeriauthor=P.+Dobrzanski&title=Lestaurtinib+%28CEP701%29+is+a+JAK2+inhibitor+that+suppresses+JAK2%2FSTAT5+signaling+and+the+proliferation+of+primary+erythroid+cells+from+patients+with+myeloproliferative+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35h&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHexner%26aufirst%3DE.%2BO.%26aulast%3DSerdikoff%26aufirst%3DC.%26aulast%3DJan%26aufirst%3DM.%26aulast%3DSwider%26aufirst%3DC.%2BR.%26aulast%3DRobinson%26aufirst%3DC.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DAngeles%26aufirst%3DT.%26aulast%3DEmerson%26aufirst%3DS.%2BG.%26aulast%3DCarroll%26aufirst%3DM.%26aulast%3DRuggeri%26aufirst%3DB.%26aulast%3DDobrzanski%26aufirst%3DP.%26atitle%3DLestaurtinib%2520%2528CEP701%2529%2520is%2520a%2520JAK2%2520inhibitor%2520that%2520suppresses%2520JAK2%252FSTAT5%2520signaling%2520and%2520the%2520proliferation%2520of%2520primary%2520erythroid%2520cells%2520from%2520patients%2520with%2520myeloproliferative%2520disorders%26jtitle%3DBlood%26date%3D2008%26volume%3D111%26spage%3D5663%26epage%3D5671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kulagowski, J. J.; Blair, W.; Bull, R. J.; Chang, C.; Deshmukh, G.; Dyke, H. J.; Eigenbrot, C.; Ghilardi, N.; Gibbons, P.; Harrison, T. K.; Hewitt, P. R.; Liimatta, M.; Hurley, C. A.; Johnson, A.; Johnson, T.; Kenny, J. R.; Bir Kohli, P.; Maxey, R. J.; Mendonca, R.; Mortara, K.; Murray, J.; Narukulla, R.; Shia, S.; Steffek, M.; Ubhayakar, S.; Ultsch, M.; van Abbema, A.; Ward, S. I.; Waszkowycz, B.; Zak, M.</span><span> </span><span class="NLM_article-title">Identification of imidazo-pyrrolopyridines as novel and potent JAK1 Inhibitors</span>.  <span class="citation_source-journal">J. Med. Chem.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1021/jm300438j</span> . Published online: May 16,<span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/jm300438j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=J.+J.+Kulagowski&author=W.+Blair&author=R.+J.+Bull&author=C.+Chang&author=G.+Deshmukh&author=H.+J.+Dyke&author=C.+Eigenbrot&author=N.+Ghilardi&author=P.+Gibbons&author=T.+K.+Harrison&author=P.+R.+Hewitt&author=M.+Liimatta&author=C.+A.+Hurley&author=A.+Johnson&author=T.+Johnson&author=J.+R.+Kenny&author=P.+Bir+Kohli&author=R.+J.+Maxey&author=R.+Mendonca&author=K.+Mortara&author=J.+Murray&author=R.+Narukulla&author=S.+Shia&author=M.+Steffek&author=S.+Ubhayakar&author=M.+Ultsch&author=A.+van+Abbema&author=S.+I.+Ward&author=B.+Waszkowycz&author=M.+Zak&title=Identification+of+imidazo-pyrrolopyridines+as+novel+and+potent+JAK1+Inhibitors&doi=10.1021%2Fjm300438j"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm300438j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300438j%26sid%3Dliteratum%253Aachs%26aulast%3DKulagowski%26aufirst%3DJ.%2BJ.%26atitle%3DIdentification%2520of%2520imidazo-pyrrolopyridines%2520as%2520novel%2520and%2520potent%2520JAK1%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm300438j%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">Prior to commencement of our work, a series of related, imidazolone-containing compounds had been described as JAK3 inhibitors: </p></div><div class="NLM_citation" id="rightTab-cit37a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Inoue, T.; Tanaka, A.; Nakai, K.; Sasaki, H.; Takahashi, F.; Shirakami, S.; Hatanaka, K.; Nakajima, Y.; Mukoyoshi, K.; Hamaguchi, H.; Kunikawa, S.; Higashi, Y.</span><span> </span><span class="NLM_article-title">Heterocyclic Janus Kinase 3 Inhibitors</span>. WO2007077949,<span class="NLM_x"> </span><span class="NLM_year">2007</span>. </span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+Inoue&author=A.+Tanaka&author=K.+Nakai&author=H.+Sasaki&author=F.+Takahashi&author=S.+Shirakami&author=K.+Hatanaka&author=Y.+Nakajima&author=K.+Mukoyoshi&author=H.+Hamaguchi&author=S.+Kunikawa&author=Y.+Higashi&title=Heterocyclic+Janus+Kinase+3+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DT.%26atitle%3DHeterocyclic%2520Janus%2520Kinase%25203%2520Inhibitors%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">More recently, during the course of or after completion of our work, patent applications have appeared describing other tricyclic azaindole-containing scaffolds as JAK inhibitors. These include azaindole annelated by pyrrole:</p></div><div class="NLM_citation" id="rightTab-cit37b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shirakami, S.; Nakajima, Y.; Maeda, J.; Tominaga, H.; Yamagishi, H.; Hondo, T.; Inami, M.; Morio, H.; Inoue, T.; Mizutani, T.; Ishioka, H.</span><span> </span><span class="NLM_article-title">Fused Pyrrolopyridine Derivative</span>. WO2010119875,<span class="NLM_x"> </span><span class="NLM_year">2010</span>. <div class="note"><p class="first last">Azaindole annelated by pyrrole, pyrazole, and isoxazole:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=S.+Shirakami&author=Y.+Nakajima&author=J.+Maeda&author=H.+Tominaga&author=H.+Yamagishi&author=T.+Hondo&author=M.+Inami&author=H.+Morio&author=T.+Inoue&author=T.+Mizutani&author=H.+Ishioka&title=Fused+Pyrrolopyridine+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShirakami%26aufirst%3DS.%26atitle%3DFused%2520Pyrrolopyridine%2520Derivative%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Wishart, N.; Argiriadi, M.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R.</span><span> </span><span class="NLM_article-title">Novel Tricyclic Compounds</span>. WO2009152133,<span class="NLM_x"> </span><span class="NLM_year">2009</span>. <div class="note"><p class="first last">Azaindole annelated by isothiazole, triazole, and imidazole:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=N.+Wishart&author=M.+Argiriadi&author=D.+J.+Calderwood&author=A.+M.+Ericsson&author=B.+A.+Fiamengo&author=K.+E.+Frank&author=M.+Friedman&author=D.+M.+George&author=E.+R.+Goedken&author=N.+S.+Josephsohn&author=B.+C.+Li&author=M.+J.+Morytko&author=K.+D.+Stewart&author=J.+W.+Voss&author=G.+A.+Wallace&author=L.+Wang&author=K.+R.+Woller&title=Novel+Tricyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DNovel%2520Tricyclic%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Wishart, N.; Argiriadi, M.; Breinlinger, E. C.; Calderwood, D. J.; Ericsson, A. M.; Fiamengo, B. A.; Frank, K. E.; Friedman, M.; George, D. M.; Goedken, E. R.; Josephsohn, N. S.; Li, B. C.; Morytko, M. J.; Mullen, K. D.; Somal, G.; Stewart, K. D.; Voss, J. W.; Wallace, G. A.; Wang, L.; Woller, K. R.</span><span> </span><span class="NLM_article-title">Novel Tricyclic Compounds</span>. WO2011068899,<span class="NLM_x"> </span><span class="NLM_year">2011</span>. <div class="note"><p class="first last">Tricyclic systems related to <b>3</b> but having distinct substitution on the core and probably employing an alternative hinge-binding mode have recently appeared as JAK2 inhibitors:</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=N.+Wishart&author=M.+Argiriadi&author=E.+C.+Breinlinger&author=D.+J.+Calderwood&author=A.+M.+Ericsson&author=B.+A.+Fiamengo&author=K.+E.+Frank&author=M.+Friedman&author=D.+M.+George&author=E.+R.+Goedken&author=N.+S.+Josephsohn&author=B.+C.+Li&author=M.+J.+Morytko&author=K.+D.+Mullen&author=G.+Somal&author=K.+D.+Stewart&author=J.+W.+Voss&author=G.+A.+Wallace&author=L.+Wang&author=K.+R.+Woller&title=Novel+Tricyclic+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DWishart%26aufirst%3DN.%26atitle%3DNovel%2520Tricyclic%2520Compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit37e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Purandare, A. V.; Grebinski, J. W.; Hart, A.; Inghrim, J.; Schroeder, G.; Wan, H.</span><span> </span><span class="NLM_article-title">JAK2 Inhibitors and Their Use for the Treatment of Myeloproliferative Diseases and Cancer</span>. WO2011028864,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+V.+Purandare&author=J.+W.+Grebinski&author=A.+Hart&author=J.+Inghrim&author=G.+Schroeder&author=H.+Wan&title=JAK2+Inhibitors+and+Their+Use+for+the+Treatment+of+Myeloproliferative+Diseases+and+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DPurandare%26aufirst%3DA.%2BV.%26atitle%3DJAK2%2520Inhibitors%2520and%2520Their%2520Use%2520for%2520the%2520Treatment%2520of%2520Myeloproliferative%2520Diseases%2520and%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="note"><p class="first last">EC<sub>50</sub> values for compounds that do not achieve at least 50% inhibition at the highest concentration tested (10000 nM) in the cell based assays are considered to be noncalculable and are reported as >10000 nM. Because of normal run-to-run variability, some weakly potent compounds achieve >50% inhibition in some, but not all, of the replicate runs. In these cases, we report EC<sub>50</sub> > <i>X</i>, where <i>X</i> is the arithmetic mean of all the individual EC<sub>50</sub> values, both calculable and noncalculable. For example, compound <b>3</b> displayed replicate EC<sub>50</sub> values of 6300, >10000, and >10000 nM in the EPO-pSTAT5 assay; thus, the average EC<sub>50</sub> is reported as >8800 nM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Ertl, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohde, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selzer, P.</span><span> </span><span class="NLM_article-title">Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">3714</span><span class="NLM_x">–</span> <span class="NLM_lpage">3717</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm000942e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=3714-3717&author=P.+Ertlauthor=B.+Rohdeauthor=P.+Selzer&title=Fast+calculation+of+molecular+polar+surface+area+as+a+sum+of+fragment-based+contributions+and+its+application+to+the+prediction+of+drug+transport+properties"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties</span></div><div class="casAuthors">Ertl, Peter; Rohde, Bernhard; Selzer, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3714-3717</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mol. polar surface area (PSA), i.e., surface belonging to polar atoms, is a descriptor that was shown to correlate well with passive mol. transport through membranes and, therefore, allows prediction of transport properties of drugs.  The calcn. of PSA, however, is rather time-consuming because of the necessity to generate a reasonable 3D mol. geometry and the calcn. of the surface itself.  A new approach for the calcn. of the PSA is presented here, based on the summation of tabulated surface contributions of polar fragments.  The method, termed topol. PSA (TPSA), provides results which are practically identical with the 3D PSA (the correlation coeff. between 3D PSA and fragment-based TPSA for 34 810 mols. from the World Drug Index is 0.99), while the computation speed is 2-3 orders of magnitude faster.  The new methodol. may, therefore, be used for fast bioavailability screening of virtual libraries having millions of mols.  This article describes the new methodol. and shows the results of validation studies based on sets of published absorption data, including intestinal absorption, Caco-2 monolayer penetration, and blood-brain barrier penetration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhP6Qncx_h6LVg90H21EOLACvtfcHk0ljkfQgud7qYZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmsFeitb4%253D&md5=23ae4e7708bd8ddeb4a24ad160a29bd6</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm000942e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000942e%26sid%3Dliteratum%253Aachs%26aulast%3DErtl%26aufirst%3DP.%26aulast%3DRohde%26aufirst%3DB.%26aulast%3DSelzer%26aufirst%3DP.%26atitle%3DFast%2520calculation%2520of%2520molecular%2520polar%2520surface%2520area%2520as%2520a%2520sum%2520of%2520fragment-based%2520contributions%2520and%2520its%2520application%2520to%2520the%2520prediction%2520of%2520drug%2520transport%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D3714%26epage%3D3717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="note"><p class="first last">Prior to synthesis, predicted log <i>D</i> values were calculated using the MoKa sofware (<a href="http://www.moldiscovery.com" class="extLink">www.moldiscovery.com</a> (ref <a class="ref internalNav" href="#cit40a" aria-label="40a">40a</a>) and a custom p<i>K</i><sub>a</sub> model (ref <a class="ref internalNav" href="#cit40b" aria-label="40b">40b</a>). </p></div><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sforna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">New and original p<i>K</i><sub>a</sub> prediction method using grid molecular interaction fields</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">2172</span><span class="NLM_x">–</span> <span class="NLM_lpage">2181</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci700018y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2007&pages=2172-2181&author=F.+Millettiauthor=L.+Storchiauthor=G.+Sfornaauthor=G.+Cruciani&title=New+and+original+pKa+prediction+method+using+grid+molecular+interaction+fields"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">New and Original pKa Prediction Method Using Grid Molecular Interaction Fields</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Sforna, Gianluca; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2172-2181</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">One of the most important physicochem. properties of a mol. is pKa.  It is known that two parameters imperative in ADME profiling, soly., and lipophilicity are governed by pKa, and receptor binding can be influenced by pKa.  Because most drugs are ionized in physiol. conditions, pKa is particularly relevant to medicinal chem.  Despite the numerous advances in high-throughput measurements, in silico detn. is still the fastest and cheapest way of obtaining pKa.  This paper presents a new original computational method for pKa prediction of org. compds.  Descriptors were generated using the program GRID, and these descriptors are based on mol. interaction fields precomputed on a set of mol. fragments.  The new method was developed, trained, and cross-validated by using a large and diverse data set of 24 617 pKa values.  This paper presents the results for a class of 421 acidic nitrogen compds. (RMSE = 0.41, r2 = 0.97, q2 = 0.87) and for a class of 947 six-membered N-heterocyclic bases (RMSE = 0.60, r2 = 0.93, q2 = 0.85).  For external validation 28 novel compds. were selected that covered nine different ionizable groups, and 39 pKa values could be exptl. detd. by spectral gradient anal. (SGA).  Comparison of exptl. pKa with calcd. pKa demonstrated that the predictive ability of the method is good (external set, r2 = 0.85, RMSE = 0.90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzEk0uiS1E6rVg90H21EOLACvtfcHk0li_rja6u15RLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFSnsLrF&md5=f2b1dec853ccb0ef1a40540d234232fb</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1021%2Fci700018y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci700018y%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DSforna%26aufirst%3DG.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DNew%2520and%2520original%2520pKa%2520prediction%2520method%2520using%2520grid%2520molecular%2520interaction%2520fields%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2007%26volume%3D47%26spage%3D2172%26epage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Milletti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storchi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goracci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendels, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruciani, G.</span><span> </span><span class="NLM_article-title">Extending p<i>K</i><sub>a</sub> prediction accuracy: high-throughput p<i>K</i><sub>a</sub> measurements to understand p<i>K</i><sub>a</sub> modulation of new chemical series</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">4270</span><span class="NLM_x">–</span> <span class="NLM_lpage">4279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1016%2Fj.ejmech.2010.06.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=20633962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=4270-4279&author=F.+Millettiauthor=L.+Storchiauthor=L.+Goracciauthor=S.+Bendelsauthor=B.+Wagnerauthor=M.+Kansyauthor=G.+Cruciani&title=Extending+pKa+prediction+accuracy%3A+high-throughput+pKa+measurements+to+understand+pKa+modulation+of+new+chemical+series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">Extending pKa prediction accuracy: High-throughput pKa measurements to understand pKa modulation of new chemical series</span></div><div class="casAuthors">Milletti, Francesca; Storchi, Loriano; Goracci, Laura; Bendels, Stefanie; Wagner, Bjoern; Kansy, Manfred; Cruciani, Gabriele</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4270-4279</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We have recently developed a tool, MoKα, to predict the pKa of org. compds. using a large dataset of over 26,500 literature pKa values as a training set.  However, predicting accurately pKa (<0.5 pH units) remains challenging for novel series, and this can be a drawback in the optimization of activity and ADME properties of lead compds.  To address this issue it is important to expand our knowledge of pKa determinants, therefore we have conducted high-throughput pKa measurements by using Spectral Gradient Anal. (SGA) on novel series of compds. selected from vendor databases.  Here we report our findings on the effect of specific chem. groups and steric constraints on the pKa of common functionalities in medicinal chem., such as amines, sulfonamides, and amides.  Furthermore, we report the pKa of ionizable groups that were not well represented in the database of literature pKa of MoKα, such as hydrazide derivs.  These findings helped us to enhance MoKα, which is here benchmarked on a set of exptl. pKa values from the Roche inhouse library (N = 5581; RMSE = 1.09; R2 = 0.82).  The accuracy of the predictions was greatly improved (RMSE = 0.49, R2 = 0.96) after training the software by using the automated tool Kibitzer with 6226 pK a values taken from a different set of Roche compds. appropriately selected, and this demonstrates the value of using high-throughput pKa measurements to expand the training set of pKa values used by the software MoKα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQ9UJOAhB-rVg90H21EOLACvtfcHk0li_rja6u15RLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvFKhtLo%253D&md5=e4c579032df7fa37ec3551c69a09257a</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2010.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2010.06.026%26sid%3Dliteratum%253Aachs%26aulast%3DMilletti%26aufirst%3DF.%26aulast%3DStorchi%26aufirst%3DL.%26aulast%3DGoracci%26aufirst%3DL.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DWagner%26aufirst%3DB.%26aulast%3DKansy%26aufirst%3DM.%26aulast%3DCruciani%26aufirst%3DG.%26atitle%3DExtending%2520pKa%2520prediction%2520accuracy%253A%2520high-throughput%2520pKa%2520measurements%2520to%2520understand%2520pKa%2520modulation%2520of%2520new%2520chemical%2520series%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D4270%26epage%3D4279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="note"><p class="first last">The <i>t</i> tests were conducted on the JAK1 and JAK2 <i>K</i><sub>i</sub> values for <b>4</b>, <b>11</b>, <b>14</b>, and <b>20</b>. In each case, JAK1 biochemical activity was found to be inhibited to a greater extent than the corresponding JAK2 biochemical activity by a statistically significant margin (<i>p</i> < 0.02 for <b>14</b>, <i>p</i> < 0.001 for <b>4</b>, <b>11</b>, and <b>20</b>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Balague, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pont, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prats, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godessart, N.</span><span> </span><span class="NLM_article-title">Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">1320</span><span class="NLM_x">–</span> <span class="NLM_lpage">1332</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1111%2Fj.1476-5381.2012.01836.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=22229697" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BC38XotlWmt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2012&pages=1320-1332&author=C.+Balagueauthor=M.+Pontauthor=N.+Pratsauthor=N.+Godessart&title=Profiling+of+dihydroorotate+dehydrogenase%2C+p38+and+JAK+inhibitors+in+the+rat+adjuvant-induced+arthritis+model%3A+a+translational+study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study</span></div><div class="casAuthors">Balague, C.; Pont, M.; Prats, N.; Godessart, N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1320-1332</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose Translational animal models are essential in the prediction of the efficacy and side effects of new chem. entities.  We have carried out a thorough study of three distinct disease-modifying antirheumatic drugs (DMARDs) in an adjuvant-induced arthritis (AIA) model in the rat and critically appraised the results in the context of the reported clin. experience in rheumatoid arthritis (RA) patients.  Exptl. Approach Teriflunomide - a dihydroorotate dehydrogenase (DHODH) inhibitor; AL8697 - a selective p38 MAPK inhibitor; and tofacitinib - a Janus kinase (JAK) inhibitor; were selected as representatives of their class and dose-response studies carried out using a therapeutic 10-day administration scheme in arthritic rats.  Paw swelling and body wt. were periodically monitored, and joint radiol. and histol., lymph organ wt. and haematol. and biochem. parameters evaluated at study completion.  Key Results All three drugs demonstrated beneficial effects on paw swelling, bone lesions and splenomegalia, with p38 inhibition providing the best anti-inflammatory effect and JAK inhibition the best DMARD effect.  Leukopenia, body wt. loss and gastrointestinal toxicity were dose-dependently obsd. with teriflunomide treatment.  P38 MAPK inhibition induced leukocytosis and increased total plasma cholesterol.  JAK inhibition, normalized platelet, reticulocyte and neutrophil counts, and alanine aminotransferase (ALT) levels while inducing lymphopenia and cholesterolemia.  Conclusions and Implications This multiparametric approach can reveal specific drug properties and provide translational information.  Whereas the complex profile for p38 inhibition in AIA is not obsd. in human RA, immunosuppressants such as DHODH and JAK inhibitors show DMARD properties and side effects seen in both AIA and RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTidNBvH5aRrVg90H21EOLACvtfcHk0li_rja6u15RLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotlWmt7g%253D&md5=32eb083b1793cb1a23a0cc6539a31c2a</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2012.01836.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2012.01836.x%26sid%3Dliteratum%253Aachs%26aulast%3DBalague%26aufirst%3DC.%26aulast%3DPont%26aufirst%3DM.%26aulast%3DPrats%26aufirst%3DN.%26aulast%3DGodessart%26aufirst%3DN.%26atitle%3DProfiling%2520of%2520dihydroorotate%2520dehydrogenase%252C%2520p38%2520and%2520JAK%2520inhibitors%2520in%2520the%2520rat%2520adjuvant-induced%2520arthritis%2520model%253A%2520a%2520translational%2520study%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D166%26spage%3D1320%26epage%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><div class="note"><p class="first last">The maximum achievable oral bioavailability (<i>F</i><sub>max</sub>) is the product of the fraction absorbed (<i>F</i><sub>a</sub>), the fraction escaping intestinal metabolism (<i>F</i><sub>g</sub>), and the fraction escaping hepatic metabolism (<i>F</i><sub>h</sub>), as expressed by the equation <i>F</i><sub>max</sub> = <i>F</i><sub>a</sub><i>F</i><sub>g</sub><i>F</i><sub>h</sub>. Assuming a best case scenario of no intestinal wall metabolism and complete absorption of the oral dose (<i>F</i><sub>g</sub> and <i>F</i><sub>a</sub> are 1), the equation is simplified to <i>F</i><sub>max</sub> = <i>F</i><sub>h</sub>. Since <i>F</i><sub>h</sub> = 1 – CL/<i>Q</i><sub>h</sub>, where CL is clearance and <i>Q</i><sub>h</sub> is hepatic blood flow, it is apparent that the maximum achievable bioavailability should be controlled by clearance according to the equation <i>F</i><sub>max</sub> = 1 – CL/<i>Q</i><sub>h</sub>. Assuming a hepatic blood flow in the rat of 70 mL min<sup>–1</sup> kg<sup>–1</sup>, a compound with an iv clearance of 43 mL min<sup>–1</sup> kg<sup>–1</sup> should have an <i>F</i><sub>max</sub> of 39%. See the following: </p></div><span class="NLM_contrib-group">Rautio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumpulainen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heimbach, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliyai, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Järvinen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Savolainen, J.</span><span> </span><span class="NLM_article-title">Prodrugs: design and clinical applications</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">–</span> <span class="NLM_lpage">270</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm300628c&amp;key=10.1038%2Fnrd2468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm300628c&amp;key=18219308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=255-270&author=J.+Rautioauthor=H.+Kumpulainenauthor=T.+Heimbachauthor=R.+Oliyaiauthor=D.+Ohauthor=T.+J%C3%A4rvinenauthor=J.+Savolainen&title=Prodrugs%3A+design+and+clinical+applications"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs: design and clinical applications</span></div><div class="casAuthors">Rautio, Jarkko; Kumpulainen, Hanna; Heimbach, Tycho; Oliyai, Reza; Oh, Dooman; Jaervinen, Tomi; Savolainen, Jouko</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">255-270</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Prodrugs are bioreversible derivs. of drug mols. that undergo an enzymic and/or chem. transformation in vivo to release the active parent drug, which can then exert the desired pharmacol. effect.  In both drug discovery and development, prodrugs have become an established tool for improving physicochem., biopharmaceutical or pharmacokinetic properties of pharmacol. active agents.  About 5-7% of drugs approved worldwide can be classified as prodrugs, and the implementation of a prodrug approach in the early stages of drug discovery is a growing trend.  To illustrate the applicability of the prodrug strategy, this article describes the most common functional groups that are amenable to prodrug design, and highlights examples of prodrugs that are either launched or are undergoing human trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxnlEXYMLCVbVg90H21EOLACvtfcHk0lhrGygKEEidog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFOrs7w%253D&md5=481a088ad2ee4da062779b5b28a33cbb</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1038%2Fnrd2468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2468%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DKumpulainen%26aufirst%3DH.%26aulast%3DHeimbach%26aufirst%3DT.%26aulast%3DOliyai%26aufirst%3DR.%26aulast%3DOh%26aufirst%3DD.%26aulast%3DJ%25C3%25A4rvinen%26aufirst%3DT.%26aulast%3DSavolainen%26aufirst%3DJ.%26atitle%3DProdrugs%253A%2520design%2520and%2520clinical%2520applications%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26spage%3D255%26epage%3D270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bondi, D.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44a&amp;dbid=32&amp;doi=10.1021%2Fjm300628c&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=D.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44aR"><div class="casContent"><span class="casTitleNuber">44a</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0lhrGygKEEidog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit44a&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DD.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit44b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Li, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussinov, R.</span><span> </span><span class="NLM_article-title">A set of van der Waals and coulombic radii of protein atoms for molecular and solvent-accessible surface calculation, packing evaluation and docking</span> <span class="citation_source-journal">Proteins: Struct., Funct., Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">127</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1998&pages=111-127&author=A.+Liauthor=R.+Nussinov&title=A+set+of+van+der+Waals+and+coulombic+radii+of+protein+atoms+for+molecular+and+solvent-accessible+surface+calculation%2C+packing+evaluation+and+docking"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DA.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DA%2520set%2520of%2520van%2520der%2520Waals%2520and%2520coulombic%2520radii%2520of%2520protein%2520atoms%2520for%2520molecular%2520and%2520solvent-accessible%2520surface%2520calculation%252C%2520packing%2520evaluation%2520and%2520docking%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D1998%26volume%3D32%26spage%3D111%26epage%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="note"><p class="first last">Further details on the quantum mechanical calculations may be found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">van Niel, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beer, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broughton, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodacre, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Locker, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacLeod, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyes, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sohal, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stanton, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verrier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castro, J. L.</span><span> </span><span class="NLM_article-title">Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">2087</span><span class="NLM_x">–</span> <span class="NLM_lpage">2104</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm981133m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=2087-2104&author=M.+B.+van+Nielauthor=I.+Collinsauthor=M.+S.+Beerauthor=H.+B.+Broughtonauthor=S.+K.+Chengauthor=S.+C.+Goodacreauthor=A.+Healdauthor=K.+L.+Lockerauthor=A.+M.+MacLeodauthor=D.+Morrisonauthor=C.+R.+Moyesauthor=D.+O%E2%80%99Connorauthor=A.+Pikeauthor=M.+Rowleyauthor=M.+G.+Russellauthor=B.+Sohalauthor=J.+A.+Stantonauthor=S.+Thomasauthor=H.+Verrierauthor=A.+P.+Wattauthor=J.+L.+Castro&title=Fluorination+of+3-%283-%28piperidin-1-yl%29propyl%29indoles+and+3-%283-%28piperazin-1-yl%29propyl%29indoles+gives+selective+human+5-HT1D+receptor+ligands+with+improved+pharmacokinetic+profiles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46a&amp;dbid=16384&amp;doi=10.1021%2Fjm981133m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm981133m%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BNiel%26aufirst%3DM.%2BB.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DBeer%26aufirst%3DM.%2BS.%26aulast%3DBroughton%26aufirst%3DH.%2BB.%26aulast%3DCheng%26aufirst%3DS.%2BK.%26aulast%3DGoodacre%26aufirst%3DS.%2BC.%26aulast%3DHeald%26aufirst%3DA.%26aulast%3DLocker%26aufirst%3DK.%2BL.%26aulast%3DMacLeod%26aufirst%3DA.%2BM.%26aulast%3DMorrison%26aufirst%3DD.%26aulast%3DMoyes%26aufirst%3DC.%2BR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRussell%26aufirst%3DM.%2BG.%26aulast%3DSohal%26aufirst%3DB.%26aulast%3DStanton%26aufirst%3DJ.%2BA.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DVerrier%26aufirst%3DH.%26aulast%3DWatt%26aufirst%3DA.%2BP.%26aulast%3DCastro%26aufirst%3DJ.%2BL.%26atitle%3DFluorination%2520of%25203-%25283-%2528piperidin-1-yl%2529propyl%2529indoles%2520and%25203-%25283-%2528piperazin-1-yl%2529propyl%2529indoles%2520gives%2520selective%2520human%25205-HT1D%2520receptor%2520ligands%2520with%2520improved%2520pharmacokinetic%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D2087%26epage%3D2104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit46b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Basarab, G.; Ni, H.; Sherer, B; Zhou, F.</span><span> </span><span class="NLM_article-title">Chemical Compounds</span>. WO2007071965,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=G.+Basarab&author=H.+Ni&author=B+Sherer&author=F.+Zhou&title=Chemical+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%26atitle%3DChemical%2520Compounds%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shirakami, S.; Takayuki, I.; Mukoyoshi, K.; Nakajima, Y.; Usuda, H.; Hamaguchi, H.; Higashi, Y.; Hatanaka, K.</span><span> </span><span class="NLM_article-title">Condensed Pyridine Compounds</span>. EP2123651,<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=S.+Shirakami&author=I.+Takayuki&author=K.+Mukoyoshi&author=Y.+Nakajima&author=H.+Usuda&author=H.+Hamaguchi&author=Y.+Higashi&author=K.+Hatanaka&title=Condensed+Pyridine+Compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DShirakami%26aufirst%3DS.%26atitle%3DCondensed%2520Pyridine%2520Compounds%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit47b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Remen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezencon, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richard-Bildstein, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bur, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prade, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corminboeuf, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grisostomi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sifferlen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strickner, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delahaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binkert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischli, W.</span><span> </span><span class="NLM_article-title">New classes of potent and bioavailable human renin inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">6762</span><span class="NLM_x">–</span> <span class="NLM_lpage">6765</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=6762-6765&author=L.+Remenauthor=O.+Bezenconauthor=S.+Richard-Bildsteinauthor=D.+Burauthor=L.+Pradeauthor=O.+Corminboeufauthor=C.+Bossauthor=C.+Grisostomiauthor=T.+Sifferlenauthor=P.+Stricknerauthor=P.+Hessauthor=S.+Delahayeauthor=A.+Treiberauthor=T.+Wellerauthor=C.+Binkertauthor=B.+Steinerauthor=W.+Fischli&title=New+classes+of+potent+and+bioavailable+human+renin+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRemen%26aufirst%3DL.%26aulast%3DBezencon%26aufirst%3DO.%26aulast%3DRichard-Bildstein%26aufirst%3DS.%26aulast%3DBur%26aufirst%3DD.%26aulast%3DPrade%26aufirst%3DL.%26aulast%3DCorminboeuf%26aufirst%3DO.%26aulast%3DBoss%26aufirst%3DC.%26aulast%3DGrisostomi%26aufirst%3DC.%26aulast%3DSifferlen%26aufirst%3DT.%26aulast%3DStrickner%26aufirst%3DP.%26aulast%3DHess%26aufirst%3DP.%26aulast%3DDelahaye%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DA.%26aulast%3DWeller%26aufirst%3DT.%26aulast%3DBinkert%26aufirst%3DC.%26aulast%3DSteiner%26aufirst%3DB.%26aulast%3DFischli%26aufirst%3DW.%26atitle%3DNew%2520classes%2520of%2520potent%2520and%2520bioavailable%2520human%2520renin%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D6762%26epage%3D6765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Brocklehurst, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laumen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Vecchia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vögtle, M.</span><span> </span><span class="NLM_article-title">Diastereoisomeric salt formation and enzyme-catalyzed kinetic resolution as complementary methods for the chiral separation of <i>cis</i>-/<i>trans</i>-enantiomers of 3-aminocyclohexanol</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">294</span><span class="NLM_x">–</span> <span class="NLM_lpage">300</span></span><div class="citationLinks">[<a href="/doi/10.1021/op1002424" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=294-300&author=C.+E.+Brocklehurstauthor=K.+Laumenauthor=L.+La+Vecchiaauthor=D.+Shawauthor=M.+V%C3%B6gtle&title=Diastereoisomeric+salt+formation+and+enzyme-catalyzed+kinetic+resolution+as+complementary+methods+for+the+chiral+separation+of+cis-%2Ftrans-enantiomers+of+3-aminocyclohexanol"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fop1002424&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop1002424%26sid%3Dliteratum%253Aachs%26aulast%3DBrocklehurst%26aufirst%3DC.%2BE.%26aulast%3DLaumen%26aufirst%3DK.%26aulast%3DLa%2BVecchia%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DD.%26aulast%3DV%25C3%25B6gtle%26aufirst%3DM.%26atitle%3DDiastereoisomeric%2520salt%2520formation%2520and%2520enzyme-catalyzed%2520kinetic%2520resolution%2520as%2520complementary%2520methods%2520for%2520the%2520chiral%2520separation%2520of%2520cis-%252Ftrans-enantiomers%2520of%25203-aminocyclohexanol%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2011%26volume%3D15%26spage%3D294%26epage%3D300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Erickson, S. D.; Qian, Y.; Tilley, J. W.</span><span> </span><span class="NLM_article-title">Diaminocyclohexane and Diaminocyclopentane Derivatives</span>. WO2008065021,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=S.+D.+Erickson&author=Y.+Qian&author=J.+W.+Tilley&title=Diaminocyclohexane+and+Diaminocyclopentane+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DS.%2BD.%26atitle%3DDiaminocyclohexane%2520and%2520Diaminocyclopentane%2520Derivatives%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F08" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F08','PDB','4F08'); return false;">PDB: 4F08</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EHZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EHZ','PDB','4EHZ'); return false;">PDB: 4EHZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F09" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4F09','PDB','4F09'); return false;">PDB: 4F09</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EI4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4EI4','PDB','4EI4'); return false;">PDB: 4EI4</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i48"><a href="/doi/suppl/10.1021/jm300628c">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_52066"></div></div></div></div></div><hr /></hr><p class="last">Details of analytical LCMS and SFC methods; experimental log <i>D</i> measurement procedures; thermodynamic solubility measurement procedures; in vitro and in vivo ADME experimental procedures; experimental details for IL6-induced pSTAT3 PK/PD study of compound <b>20</b> in the mouse; protein expression/purification and crystallographic methods and procedures for <b>3</b> (in complex with JAK2), <b>4</b> (in complex with JAK1 and JAK2), <b>20</b> (in complex with JAK1); details of JAK biochemical and cell-based assays; details of in vitro hERG assay; details of QM calculations and methods; biochemical inhibition of JAK3 and TYK2 by compounds <b>3</b>–<b>24</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300628c/suppl_file/jm300628c_si_001.pdf">jm300628c_si_001.pdf (287.3 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300628c&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm300628c%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300628c" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e1092ec91ad96e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
